zoledronic acid has been researched along with Bone Cancer in 918 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (0.54) | 18.2507 |
| 2000's | 347 (37.80) | 29.6817 |
| 2010's | 476 (51.85) | 24.3611 |
| 2020's | 90 (9.80) | 2.80 |
| Authors | Studies |
|---|---|
| Ceruso, M; Loiodice, F; Supuran, CT; Tauro, M; Tortorella, P | 1 |
| Damron, TA | 1 |
| Doi, K; Hashida, T; Hirabatake, M; Ikesue, H; Morimoto, M; Muroi, N; Takenobu, T; Yamamoto, S | 2 |
| Andoh, K; Burdalski, C; Burton, B; Gilmore, S; Goldenhorn, M; Porter, T; Proctor, C; Sproat, MR | 1 |
| Lewis, K; Marongiu, A; Massey, L; Rider, A; Seesaghur, A; von Moos, R | 1 |
| Artioli, F; Bongiovanni, A; Burgio, MA; Fantini, M; Fausti, V; Foca, F; Forcignanò, MR; Guadalupi, V; Ibrahim, T; Menis, J; Mercatali, L; Miserocchi, A; Recine, F; Spadazzi, C; Stucci, SL | 1 |
| Flux, G; Liepe, K; Murray, I | 1 |
| Gong, H; Xu, H; Zhang, G | 1 |
| Alshamsan, B; Alzahrani, M; Awan, A; Clemons, M; Liu, M; Ng, TL; Pond, G; Stober, C; Vandermeer, L | 1 |
| Fujimoto, K; Harabayashi, T; Hata, H; Hiraga, H; Imamachi, K; Kitagawa, Y; Matsuzaka, M; Oizumi, S; Osanai, T; Sato, J; Takahashi, M; Ueda, M; Yamazaki, Y; Yoshikawa, K | 1 |
| Dong, W; Ge, F; Ge, T; Gui, L; Li, W; Song, P; Tao, Y; Weiwei, Z; Yang, K; Zhu, L | 1 |
| Bryan, JN; Ehling, TJ; Flesner, BK; Keys, DA; Lattimer, JC; Maitz, CA; Moore, M; Norquest, CJ | 1 |
| Bedogni, A; Campisi, G; Fusco, V | 1 |
| Errani, C; Marchetti, A; Massari, F; Mollica, V; Nigro, MC; Nuvola, G; Rizzo, A; Rosellini, M; Tassinari, E | 1 |
| Au, PC; Baek, YH; Cheung, CL; Chung, WP; Kim, JH; Kleinman, NJ; Lai, EC; Lam, TC; Liao, TC; Lin, TC; Shen, CY; Shin, JY; Sing, CW; Wong, ICK | 1 |
| Cao, W; Dong, N; Hu, A; Qi, Y; Xiang, S; Xiao, J; Zhang, P; Zou, D | 1 |
| Farooki, A; Lipitz-Snyderman, A; Meza, AM; Mitchell, AP; Morris, MJ; Panageas, KS | 1 |
| Bovée, JVMG; Gelderblom, H; Lipplaa, A; van de Sande, MAJ; van der Heijden, L; van Langevelde, K | 1 |
| Fasciolo, A; Fusco, V; Gambino, A; Palmeri, S; Rossi, M | 1 |
| Jeong, YH; Ko, Y; Lee, JA | 1 |
| Akazawa, K; Horiguchi, J; Ishikawa, T; Kaise, H; Kohno, N; Kubota, T; Machida, Y; Miura, D; Narui, K; Suzuki, M; Taguchi, T; Takao, S; Tawaraya, K; Yamada, K | 1 |
| Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M | 1 |
| Chen, C; Fan, X; Guo, L; Huang, R; Lin, M; Qin, W; Xiang, S; Yu, D; Zhou, J | 1 |
| Abe, K; Harata, S; Hongo, M; Igarashi, S; Kasama, F; Kasukawa, Y; Kudo, D; Miyakoshi, N; Nagasawa, H; Nozaka, K; Saito, H; Shoji, R; Tsuchie, H | 1 |
| Almond, GT; Bergman, NS; Lindley, SES; Matz, BM; Smith, AA; Smith, AN | 1 |
| Aerxiding, P; Aosiman, A; Liu, J; Nuermaimaiti, G; Yuan, M | 1 |
| Ahlers, AK; Baranowsky, A; Böckelmann, LC; Freytag, V; Gosau, T; Haider, MT; Lange, T; Maar, H; Pantel, K; Schmitz, R; Schumacher, U | 1 |
| Haonan, L; Jiacong, H; Keng, C; Qirui, Y; Yan, C; Yichang, S | 1 |
| Barbanente, A; Ditaranto, N; Intini, FP; Laghezza, A; Margiotta, N; Natile, G; Pacifico, C; Tortorella, P | 1 |
| Borges, R; de Araujo, DR; Justo, GZ; Machado, J; Marchi, J; Pelosine, AM; Schneider, JF; Souza, ACS; Zambanini, T | 1 |
| Jacquier, C; Lafforgue, P; Laredo, JD; Larid, G; Pham, T; Valayer, S | 1 |
| Cheng, Y; Ji, Q; Liu, B; Liu, D; Liu, M; Yang, Q; Yang, Z; Zhang, B; Zhou, S | 1 |
| Hata, A; Hatachi, Y; Hidaka, Y; Hirashima, T; Kaneda, T; Katakami, N; Mori, M; Morita, S; Nishimura, T; Nishino, K; Ohnishi, H; Takase, N | 1 |
| Iijima, H; Imamura, M; Ito, K; Kumagai, M; Muro, Y; Shiraishi, Y; Yabusaki, R; Yoshimura, K | 1 |
| Dash, M; Dash, P; Piras, AM; Prasad Panda, G; Samal, S | 1 |
| Barcenas, CH; Bassett, R; Jayan, A; Raghavendra, AS | 1 |
| Baima, G; Bosso, I; Erovigni, F; Mussano, F; Pavone, L; Pedraza, R; Roato, I | 1 |
| Diel, I; Holtmann, L; Kerkmann, M; Link, H; Ohlmann, CH | 1 |
| Chen, QY; Liang, YJ; Lin, C; Mai, HQ; Sun, XS; Tang, LQ | 1 |
| George, DJ | 1 |
| Kushima, C; Nakazato, M; Uchida, T; Yamaguchi, H; Yonekawa, T | 1 |
| Ahmed, GA; Farag, K; Mohamed, W; Yousof, O; Zabani, Y; Zekri, J | 1 |
| Chen, J; Qi, WX; Zhao, S | 1 |
| Baba, N; Iguchi, H; Kawabata, H; Kinowaki, K; Kizawa, R; Kondoh, C; Masuda, J; Miura, Y; Ozaki, Y; Sakamaki, K; Shigekawa, T; Takahashi, M; Takano, T; Tamura, N; Tanabe, Y; Umezu, T | 1 |
| Baek, YH; Hong, S; Jeon, HL; Oh, IS; Park, J; Shin, JY; Yang, H | 1 |
| Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH | 1 |
| Elazzazy, S; Hamad, A; Nasser, SM; Sahal, A | 1 |
| Chen, G; John, J; Lu, C; Tang, L; Wang, Q | 1 |
| Ando, Y; Arai, E; Hase, T; Ikuta, K; Ishiguro, N; Kikumori, T; Maeda, O; Mitsuma, A; Nishida, Y; Shimokata, T; Sugishita, M; Urakawa, H | 1 |
| Cao, W; Cao, X; Fan, C; Fu, Y; He, W; Hu, X; Kong, X; Li, C; Li, Q; Ling, D; Pang, Y; Qin, A; Sun, X; Wu, Z; Yang, C | 1 |
| Anderton, J; Brennan, B; Evans, A; Fenwick, N; Fernández-Pinto, M; Gaspar, N; Gelderblom, H; Kaiser, S; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J | 1 |
| Ehresman, J; Khan, M; Luna, LP; Sankaran, N; Sciubba, DM | 1 |
| Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H | 1 |
| Ahmadzadehfar, H; Bundschuh, RA; Essler, M; Gaertner, FC; Khawar, A; Kreppel, B; Kürpig, S; Meisenheimer, M; Roesch, F | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Ohta, K; Yoshimura, H | 1 |
| Cruz, C; Malamud, S; Miyashita, H | 1 |
| Chang, CS; Chng, WJ; Gao, S; Glennane, A; Gordon, SW; Huang, SY; Min, CK; Shimizu, K; Wang, Y; Wong, RS; Yoon, SS | 1 |
| Dijkstra, S; Gelderblom, H; van de Sande, M; van der Heijden, L | 1 |
| Lin, CW; Lu, EW; Lu, KH; Yang, JS; Yang, SF | 1 |
| Eppard, E; Essler, M; Kürpig, S; Meisenheimer, M | 1 |
| Sözel, H; Yilmaz, F | 1 |
| Chen, C; Cui, Y; Li, M; Li, R; Ma, L; Yang, T; Zhou, S; Zhou, Y | 1 |
| Coleman, R | 3 |
| Cruz, C; Miyashita, H; Smith, C | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Harada, H; Hayakawa, K; Katagiri, H; Miyazawa, K; Nagakura, H; Nakamura, N; Nozaki, M; Ogawa, H; Shikama, N; Uchida, N; Wada, H; Yamada, K | 1 |
| Ishibashi, M; Kakimoto, KI; Kanaki, T; Nagahara, A; Nakai, Y; Nakayama, M; Nishimura, K; Tanaka, R; Yamamoto, A; Yamamoto, Y | 1 |
| Chen, J; Li, H; Li, W; Liu, X; Wen, X; Zhou, L | 1 |
| Li, J; Liu, Y; Song, W; Sun, X; Zhou, J | 1 |
| Nachar, VR; Qin, A; Schepers, AJ; Tam, AH | 1 |
| Fang, D; Luo, R; Wang, L; Xu, J | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Chang, HH; Cheng, SJ; Chiu, WY; Kok, SH; Lee, JJ; Lee, YC; Wang, JJ; Wei, LY | 1 |
| Bagramian, RA; Dakhil, SR; Darke, AK; Fisch, MJ; Floyd, JD; Gralow, J; Hansen, LK; Henry, NL; Hershman, DL; Lew, DL; Moinpour, C; Schubert, MM; Unger, JM; Van Poznak, CH; Wade, JL | 1 |
| Ebata, T; Ishiwata, T; Iwasawa, S; Saito, G; Takiguchi, Y; Tatsumi, K; Yoshino, I | 1 |
| Billias, C; Langer, M; Schorr, R; Ursu, S | 1 |
| Hu, MI; Jara, MA; Varghese, J | 1 |
| Brown, JE; D'Oronzo, S; Wood, S | 1 |
| Ahn, JH; Choi, IS; Choi, YJ; Jung, KH; Kang, SY; Kim, HJ; Kim, HS; Kim, HY; Kim, JW; Lee, KE; Lee, KH; Lee, S; Oh, HS; Park, IH; Park, KH; Park, KU; Park, YH; Seo, JH; Yoo, J | 1 |
| Abbas, U; Axelrod, D; Bhasin, R; Bozzo, A; Deng, J; Deodat, M; Ghert, M; Masrouha, K; Sanger, S; Turcotte, R; Wariach, S; Wilson, D | 1 |
| Ikeguchi, R; Kaizawa, Y; Matsuda, S; Noguchi, T; Ohta, S | 1 |
| Chen, L; Geng, H; Liu, L; Mei, C | 1 |
| Shapiro, CL | 1 |
| Ding, Z; Feng, H; Feng, W; Li, J; Li, X; Tang, N; Wang, J; Wu, X; Zhang, P; Zhang, X; Zhao, Q | 1 |
| Cui, X; Jiang, L; Ma, H; Tang, X | 1 |
| Falvello, V; Van Poznak, C | 1 |
| Hakim, SG; Pries, R; Simon, R; Steller, D; Von Bialy, R | 1 |
| Akre, O; Ehrenstein, V; Glennane, A; Hansen, S; Heide-Jørgensen, U; Herlofson, BB; Kjellman, A; Larsson Wexell, C; Lowe, KA; Nørholt, SE; Schiødt, M; Sørensen, HT; Tretli, S | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Cruz, C; Miyashita, H; Patel, V | 1 |
| Kiatisevi, P; Kittithamvongs, P; Piakong, P; Sukanthanak, B | 1 |
| Mi, J; Xu, Q; Zhang, Y | 1 |
| Casimiro, S; Costa, L; Gomes, I; Vilhais, G | 1 |
| Bastida, C; Chaguaceda, C; Creus-Baró, N; Manzaneque, A; Mensa, M | 1 |
| Goldoni, M; Manfredi, M; Meleti, M; Mergoni, G; Merigo, E; Salvagni, S; Vescovi, P | 1 |
| Evdokiou, A; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Shiu, HT; Shum, WT; Siu, WS; Yue, GG | 1 |
| Chen, WL; Han, XH; Hu, QW; Li, JJ; Liu, S; Sun, ZP; Wang, JY; Zhang, S | 1 |
| Adamo, V; Body, JJ; Caraceni, A; De Cock, E; Gatta, F; Hechmati, G; Kritikou, P; Mebis, J; Pedrazzoli, P; Peeters, M; Tao, S; Wimberger, P | 1 |
| Fietz, T; Fleitz, A; Jänicke, M; Köhler, A; Marschner, N; Petersen, V; Schröder, J; Spring, L; Tesch, H | 1 |
| Higashino, M; Hozumi, T; Kogo, M; Kokubu, F; Matsui, M; Nagatani, A; Nakamura, S; Sasaki, T; Shimamoto, K; Sunaga, T; Takahashi, N | 1 |
| Saad, F; Traboulsi, SL | 1 |
| Caldas, RJ; Maluf, G; Silva Santos, PS | 1 |
| Jun, JH | 1 |
| Fujiwara, T; Hasei, J; Kagawa, S; Komatsubara, T; Kunisada, T; Omori, T; Osaki, S; Ozaki, T; Sugiu, K; Tazawa, H; Uotani, K; Urata, Y; Yamakawa, Y; Yoshida, A | 1 |
| Bu, W; Cui, Z; Fan, Q; Han, X; He, XP; Ji, D; Qiao, H; Qin, A; Tang, T; Wang, T; Wang, Y; Yang, S; Yang, Y | 1 |
| Biskup, E; Cai, F; Vetter, M | 1 |
| Taneja, SS | 1 |
| Rades, D | 1 |
| Cao, H; Nguyen, AL; Thinn, MM | 1 |
| Gamper, J; Grunt, TW; Gschwantler-Kaulich, D; Mairhofer, M; Singer, CF; Tan, Y; Weingartshofer, S | 1 |
| Borah, BJ; Dusetzina, S; Foster, JC; Grubbs, SS; Himelstein, AL; Moriarty, JP; Novotny, PJ; Shapiro, CL | 1 |
| Moy, B; Somerfield, MR; Van Poznak, C | 1 |
| Barlow, WE; Biermann, JS; Bosserman, LD; Clemons, MJ; Dhesy-Thind, SK; Dillmon, MS; Eisen, A; Frank, ES; Jagsi, R; Jimenez, R; Moy, B; Somerfield, MR; Theriault, RL; Van Poznak, C; Vandenberg, TA; Yee, GC | 1 |
| Costa, L; Ferreira, AR | 1 |
| Raje, NS; Yee, AJ | 1 |
| Lüftner, D; Niepel, D; Steger, GG | 1 |
| Goodwin, A; O'Carrigan, B; Pavlakis, N; Stockler, MR; Willson, ML; Wong, MH | 1 |
| Dezawa, A; Kamijo, R; Karakawa, A; Miyamoto, A; Nakamura, S; Shibuya, I; Takami, M | 1 |
| Parker, C | 1 |
| Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C | 1 |
| Abernethy, AP; Alan Brookhart, M; Butler, AM; Cetin, K; Diane Reams, B; Hernandez, RK; Hirsch, BR; I Kim, J; Liede, A; Overman, RA | 1 |
| Buehlmann, D; Grandjean, J; Rudin, M; Xandry, J | 1 |
| Abernethy, AP; Finelli, A; Hernandez, RK; Lethen, J; Liede, A; Wade, S; Warner, D | 1 |
| Bell, R; Bertelli, G; Bowman, A; Brown, J; Burkinshaw, R; Cameron, D; Coleman, R; Gossiel, F; Gregory, W; Hanby, A; Hinsley, S; Maccon, K; Marshall, H; Rathbone, E; Shulver, H; Thandar, H | 1 |
| Cheng, P; Durie, B; García-Sanz, R; Krejčí, M; Laribi, K; Legieć, W; Raje, N; Roodman, GD; Shimizu, K; Terpos, E; Warner, D; Willenbacher, W; Zhu, L | 1 |
| Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J | 1 |
| García-Sanz, R; Hechmati, G; Intorcia, M; Kennedy, L; Raje, N; Roodman, GD; Sabatelli, L; Shimizu, K; Terpos, E; Willenbacher, W | 1 |
| Higuchi, T; Kajizono, M; Kitamura, Y; Muro, M; Sasaki, A; Sendo, T; Soga, Y | 1 |
| Arai, Y; Kawakami, S; Kitayama, S; Otsuka, Y; Shirotake, S; Yano, A | 1 |
| Mulders, PFA; Niepel, D; Saad, F; Sternberg, CN; Tombal, BF | 1 |
| Bausbacher, N; Miederer, M; Pektor, S; Pfannkuchen, N; Rosch, F | 1 |
| Harada, H; Hosaka, S; Katagiri, H; Murata, H; Niwakawa, M; Takahashi, M; Wasa, J | 1 |
| Abdel-Rahman, O | 1 |
| Li, M; Lu, Y; Mao, C; Wan, P; Wang, W; Yang, K; Zhang, Y; Zhu, Y | 1 |
| Alexander, S; De-Juan-Pardo, EM; Dondossola, E; Filippini, S; Friedl, P; Hoffman, RM; Holzapfel, BM; Hutmacher, DW; Logothetis, CJ; Navone, N; Starbuck, MW | 1 |
| Berk, LB; Clarkson, JE; Clausen, CL; Cleary, SF; Demas, W; Derdel, JD; Kachnic, LA; Langer, C; Peters, CA; Pugh, SL; Rabinovitch, RA; Ramalingam, A; Rashtian, A; Seider, MJ; Tomblyn, M; Wyatt, G | 1 |
| Clézardin, P; Lelièvre, L; Magaud, L; Mathevet, P; Mouret-Reynier, MA; Raban, N; Roche, L; Tigaud, JD; Topart, D; Tubiana-Mathieu, N | 1 |
| Han, L; Liu, X; Wang, T; Yu, H; Zhang, H; Zhang, J; Zhang, L | 1 |
| Han, J; Han, L; Liu, X; Wang, T; Zhang, H; Zhang, J; Zhang, L | 1 |
| Kahn, JG; Matuoka, JY; Secoli, SR | 1 |
| Brown, JE; Cairns, DA; Coleman, RE; Dunning, MJ; Gahlaut, R; Hanby, AM; Marshall, H; Mavria, G; McMahon, K; Oliva, MR; Roberts, S; Selby, PJ; Shires, M; Speirs, V; Thygesen, H; Westbrook, JA; Wood, SL | 1 |
| Choi, J; Im, YR; Lee, EJ; Seong, J; Yang, SH | 1 |
| Couch, C; Emory, CL; Montgomery, C; Nicholas, R | 1 |
| Bhowmik, D; Body, JJ; De Courcy, J; Gatta, F; Hechmati, G; Henry, D; Qian, Y; Rider, A; von Moos, R | 1 |
| Aragon-Ching, JB; Finianos, A | 1 |
| Chen, P; Li, S; Pei, Y; Qiu, E; Wang, W; Zhang, X; Zheng, K | 1 |
| Chen, W; Cui, Y; Liu, H; Liu, Y; Ma, R; Yu, Z; Zhan, H | 1 |
| Bellarosa, C; Cardano, R; Dionisi, V; Fanti, S; Ghedini, P; Monari, F; Morganti, AG; Rizzini, EL | 1 |
| Dass, CR; Doschak, MR; Elahy, M; Friedhuber, AM; Hughes, JD; Wei, Y; Wong, JY | 1 |
| Brickman, A; Cameron, J; Danforth, OM; Ebersole, J; Kent, P; Mahon, B; Oh, C; Tamulonis, K; Vavra, K | 1 |
| Body, JJ; Costa, L; Gonzalez-Suarez, E; Niepel, D; Terpos, E; von Moos, R | 1 |
| Bjartell, A; Caris, C; Cicalese, V; Debruyne, F; Edenbrandt, L; Miller, K; Mulders, P; Ohlsson, M; Patel, A; Reza, M; Tammela, T; Thorsson, O; Trägårdh, E; Tubaro, A; Veiga, FG; Wirth, M; Witjes, W; Wollmer, P | 1 |
| Anract, P; Bertucci, F; Blay, JY; Bompas, E; Brugieres, L; Collard, O; Cupissol, D; de Pinieux, G; Delaye, J; Duffaud, F; Italiano, A; Laurence, V; Le Cesne, A; Le Deley, MC; Occean, BV; Penel, N; Perrin, C; Piperno-Neumann, S; Ray-Coquard, I; Rios, M | 1 |
| Ge, K; Han, Y; Jin, Y; Liang, XJ; Liu, D; Liu, H; Sun, W; Yang, X; Zhang, H; Zhang, J; Zhou, G | 1 |
| Chaurand-Lara, J; Facio-Umaña, JA; Mora-Pérez, J; Pacheco-Ruiz, L; Trejo-Campos, JL | 1 |
| Li, JJ; Li, S | 1 |
| Badalamenti, G; Bazan, V; Castellana, L; Galvano, A; Giuliana, G; Guadagni, F; Incorvaia, L; Pantano, F; Rizzo, S; Russo, A; Santini, D; Toia, F; Tonini, G; Vincenzi, B | 1 |
| Kaneko, M; Murata, T; Yamada, T; Yoshino, H | 1 |
| Delaissé, JM; Hansen, CT; Jakobsen, EH; Jørgensen, HB; Plesner, T; Søe, K | 1 |
| Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
| Bastit, L; Guérif, S; Khemaies, S; Kouri, CE; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X | 1 |
| Chow, E; Dennis, K; Konski, A; Koo, K; Lam, H; Lam, K; Mittmann, N; Zeng, L | 1 |
| Afonso, R; Bosch-Barrera, J; Isla, D; Martínez, N | 1 |
| Aktas, B; Kasimir-Bauer, S; Kimmig, R; Lehmann, N; Tewes, M | 1 |
| Anido, U; Climent, MA; Méndez-Vidal, MJ; Puente, J | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| Coleman, RE; Young, RJ | 1 |
| Carlton, MM; Dirksen, WP; Hildreth, BE; Lanigan, LG; London, CA; Martin, CK; Pillai, SP; Rosol, TJ; Simmons, JK; Toribio, RE; Werbeck, JL | 1 |
| Huang, Q; Ouyang, X | 1 |
| Bernstein, M; Fan, TM; Goldsby, RE; Gorlick, R; Isakoff, MS; Kim, G; Krailo, M; Lee, S; Marina, N; Meyer, J; Randall, RL; Villaluna, D; Wagner, LM | 1 |
| Alhoniemi, E; Fagerlund, KM; Halleen, JM; Käkönen, R; Käkönen, SM; Mumberg, D; Rissanen, JP; Scholz, A; Suominen, MI; Ziegelbauer, K | 1 |
| López-Tarruella, S; Martin, M | 1 |
| Aglietta, M; Alessi, B; Amadori, D; Bertoldo, F; Bogani, P; Farina, G; Gaion, F; Gianni, L; Ibrahim, T; Ripamonti, CI; Rondena, R; Santini, D | 1 |
| Aksoy, S; Arik, Z; Demir, M; Eren, T; Ozdemir, N; Sendur, MA; Ucar, O; Uncu, D; Yaman, S; Yazici, O; Zengin, N | 1 |
| Amadori, D; Fabbri, F; Gunelli, E; Ibrahim, T; Liverani, C; Maltoni, R; Mercatali, L; Ricci, M; Ricci, R; Scarpi, E; Serra, P; Zanoni, M; Zoli, W | 1 |
| Coleman, RE; Fizazi, K; Galsky, MD; Gartrell, BA; Miller, K; Saad, F; Sternberg, CN | 1 |
| Alcaraz, A; Álvarez-Ossorio, JL; Anido, U; Bellmunt, J; Calderero, V; Carles, J; Comet-Batlle, J; Constela, M; Contreras, JA; de la Piedra, C; del Alba, AG; Delgado, D; Esteban, E; Fernández, JM; García-Escudero, A; Gómez-Caamano, A; Gómez-Veiga, F; González-Enguita, C; González-Gragera, B; Lara, PC; Lassa, A; Mahillo-Fernández, I; Mañas, A; Martín-Fernández, M; Martínez-Javaloyas, JM; Méndez, MJ; Meseguer, C; Morote, J; Murias, A; Quicios, C; Reynes, G; Ribal, MJ; Rodriguez, B; Rubio, G; Samper, P; San José, LA; Sánchez, E; Segarra, J; Solsona, E; Tabernero, AJ; Unda, M; Vázquez, F; Virizuela, JA | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Alcaraz, A; Alvarez-Ossorio, JL; Bellmunt, J; Calderero, V; Carles, J; Chirivella, I; Climent, M; Comet-Batlle, J; Contreras, JA; de la Piedra, C; Esteban, E; González-Del Alba, A; González-Enguita, C; González-Gragera, B; González-López, R; Lara, PC; Lassa, A; León-Mateos, L; Mahillo-Fernández, I; Mañas, A; Mellado, B; Méndez, MJ; Meseguer, C; Morote, J; Murias, A; Samper, P; Segarra, J; Unda, M; Vázquez, F | 1 |
| Anghel, R; Bachmann, A; Bekşac, M; Brodowicz, T; Finek, J; Komadina, R; Krzemieniecki, K; Lang, I; Marencak, J; Pecherstorfer, M; Rordorf, T; von Moos, R; Vrbanec, D; Zielinski, C | 1 |
| Natori, T; Yamaguchi, M | 1 |
| Hayata, A; Ikeda, T; Nakanishi, H | 1 |
| Chen, H; Chen, W; Duan, F; Jin, H; Li, C; Liu, Q; Mo, L; Wang, F; Weng, Z; Yu, Z | 1 |
| Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
| Esa, A; Hara, I; Imanishi, M; Inagaki, T; Kajikawa, H; Kitagawa, M; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| Efthymiadou, A; Gkentzi, D; Karana-Ginopoulou, A; Kolyva, S; Varvarigou, A | 1 |
| Clarke, NW | 1 |
| Delabaye, I; Delforge, M; Doyen, C; Duck, L; Van den Wyngaert, T; Wildiers, H; Wouters, C; Wouters, K | 1 |
| Body, JJ; Braun, A; Brown, JE; Chung, K; Cleeland, CS; Damyanov, D; Egerdie, B; Fallowfield, LJ; Marx, G; Palazzo, FG; Patrick, DL; Qian, Y; Stopeck, A; von Moos, R | 1 |
| Arai, G; Fujimoto, N; Fukagai, T; Horie, S; Ide, H; Ikeda, D; Ishida, T; Kawaguchi, K; Kondo, Y; Mizokami, A; Namiki, M; Oh-Oka, H; Orito, M; Shimamura, M; Ueki, O; Ueno, S | 1 |
| Assaf, AT; Blessmann, M; Friedrich, RE; Gerhards, F; Gröbe, A; Heiland, M; Hoelzle, F; Riecke, B; Smeets, R; Steiner, T; Weise, E; Wikner, J | 1 |
| Dellis, A; Papatsoris, AG | 1 |
| Jung, HD; Jung, YS; Kim, DW; Park, HS | 1 |
| Cueva, J; Lluch, A; Pérez-Fidalgo, JA; Ponce, J; Ruiz-Borrego, M | 1 |
| Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN | 1 |
| Barrett-Lee, P; Fenlon, D; Griffiths, G; Harrop, E; Hood, K; Morris, J; Murray, N; Nelson, A; Sampson, C; Wheatley, D | 1 |
| Fujimoto, N; Fukumoto, R; Hayashi, T; Koide, T; Oka, D; Soda, T | 1 |
| Amoretti, N; Cornelis, F; Fournier, C; Gille, O; Hauger, O; Pillet, O; Truchetet, ME; Verdier, D | 1 |
| Body, JJ | 6 |
| Debiais, F | 1 |
| Bronte, G; Campelo, RG; Papadimitriou, K; Raez, LE; Reguart, N; Rolfo, C; Russo, A; Silvestris, F | 1 |
| Costa, L; Dansey, R; Feng, A; Henry, D; Hirsh, V; Hungria, V; Jun, S; Scagliotti, G; Smith, G; Vadhan-Raj, S; von Moos, R; Woll, PJ; Yeh, H | 1 |
| Delaissé, JM; Hansen, CT; Jakobsen, EH; Plesner, T; Søe, K | 1 |
| Li, M; Lin, X; Yang, T; Yin, QS; Zheng, XF | 1 |
| Abbadessa, G; Broggini, M; Chilà, R; Previdi, S; Ricci, F; Scolari, F | 1 |
| Chang, KJ; Chao, TC; Chao, TY; Chen, DR; Chen, SC; Hou, MF; Huang, WT; Lee, KD; Rau, KM; Tai, CJ; Tseng, LM; Wang, HC; Yang, TL; Yeh, DC | 1 |
| Costa, L | 2 |
| Abraham, J; Barrett-Lee, P; Casbard, A; Coleman, R; Grieve, R; Griffiths, G; Hood, K; Murray, N; Simmonds, P; Timmins, H; Wheatley, D | 1 |
| Balakumaran, A; Chung, K; Dodge, T; Edelsberg, J; Glass, AG; Lamerato, L; Lopez, A; Oster, G; Richert-Boe, KE; Richhariya, A; Wolff, GG | 1 |
| Abreu, A; Cohen, RJ; Denham, JW; Joseph, DJ; Kautto, A; Moseshvili, E; Spry, NA | 1 |
| Berk, V; Cetin, M; Elmali, F; Enhos, S; Eser, B; Inanc, M; Karaca, H; Kaynar, L; Ozkan, M; Pala, C; Sıvgın, S | 1 |
| Gerngroß, C; Hohlweg-Majert, B; Koerdt, S; Otto, S; Pautke, C; Ristow, M; Ristow, O; Schuster, R; Schwaiger, M | 1 |
| Andreis, D; Bertoni, R; Bonelli, M; Bottini, A; Brugnoli, G; Cappelletti, M; Ferrero, G; Foroni, C; Fox, SB; Fumarola, C; Generali, D; Maldotti, M; Milan, M; Parissenti, A; Petronini, PG; Pritzker, K; Pritzker, L; Santini, D; Strina, C; Takano, E; Venturini, S; Zanoni, V | 1 |
| Gerngroß, C; Hahnefeld, L; Hohlweg-Majert, B; Jansen, H; Kehl, V; Otto, S; Pautke, C; Ristow, O; Schwaiger, M | 1 |
| Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP | 1 |
| Baretton, GB; Bauer, T; Benad-Mehner, P; Bornhäuser, M; Ebert, R; Göbel, A; Hadji, P; Hofbauer, LC; Jakob, F; Muders, MH; Rachner, TD; Rauner, M; Schem, C; Thiele, S | 1 |
| Della Coletta, R; dos Santos-Silva, AR; Flores, IL; Lopes, MA; Vargas, PA | 1 |
| Song, Z; Zhang, Y | 1 |
| Gerngroß, C; Hahnefeld, L; Hohlweg-Majert, B; Jansen, H; Kehl, V; Koerdt, S; Otto, S; Pautke, C; Ristow, O; Schwaiger, M | 1 |
| Bhoopalam, N; Halabi, S; Hauke, RJ; Hussain, A; Kelly, WK; Monk, JP; Morris, M; Ryan, CJ; Saad, F; Sanford, B; Saylor, P; Small, EJ; Smith, MR; Stadler, W; Vogelzang, N | 1 |
| Aono, M; Hayashi, K; Kazuki, K; Shintani, K | 1 |
| Han, X; Liu, S; Sun, Z; Wu, C; Yang, S; Ye, Y | 1 |
| Amiaud, J; Battaglia, S; Charrier, C; Gouin, F; Heymann, D; Kim, PP; Lamoureux, F; Odri, G; Redini, F | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Caris, C; Cicalese, V; Debruyne, F; Delaere, K; Gomez Veiga, F; Huland, H; Lecouvet, F; Miller, K; Patel, A; Schulze, M; Tammela, T; Tubaro, A; Wirth, M; Witjes, W | 1 |
| Brown, HK; Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Ottewell, PD; Reeves, KJ; Wang, N | 1 |
| Saad, F | 6 |
| Angelis, CD; Burke, N; Giotis, A; Goeree, R; Habib, M; Hopkins, RB; Pasetka, M; Xie, F | 1 |
| Amoroso, L; Blasi, L; DE Iuliis, F; Lanza, R; Salerno, G; Scarpa, S; Taglieri, L; Vendittozzi, S | 1 |
| Chang, Y; Guo, G; He, X; Li, F; Li, L; Li, M; Su, D; Wang, W | 1 |
| Bajory, Z; Bouzid, M; Cathomas, R; El Ghoneimy, A; Gillessen, S; Goncalves, F; Kacso, G; Kramer, G; Lesniewski-Kmak, K; Milecki, P; Pacik, D; Tantawy, W | 1 |
| Geist, A; Grimm, M; Hoefert, S; Krimmel, M; Reinert, S; Sharghi, F | 1 |
| Atagi, S; Fukuoka, M; Hirashima, T; Murakami, H; Nakagawa, K; Nakanishi, Y; Okamoto, I; Sawa, T; Seto, T; Sugio, K; Takeda, K; Yamamoto, N; Yamanaka, T | 1 |
| Arellano, J; Bahl, A; Body, JJ; Gatta, F; Hauber, AB; Haynes, I; Hechmati, G; Mohamed, AF; Qian, Y; von Moos, R | 1 |
| Brown, HK; Dear, TN; Haider, MT; Holen, I; Hunter, K | 1 |
| Bouvet, M; Hayashi, K; Hiroshima, Y; Hoffman, RM; Kimura, H; Matsumoto, Y; Miwa, S; Sugimoto, N; Tsuchiya, H; Uehara, F; Yamamoto, M; Yamamoto, N; Yano, S; Zhang, Y | 1 |
| Bäuerle, T; Bendl, R; Bretschi, M; Fränzle, A; Hillengass, J; Merz, M; Semmler, W | 1 |
| Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Meek, J; Ottewell, PD; Wang, N | 1 |
| Kohno, N | 1 |
| Asaoka, H; Higaki, M; Higashihara, E; Kase, H; Matsumoto, T; Murata, A; Noda, H; Noda, K; Nutahara, K; Okegawa, T; Oshi, M; Tomoishi, J; Uchida, H | 1 |
| Anract, P; Bonnevialle, P; Di Marco, A; Fiorenza, F; Gouin, F; Rochwerger, AR; Rosset, P | 1 |
| Lu, S; Song, Z; Yang, S; Yang, X; Yu, Y; Zhang, J | 1 |
| Antón, A; Arizcuma, A; Barnadas, A; Calvo, L; Chacón, JI; Codes, M; Crespo, C; de Juan, A; de la Piedra, C; Gavilá, J; Gómez, P; Heras, L; Luque, M; Mahillo-Fernández, I; Manso, L; Margelí, M; Martin-Fernández, M; Martinez, P; Meseguer, C; Murias, A; Perelló, A; Pérez, D; Ruiz-Borrego, M; Salvador, J; Seguí, MÁ; Tusquets, I; Zamora, P | 1 |
| Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF | 1 |
| Froehner, M; Hakenberg, OW; Hölscher, T; Wirth, MP | 1 |
| Abiko, M; Harada, M; Sato, T; Shiono, S; Takanashi, I | 1 |
| Baud'huin, M; Gleave, M; Guiho, R; Heymann, D; Lamoureux, F; Ory, B; Rédini, F; Zoubeidi, A | 1 |
| Aparicio, A; Araujo, JC; Bilen, MA; Corn, PG; Fisch, MJ; Johnson, MM; Logothetis, CJ; Mathew, P; Pagliaro, LC; Tannir, NM; Tu, SM; Wong, FC | 1 |
| Broom, RJ; Deva, S; Duffey, S; Findlay, MP; Fong, PC; Forgeson, G; Grey, A; Hanning, FJ; Harris, DL; Hinder, V; Jameson, MB; North, RT; O'Donnell, A; Pollard, S; Proctor, J; Sharples, K | 1 |
| Gartrell, BA; Saad, F | 1 |
| Abe, H; Aikata, H; Chayama, K; Hiraga, N; Honda, Y; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Ochi, H; Ono, A; Shi, N; Takahashi, S; Tsuge, M; Zhang, Y | 1 |
| Ngarmukos, S; Tanavalee, A; Tantavisut, S; Thanakit, V; Wangroongsub, Y; Wilairatana, V | 1 |
| Gao, AC; Ghosh, PM | 1 |
| Battaglia, S; Brion, R; Castaneda, B; Chesneau, J; Farges, JC; Heymann, D; Lézot, F; Rédini, F | 1 |
| Chen, W; Jin, H; Pan, Y; Wang, F; Weng, Z; Ye, T; Yu, Z; Zheng, Y | 1 |
| Cappetta, A; Evangelista, L; Opocher, G; Pastorelli, D; Spano, L; Zovato, S | 1 |
| Baamonde, A; Cal, S; Fernández-García, MT; Hidalgo, A; Lastra, A; Llorián-Salvador, M; Menéndez, L; Obaya, A; Pevida, M | 1 |
| Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| Gamie, Z; Kenanidis, E; Kostakos, T; Kyrkos, J; Papamerkouriou, YM; Papavasiliou, K; Potoupnis, M; Sarris, I; Tsiridis, E | 1 |
| Açil, Y; Gierloff, M; Gülses, A; Niehoff, P; Reutemann, M; Wiltfang, J | 1 |
| Evdokiou, A; Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG | 1 |
| Brown, J; Carducci, M; Damião, R; Fizazi, K; Goessl, C; Karsh, L; Massard, C; Milecki, P; Oudard, S; Rader, M; Shore, N; Smith, M; Wang, H; Ying, W | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Hanaoka, N; Kenji, E; Miyagi, R; Nishisho, T; Sairyo, K; Sakai, T; Takahashi, M; Toki, S; Yasui, N | 1 |
| El Osta, B; El Osta, L; El Osta, N; Hennequin, M; Lakiss, S | 1 |
| Abe, Y; Hirai, R; Ikeda, E; Kashima, H; Kuroda, M; Kurosaki, T; Miyahara, K; Moriyama, S; Takagi, S; Tsuji, H; Yamano, T; Yoshitomi, S | 1 |
| Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H | 1 |
| Bohlmann, MK; Luedders, DW; Rody, A; Steinhoff, J; Thill, M | 1 |
| Manabe, J; Miyata, S; Orita, Y; Sugitani, I; Takao, S; Toda, K | 1 |
| Chen, CF; Chen, KH; Chen, WM; Wu, PK | 1 |
| Ishii, S; Kikuchi, K; Miyajima, M; Sakuma, K; Shishido, F | 1 |
| Agacayak, F; Alco, G; Celebi, F; Demir, G; Eralp, Y; Erdogan, Z; Ilgun, S; Okkan, S; Ordu, C; Ozmen, V; Pilanci, KN; Sarsenov, D; Tecimer, C | 1 |
| Body, JJ; Braun, A; Diel, IJ; Feng, A; Goldwasser, F; Spencer, A; Steger, G; Stopeck, AT; Vadhan-Raj, S; von Moos, R | 1 |
| Ananth, CV; Burke, WM; Chen, L; Hershman, DL; Hou, JY; Neugut, AI; Richards, CA; Tergas, AI; Wright, JD | 1 |
| Li, BH; Li, HY; Li, YJ; Liu, M; Sun, LL; Ye, ZM; Zhang, J | 1 |
| Dai, K; Dass, CR; Li, H; Ouyang, Z; Qin, A; Xu, J; Zhai, Z | 1 |
| Gui, Q; Li, D; Xia, S; Xu, C; Yu, S; Zhuang, L | 1 |
| Beer, TM; Graff, JN | 1 |
| Body, JJ; Bone, HG; Bracco, OL; Braun, A; Damião, R; de Boer, RH; Fizazi, K; Henry, DH; Ibrahim, T; Kostenuik, PJ; Lipton, A; Saad, F; Shaywitz, AJ; Shore, N; Stopeck, A; Takano, T; Van Poznak, C; Wang, H | 1 |
| Body, JJ; Casimiro, S; Costa, L | 1 |
| Daga, H; Hirashima, T; Miyamoto, N; Morishita, N; Okada, H; Okamoto, N; Otsuka, T; Sasada, S; Shiroyama, T; Suzuki, H; Taira, K; Takeda, K; Tamiya, M; Tokunaga, S | 1 |
| Coleman, R; Efstathiou, E; Fizazi, K; Gartrell, BA; Logothetis, CJ; Saad, F; Sartor, O; Smith, MR; Sonpavde, G | 1 |
| Hayashi, T; Kato, J; Kobune, M; Miyanishi, K; Okagawa, Y; Onuma, H; Osuga, T; Sato, T; Sato, Y; Takimoto, R | 1 |
| Bienz, M; Saad, F | 1 |
| Huang, L; Kumta, SM; Lau, CP; Li, G; Tsui, SK; Wong, KC | 1 |
| Balakumaran, A; Body, JJ; Braun, A; Brown, J; Cleeland, C; Damyanov, D; Egerdie, B; Fallowfield, L; Marx, G; Palazzo, FS; Patrick, DL; Qian, Y; Stopeck, A; von Moos, R; Zhou, Y | 1 |
| Arellano, J; Body, JJ; Braun, A; Brown, JE; Carducci, M; Diel, I; Fizazi, K; Fujiwara, Y; Karsh, L; Kueppers, F; Maniar, T; Martín, M; Paterson, A; Shore, N; Sieber, P; Stopeck, AT; Tonkin, K; Wang, H; Yardley, D | 1 |
| Arai, S; Fukuda, K; Hara, E; Kita, K; Nanjo, S; Nishihara, H; Takeuchi, S; Uehara, H; Yamada, T; Yano, S | 1 |
| Bouvet, M; Hoffman, RM; Hu, C; Matsumoto, Y; Miwa, S; Nakanishi, H; Toneri, M; Yano, S; Zhang, Y; Zhao, M | 1 |
| Cohen, PR | 1 |
| Aoyama, Y; Morii, K; Nakamura, S; Okushin, H | 1 |
| Du, S; Yang, L | 1 |
| Clézardin, P; Gineyts, E; Melodelima, D; Ngo, J; Roux, JP; Tardoski, S | 1 |
| Eaton, CL; Evans, CA; Fowles, A; Holen, I; Nutter, F; Ottewell, PD; Walker, M | 1 |
| Dellis, A; Papatsoris, A | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Bouganim, N; Cella, D; Clemons, M; Dent, S; Dranitsaris, G; Gertler, S; Jacobs, C; Kuchuk, I; Mazzarello, S; Simos, S; Smith, S; Song, X; Vandermeer, L; Verma, S | 1 |
| Jiang, Z; Li, B; Li, H; Li, Y; Sun, L; Ye, Z; Zhang, J | 1 |
| Aapro, M; Albert, US; Bergh, J; Body, JJ; Cameron, D; Clézardin, P; Coleman, RE; Conte, PF; Cortes, J; Costa, L; Di Leo, A; Diel, I; Dodwell, D; Ejlertsen, B; Gnant, M; Gray, R; Hadji, P; Harbeck, N; Holen, I; Kaufmann, M; Markopoulos, C; Martin, M; Powles, TJ; Santini, D; Smith, I; Thurlimann, B; Untch, M; Wilson, C | 1 |
| Balakumaran, A; Braun, A; Brown, JE; Fizazi, K; Henry, DH; Lipton, A; Martin, M; Richardson, GE; Saad, F; Shore, N; Smith, MR; Stopeck, AT; Vadhan-Raj, S; Yardley, DA; Zhou, K | 1 |
| Albiges, L; Burdett, S; Clarke, NW; Fisher, D; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LHM; Sweeney, CJ; Sydes, MR; Tierney, JF; Tombal, B; Vale, CL | 1 |
| Alexeeva, Y; Balakumaran, A; Braun, A; Facon, T; Feng, A; Hungria, V; Raje, N; Roodman, GD; Spencer, A; Stewart, AK; Terpos, E; Vadhan-Raj, S; Willenbacher, W | 1 |
| Banks, RE; Brown, JE; Cairns, DA; Coleman, RE; Hanby, AM; Holen, I; Marshall, H; Ottewell, PD; Peng, J; Selby, PJ; Speirs, V; Westbrook, JA; Wood, SL | 1 |
| Cheng, HL; Hsieh, MJ; Lin, CW; Lu, KH; Yang, JS; Yang, SF | 1 |
| Aoyagi, T; Ichimura, S; Mochizuki, K; Morii, T; Ohnishi, H; Ohtsuka, K; Satomi, K; Tajima, T; Yoshiyama, A | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Fujimoto, M; Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kinoshita, F; Kodaira, M; Shimizu, C; Takahashi, N; Tamura, K; Tanaka, R; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Boychuk, SI; Dedkov, AG; Yugrinova, LG | 1 |
| Higuchi, T; Imamura, M; Miyagawa, Y; Miyoshi, Y; Murase, K; Nishimukai, A; Ozawa, H; Takatsuka, Y; Yanai, A | 1 |
| Braun, A; Draenert, GF; Heymann, PG; Kämmerer, PW; Mandic, R; Neff, A; Saydali, A; Ziebart, T | 1 |
| Brown, JE; Fizazi, K; Henry, D; Lipton, A; Saad, F; Shore, ND; Smith, MR; Spencer, A; Stopeck, AT; Warner, DJ; Zhu, L | 1 |
| Blackwell, K; Brewster, AM; Costelloe, CM; Hood, I; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Mitri, Z; Moulder-Thompson, S; Nanda, R; Rimawi, MF; Van Poznak, C; Wei, C | 1 |
| Byrum, ML; Fan, TM; Fredrickson, RL; Pondenis, HC; Wycislo, KL | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, LJ; Birtle, A; Brown, JE; Chakraborti, P; Collins, S; Daunton, A; Goranitis, I; Hussain, SA; James, ND; McLaren, D; O'Sullivan, JM; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, JM; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Fan, TM; Howes, ME; Lundberg, AP; Roady, PJ; Somrak, AJ | 1 |
| Blohmer, JU; Burchardi, N; Costa, SD; Denkert, C; Dubsky, P; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G; Zahm, DM | 1 |
| Blay, JY; Bompas, E; Bonnet, N; Brisse, H; Brugières, L; Chevance, A; Corradini, N; Entz-Werlé, N; Gentet, JC; Gomez-Brouchet, A; Gouin, F; Guinebretière, JM; Italiano, A; Le Deley, MC; Lervat, C; Marec-Bérard, P; Mascard, E; Pacquement, H; Penel, N; Petit, P; Piperno-Neumann, S; Rédini, F; Tabone, MD | 1 |
| Bonanini, M; Fornaini, C; Giovannacci, I; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P | 1 |
| Giusti, R; Lucchesi, M; Ripamonti, CI | 1 |
| Fujii, Y; Fukui, I; Masuda, H; Uehara, S; Yamamoto, S; Yamasaki, M; Yonese, J; Yuasa, T | 1 |
| Chang, B; Du, SX; Hu, QX; Li, XD; Lin, FX; Xie, D; Yu, GY; Zheng, GZ | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, L; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Goranitis, I; James, N; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Chen, F; Pu, F | 1 |
| Atkinson, C; Attia, J; Christie, D; Denham, JW; Duchesne, G; Holliday, EG; Joseph, D; Lamb, DS; Matthews, JH; Spry, NA; Sridharan, S; Steigler, A; Tai, KH | 1 |
| Ge, K; Han, Y; Li, Z; Sun, W; Zhang, J | 1 |
| Alho, I; Ali, S; Casimiro, S; Costa, L; Faria, M; Ferreira, AR; Leitzel, K; Lipton, A; Matias, M; Shan, N | 1 |
| Deppe, H; Gschwend, JE; Hein, J; Kesting, MR; Mitchell, DA; Mücke, T; Retz, M; Thalgott, M; Wolff, KD | 1 |
| Egawa, S; Fujimoto, K; Kamba, T; Kamoto, T; Kawanishi, H; Kikuchi, T; Maruo, S; Masumori, N; Namiki, S; Narita, S; Ogawa, O; Okada, Y; Saito, H; Sakai, H; Sato, F; Satoh, T; Shimizu, Y; Sugimoto, M; Teishima, J; Terachi, T | 1 |
| Jung, WG; Kim, EH; Kim, MS; Koh, JS; Kong, CB; Lee, KH | 1 |
| Amadori, D; Bongiovanni, A; De Vita, A; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Recine, F; Spadazzi, C | 1 |
| Andreadis, C; Antoniades, K; Kouvelas, D; Kyrgidis, A; Lagoudaki, R; Yavropoulou, MP | 1 |
| Atkins, G; DeNichilo, MO; Evdokiou, A; Findlay, D; Hay, S; Ingman, W; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, A; Zinonos, I; Zysk, A | 1 |
| Pinkawa, M | 1 |
| Foster, JC; Go, RS; Grubbs, SS; Himelstein, AL; Khatcheressian, JL; Loprinzi, CL; Novotny, PJ; O'Connor, T; O'Mara, A; Qin, R; Roberts, JD; Seisler, DK; Shapiro, CL; Velasco, MR; Weckstein, D | 1 |
| Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Guo, XE; Liu, Z; Marturano-Kruik, A; Robinson, ST; Villasante, A; Vunjak-Novakovic, G | 1 |
| Laghezza, A; Lynch, CC; Neuger, AM; Sansil, SS; Shay, G; Soliman, H; Tauro, M; Tortorella, P | 1 |
| Das, M | 1 |
| Chew, H; Dakhil, SR; Gradishar, WJ; Haley, BB; Harker, WG; Hortobagyi, GN; Lipton, A; Mohanlal, R; Sauter, N; Van Poznak, C; Zheng, M | 1 |
| Alibhai, SMH; Emmenegger, U; Finelli, A; Hotte, SJ; Morgan, SC; Walker-Dilks, C; Winquist, E; Zukotynski, K | 1 |
| Agrillo, A; Corsi, A; Riminucci, M; Ungari, C | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Udagawa, H; Umemura, S; Yoh, K | 1 |
| Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R | 1 |
| Dickow, B; Dobson, K; Heilbrun, LK; Lawhorn-Crews, JM; Shields, AF; Smith, D; Tehrani, OS; Vaishampayan, UN | 1 |
| Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF | 1 |
| Joensuu, TK | 1 |
| Al-Nawas, B; Beck, J; Gamm, H; Grötz, KA; Thomas, C; Thüroff, JW; Wagner, W; Walter, C; Zinser, V | 1 |
| Abascal García, JM; Alcover García, J; Barreiro Mouro, A; Búcar Terrades, S; Carballido Rodriguez, J; Cózar Olmo, JM; Gálvez, R; Garcia-Galisteo, E; GómezVeiga, F; González Enguita, C; Jamardo Gonzalez, D; Luque Galvez, P; Medina López, RA; Minguez Martínez, RJ; Regadera Sejas, FJ; Rico Morales, M; Rodriguez Antolin, A; Sanchez Chapado, M; Sánchez Sánchez, E; Tabernero Gómez, AG | 1 |
| Cheng, JC; Wong, YK | 1 |
| Clezardin, P; Coleman, RE; Cross, S; Deux, B; Holen, I; Mönkkönen, H; Ottewell, PD | 1 |
| Asakura, T; Fujinami, K; Goto, A; Jinza, S; Okajima, K; Onuki, T; Senga, Y; Yamashita, Y | 1 |
| Gallego, L; Junquera, L | 1 |
| Ascani, L; Bareggi, C; Brunelli, C; Campa, T; Cislaghi, E; Fagnoni, E; Maniezzo, M; Ripamonti, CI; Saibene, G | 1 |
| Bareggi, C; Bianchi, C; Borgonovo, K; Cobelli, S; Farina, G; Garassino, M; La Verde, N; Mantica, C; Mihali, D; Pedretti, D; Perrone, S; Rizzo, A; Sburlati, P | 1 |
| Namazi, H | 1 |
| Chen, HQ; He, WZ; Li, ZM; Liao, ML; Lu, S; Wang, JJ; Xiang, JQ; Zhang, J; Zhou, XY; Zhou, Z | 1 |
| Arima, S; Hayakawa, K; Hoshinaga, K; Kusaka, M; Maruyama, T; Miyakawa, S; Mori, S; Sasaki, H; Shiroki, R | 1 |
| Barghout, V; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR | 1 |
| Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH | 1 |
| Colombel, M | 2 |
| Kalogeropoulou, C; Kardamakis, D; Vassiliou, V | 1 |
| Baldi, A; Caruso, G; Citro, G; Santini, D; Spugnini, EP; Tonini, G; Vincenzi, B | 1 |
| Chow, E; Ehrlich, L; Hird, AE; Ko, YJ; Probyn, L; Sinclair, E; Yip, D | 1 |
| Fujii, Y; Fukui, I; Kijima, T; Masuda, H; Okubo, Y; Suyama, T; Yamamoto, S; Yonese, J | 1 |
| Ariyoshi, N; Hosoi, A; Kakimi, K; Kondo, M; Nakagawa, K; Nakajima, J; Noguchi, A; Sakuta, K; Sato, K; Sato, S; Shiraishi, K; Yoshida, Y | 1 |
| Bartl, R | 1 |
| Cheng, J; Wu, G; Wu, HG; Xue, J | 1 |
| Antràs, L; Diel, IJ; Duh, MS; Green, J; Köppler, H; Neary, M; Smith, M; Weide, R; Wintfeld, N | 1 |
| Lyseng-Williamson, KA | 1 |
| Frerich, B; Hemprich, A; Kluge, R; Sabri, O; Schulz, T; Steinhoff, K; Wilde, F; Winter, K | 1 |
| Banys, M; Beck, V; Fehm, T; Hairass, M; Krimmel, M; Lipp, HP; Reinert, S; Solomayer, EF; Wallwiener, D | 1 |
| Hanibuchi, M; Ikuta, K; Kakiuchi, S; Muguruma, H; Nishioka, Y; Ogino, H; Sone, S; Uehara, H; Yamada, T; Yano, S | 1 |
| Berruti, A; Brizzi, MP; Dogliotti, L; Gorzegno, G; Porpiglia, F; Priola, AM; Ragni, F; Sculli, CM; Tampellini, M | 1 |
| Costa, L; Major, PP | 1 |
| Rotjanapan, P | 1 |
| Harries, M; Hayday, A; Laggner, U; Lopez, JS; Nestle, FO; O'Doherty, MJ; Perera, G; Sita-Lumsden, A; Warbey, VS | 1 |
| Amir, E; Clemons, M; Fralick, M; Freedman, OC; Hardisty, M; Kumar, R; Whyne, C | 1 |
| Kressley, A; Saif, MW; Smith, A | 1 |
| Amir, E; Clemons, MJ; Dranitsaris, G; Simmons, CE; Trinkaus, M | 1 |
| Balbay, MD; Serefoglu, EC | 1 |
| Berlusconi, M; Biancofiore, G; Giordano, L; Gullo, G; Masci, G; Navarria, P; Santoro, A; Scorsetti, M; Tancioni, F; Zuradelli, M | 1 |
| De Rossi, C; Nitti, D; Pigozzo, J; Rossi, CR; Sileni, VC | 1 |
| Apicelli, AJ; Becker, SN; Deng, H; Eagleton, MC; Floyd, DH; Hirbe, AC; Lanigan, LG; Piwnica-Worms, D; Prior, JL; Roelofs, AJ; Rogers, MJ; Weilbaecher, K; Xu, Z | 1 |
| Coleman, RE | 6 |
| Akmansu, M; Atahan, L; Cengiz, M; Dinçer, M; Engin, K; Gündoğ, M; Haydaroğlu, A; Hayran, M; Kaplan, B; Korcum, AF; Ozkan, M; Sengöz, M; Yazici, G; Yildiz, F | 1 |
| Boutsikou, E; Eleftheriadou, E; Kanakis, I; Karamanos, NK; Kontakiotis, T; Lithoxopoulou, H; Tzanakakis, G; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Cruz, LS; Fonseca, M; Machado, M; Tannus, G | 1 |
| Allen, MR; Burr, DB; Kubek, DJ | 1 |
| Zatkóné Puskás, G | 1 |
| de Klerk, JM; Lam, MG; Zonnenberg, BA | 1 |
| Hirsh, V | 1 |
| Chanda, D; Folks, K; Szafran, AA; Wang, D; Warram, J; Zinn, KR | 1 |
| Campbell-Baird, C; Costa, L; Demers, L; Harvey, H; Kim, C; Lipton, A | 1 |
| Addeo, R; Capasso, E; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Frega, N; Guarrasi, R; Leopardo, D; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Pizza, C; Vincenzi, B | 1 |
| Doggrell, SA | 1 |
| Coleman, RE; Evans, CA; Holen, I; Lefley, DV; Ottewell, PD; Woodward, JK | 1 |
| Tamási, L | 1 |
| Albert, JD; Chalès, G; Duval, H; El Mansouri, L; Guggenbuhl, P; Hajjaj-Hassouni, N; Meadeb, JM | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nishioka, Y; Ogino, H; Otsuka, S; Sone, S; Takahashi, T; Yamada, T; Yano, S | 1 |
| Izumi, K; Konaka, H; Miwa, S; Mizokami, A; Namiki, M; Nohara, T | 1 |
| Anastasilakis, AD; Arsos, G; Barmpalios, G; Efstathiadou, Z; Kita, M; Litsas, I; Makrigiannaki, E; Moralidis, E; Panagiotou, A; Papatheodorou, A; Polyzos, SA; Terpos, E; Triantafillidou, E; Zafeiriadou, E | 1 |
| Hasegawa, Y; Matsubara, A; Mita, K; Ohdan, H | 1 |
| Castellana, MA; Gasparini, G; Longo, R | 1 |
| Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A | 1 |
| Saylor, PJ; Smith, MR | 1 |
| Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
| Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V | 1 |
| Hirsh, V; Langer, C | 1 |
| Baslé, MF; Blouin, S; Chappard, D; Libouban, H; Nyangoga, H | 1 |
| de Marinis, F; Ricciardi, S | 1 |
| Abrahamsson, PA; Miller, K; Saad, F | 1 |
| Berardi, R; Bertoldo, F; Calipari, N; Fratto, ME; Ibrahim, T; Ottaviani, D; Sabbatini, R; Santini, D; Virzi, V | 1 |
| Endo, T; Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H; Takano, M; Yano, M | 1 |
| Divgi, C; Grewal, RK; Hudis, CA; Larson, S; Mak, AF; Modi, S; Morris, PG; Patil, S; Poznak, CV | 1 |
| Grieve, RJ; Hamilton, E; Hickish, T; Houston, S; Percival, F | 1 |
| Bossi, A; Chauchereau, A; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Laplanche, A; Loriot, Y; Massard, C; Rajpar, S; Tournay, E | 1 |
| Habib, EE; Sabry, NA | 1 |
| Subbiah, V | 1 |
| Oreadi, D; Papageorge, MB | 1 |
| Hayashi, M; Iizuka, T; Kawabata, H; Kikuchi, D; Kishi, K; Maruno, H; Okazaki, A; Takeda, Y; Yahagi, N; Yamamoto, S | 1 |
| Boutrus, R; El-Attar, I; El-Hossieny, H; Kader, YA; Nazmy, M; Zaghloul, MS | 1 |
| Aksoy, S; Altundag, K; Arslan, C; Dede, DS; Dizdar, O; Harputluoglu, H | 1 |
| Horvath, L; Nagrial, A | 1 |
| Bamias, A; Dimopoulos, MA; Mavrikakis, M; Mountzios, G; Papadimitriou, C; Papadopoulos, G; Syrigos, K; Terpos, E | 1 |
| Hanamura, M; Iwamoto, T; Okuda, M; Soga, N; Sugimura, Y | 1 |
| Lipton, A; Saad, F | 3 |
| Dai, J; Keller, ET; Keller, JM; Lu, Y; Mizokami, A; Yu, C; Zhang, J | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Costa, L; Lipton, A | 1 |
| Chen, WS; Hu, XY; Jin, C; Li, WD; Ma, L; Zou, QF | 1 |
| Chen, YM; Saad, F; Tchekmedyian, NS | 1 |
| Clézardin, P | 2 |
| Lee, RJ; Saylor, PJ; Smith, MR | 1 |
| Arnold, RM; Weinstein, E | 1 |
| Fujiwara, I; Ichida, M; Matsumoto, M; Mizuta, M; Mizuta, N; Nishiyama, A; Ohashi, M; Sakaguchi, K; Umeda, Y | 1 |
| Brufsky, AM | 1 |
| Eastham, J; Saad, F | 2 |
| Eastham, JA; Saad, F | 1 |
| Hirsh, V; Jahanzeb, M | 1 |
| Ashihara, E; Fushiki, S; Horie, N; Itoi, M; Kimura, S; Koto, K; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Nishigaki, Y; Ryu, K; Sakabe, T; Takeshita, H | 1 |
| Van Poznak, C | 1 |
| López-Carrizosa, MC; Pérez, AR; Samper-Ots, PM | 1 |
| Clézardin, P; Contié, S; Garnero, P; Litvin, J; Voorzanger-Rousselot, N | 1 |
| Athanasou, N; Balke, M; Campanacci, L; Gebert, C; Gibbons, M; Hogendoorn, P; Kroep, J; Picci, P; Taylor, R; Wass, J | 1 |
| Hayashi, N; Hortobagyi, GN; Onishi, T; Theriault, RL; Ueno, NT | 1 |
| Botteman, MF; Chen, YM; Foley, I; Kaura, S; Meijboom, M; Stephens, JM | 1 |
| Fatatis, A; Liu, Q; Russell, MR | 1 |
| Cagli, B; Intagliata, S; Onetti Muda, A; Perrone, G; Persichetti, P; Santini, D; Segreto, F; Tonini, G | 1 |
| Battaglia, S; Corradini, N; Delattre, O; Dumoucel, S; Gouin, F; Heymann, D; Lamoureux, F; Laud, K; Odri, GA; Picarda, G; Redini, F; Rousseau, J; Tirode, F | 1 |
| Aapro, M; Coleman, R; Gnant, M; Hadji, P; Lipton, A | 1 |
| Brown, J; Clark, K; Gregory, W; Hayward, K; Jagdev, S; McParland, L; Newsham, A; Rogerson, S; Selby, P; Woodward, E | 1 |
| Allegra, C; Drane, W; Gibbs, P; Marsh, Rde W; Reith, JD; Scarborough, M; Siddiqui, T; Whittaker, D; Zlotecki, R | 1 |
| Deuber, HJ; Theiss, F | 1 |
| Chen, J; Guo, H; Guo, L; Guo, X; Hu, X; Ragaz, J; Shao, Z; Wang, Z; Wu, J; Xu, X; Zhao, X; Zhu, B; Zhu, J | 1 |
| Ahrens, H; Gosheger, G; Gouin, F; Hardes, J; Henrichs, M; Lanvers-Kaminzky, C; Streitbuerger, A | 1 |
| Bauer, F; Ehrenfeld, M; Hafner, S; Hohlweg-Majert, B; Kolk, A; Kreutzer, K; Mast, G; Otto, S; Pautke, C; Steiner, T; Stürzenbaum, SR; Tischer, T; Weitz, J; Wolff, KD | 1 |
| Battaglia, S; Blanchard, F; Brion, R; Charrier, C; Denis, MG; Heymann, D; Mitrofan, L; Mönkkönen, J; Moriceau, G; Ory, B; Pilet, P; Rédini, F; Riganti, C; Shultz, LD | 1 |
| Altundag, K; Arslan, C; Tonyali, O | 1 |
| Aapro, M; Costa, L; Saad, F | 1 |
| Carrasquillo, J; Grewal, RK; Hudis, C; Larson, S; Morris, PG; Van Poznak, C | 1 |
| Fujimoto, Y; Manabe, J; Orita, Y; Sugitani, I; Toda, K | 1 |
| Body, JJ; Braun, A; Dansey, R; de Boer, RH; Fan, M; Fujiwara, Y; Jiang, Q; Jun, S; Lichinitser, M; Lipton, A; Steger, GG; Stopeck, AT; Tonkin, K; Viniegra, M; Yardley, DA | 1 |
| Guo, A; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR | 2 |
| Missotten, G; Verheezen, Y | 1 |
| Ashcroft, AJ; Bell, SE; Byrne, J; Child, JA; Cocks, K; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Roddie, H; Ross, F; Rudin, C; Szubert, AJ | 1 |
| Rajkumar, SV | 1 |
| Berd, Y; He, W; Jensen, AB; Lombardi, A; Mehta, A; Ramirez, G; Song, Y; Wang, H; Wynne, C | 1 |
| Fan, CP; Guo, A; Liu, J; Lu, M; Sharma, H; Shi, L; Velde, NV; Wu, EQ; Yu, AP | 1 |
| Hadji, P | 1 |
| Albrecht, M; Jung, K; Lein, M; Miller, K; Wirth, M | 1 |
| Dowell, JE; Jean, GW; Keisner, SV; Shah, SR; Ussery, SM | 1 |
| Coleman, R; Cook, R; Hirsh, V; Lipton, A; Major, P | 1 |
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Chen, LK; Hou, X; Huang, Y; Li, S; Liao, H; Liu, JL; Xu, F; Xue, C; Zhang, L; Zhao, HY; Zhao, YY | 1 |
| Jahanzeb, M; Khan, R; Mahtani, R | 1 |
| August, KJ; Dalton, A; George, B; Katzenstein, HM; Olson, TA; Rapkin, LB; Wasilewski-Masker, K | 1 |
| Lipton, A | 8 |
| Costa, L; Dansey, R; Goldwasser, F; Henry, DH; Hirsh, V; Hungria, V; Jiang, Q; Jun, S; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Wang, J; Willenbacher, W; Woll, PJ; Yeh, H | 1 |
| Barlow, WE; Biermann, JS; Bosserman, LD; Geoghegan, C; Hillner, BE; Janjan, NA; Temin, S; Theriault, RL; Van Poznak, CH; Von Roenn, JH; Yee, GC; Zuckerman, DS | 1 |
| van der Pluijm, G | 1 |
| Terpos, E | 1 |
| Berenson, J; Dimopoulos, MA; Terpos, E | 1 |
| Green, JR; Guenther, A | 1 |
| Brown, J; Carducci, M; Damião, R; Dansey, R; Fizazi, K; Goessl, C; Jiang, Q; Karsh, L; Milecki, P; Rader, M; Shore, N; Smith, M; Tadros, S; Wang, H | 1 |
| Aragon-Ching, JB | 1 |
| Taguchi, T | 1 |
| Kamoto, T | 1 |
| Hildreth, BE; Lanigan, LG; Martin, CK; Pillai, SP; Rosol, TJ; Werbeck, JL; Wolfe, TD | 1 |
| Aoyama, M; Hirayama, Y; Ito, Y; Kanamaru, T; Kawamura, M; Nakamura, N; Sonoda, T | 1 |
| Chiu, CF; Lin, PH; Lu, YS | 1 |
| Aapro, MS | 1 |
| Botteman, MF; Carter, JA; Joshi, A; Kaura, S | 1 |
| Bargagli, G; Francini, E; Francini, F; Miano, ST; Pascucci, A; Petrioli, R; Ruggiero, G | 1 |
| Angeli, A; Berruti, A; Bertetto, O; Ciccone, G; Ciuffreda, L; Fusco, V; Galassi, C; Ortega, C | 1 |
| Klatte, T; Kratzik, C; Remzi, M; Sinzinger, H; Waldert, M | 1 |
| D'Alessio, A; Daniele, G; De Luca, A; Gallo, M; Giordano, P; Lamura, L; Maiello, MR; Normanno, N; Pergameno, M; Perrone, F | 1 |
| Kayata, Y; Kikawa, Y; Nakamoto, Y; Ogata, M; Yamamoto, M | 1 |
| Chen, J; Liu, ZY; Zhao, LJ | 1 |
| Itai, S; Izumi, K; Koh, E; Konaka, H; Maeda, Y; Miwa, S; Mizokami, A; Namiki, M; Shigehara, K; Shima, T | 1 |
| Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 2 |
| Chan, J; Hung, TT; Power, CA; Russell, PJ | 1 |
| Lockhart, AC; Sorscher, SM | 1 |
| Ara, T; Blaney, SM; Daldrup-Link, HE; DeClerck, YA; Groshen, SG; Hawkins, R; Jackson, HA; Katzenstein, H; Marachelian, A; Matthay, KK; Park, JR; Russell, HV; Skerjanec, A; Villablanca, JG | 1 |
| Fujitaka, K; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Murai, H; Nagao, S; Ohshimo, S | 1 |
| Furukawa, N; Haruta, S; Kawaguchi, R; Kobayashi, H; Nagai, A; Ooi, H; Shigemitsu, A; Tanase, Y; Yamada, Y; Yoshida, S | 1 |
| Calderone, R; Leary, A; Nimako, K; O'Brien, ME; Popat, S | 1 |
| Battaglia, S; Chesneau, J; Corradini, N; Dumoucel, S; Gouin, F; Heymann, D; Heymann, MF; Picarda, G; Redini, F | 1 |
| Endo, K; Hanaoka, N; Nishisho, T; Takahashi, M; Yasui, N | 1 |
| Feng, X; Fu, D; He, X; Lin, T; Xu, W; Yang, S | 1 |
| Eckardt, A; Gellrich, NC; Kokemüller, H; Lemound, J; Rana, M; Rücker, M; Tavassol, F; von See, C; Voss, PJ | 1 |
| Jacobs, I; Lipton, A | 1 |
| An, X; Cai, XY; Cai, YC; Cao, Y; Jiang, WQ; Jin, Y; Shi, YX; Tan, YT; Xia, Q | 1 |
| Enomoto, A; Hamada, S; Izumoto, T; Nakahara, H; Uchihashi, T | 1 |
| Mulders, P; Saad, F | 1 |
| Gnant, M | 2 |
| Koul, HK; Koul, S; Meacham, RB | 1 |
| Ishiguro, N; Iwase, T; Kishimoto, Y; Koyama, A; Masui, T; Matsuo, H; Yoshida, G | 1 |
| Culine, S; Pouessel, D | 1 |
| Hu, X; Jia, Z; Sun, S; Wang, B; Wang, Z; Xu, X; Zhang, J; Zhang, Q; Zhao, X | 1 |
| Culver, KW; Diener, M; Guo, A; Namjoshi, M; Parikh, K; Wu, EQ; Xie, J; Yu, AP | 1 |
| Haygood, TM; Jonasch, E; Manoukian, GE; Qiao, W; Tannir, NM; Tu, SM | 1 |
| Clézardin, P; Gnant, M | 1 |
| Barrios, CH; Brown, JE; Carrière, P; Daniels, A; Dansey, R; Diel, IJ; Facon, T; Fizazi, K; Henry, DH; Ibrahim, T; Saad, F; Senecal, F; Shore, N; Stemmer, SM; Stopeck, AT; Takahashi, S; Van Poznak, C; Zhou, L | 1 |
| Fujii, A; Fukuuchi, A; Ishizuna, K; Mori, M; Nishi, T; Ota, D; Teraoka, M | 1 |
| Henk, HJ; Kaura, S | 2 |
| Cunio Machado Fonseca, M; Etto, H; Machado, M; Santoni, N; Schiola, A; Tannus Branco de Araújo, G | 1 |
| Li, Z; Peng, H; Xu, Q; Ye, Z | 1 |
| Metcalf, S; Morgan, R; Pandha, HS | 1 |
| Ashida, C; Higashida, A; Kawara, F; Kondo, T; Mamori, S; Okutani, T; Onishi, K; Takeda, A; Yamada, H | 1 |
| Andreadis, D; Epivatianos, A; Markopoulos, A; Mauroudis, S; Poulopoulos, A | 1 |
| Beuzeboc, P; Deray, G; Gligorov, J; Janus, N; Launay-Vacher, V; Le Tourneau, C; Ray-Coquard, I; Spano, JP | 1 |
| Endo, T; Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Naoi, M; Nishimi, D; Suzuki, H; Takano, M; Yano, M | 1 |
| Hayashi, N; Hortobagyi, GN; Liu, J; Niikura, N; Palla, SL; Theriault, RL; Tokuda, Y; Ueno, NT | 1 |
| Chlebowski, RT; Col, N | 1 |
| Kumar, A; Manjappa, AS; Megraj Khandelwal, VK; Mishra, AK; Monkkonen, J; Ramachandra Murthy, RS; Ramanlal Chaudhari, K; Ukawala, M | 1 |
| Choi, YK; Jeong, J; Lee, HD; Lee, KS; Oh, YJ | 1 |
| Brountzos, E; Gouliamos, A; Kouloulias, V; Mystakidou, K; Panagiotou, I | 1 |
| Henk, HJ; Kaura, S; Teitelbaum, A | 1 |
| Addeo, R; Aglietta, M; Badalamenti, G; Barni, S; Berardi, R; Bertolini, F; Calipari, N; Caroti, C; Cascinu, S; Catalano, V; Fabbri, F; Falcone, A; Fratto, ME; Giannicola, R; Giordani, P; Ibrahim, T; Latiano, TP; Maiello, E; Masini, C; Mazzara, C; Ortega, C; Ottaviani, D; Ottone, A; Petrelli, F; Salvatore, L; Santini, D; Silvestris, N; Tampellini, M; Tonini, G; Venditti, O; Vincenzi, B; Virzi, V | 1 |
| Ho, JW; Sundar, S | 1 |
| Arora, B; Arun Kurkure, P; Jalali, R; Medhi, S; Rangarajan, V; Sondhi, V; Sridhar, E | 1 |
| Becker, S; Fehm, T; Gebauer, G; Hirnle, P; Huober, J; Janni, W; Krämer, B; Lück, HJ; Solomayer, EF; Wackwitz, B; Wallwiener, D | 1 |
| Chung, K; Cong, Z; Danese, M; Dansey, R; Halperin, M; Henry, D; Qian, Y; Rader, M; Stopeck, A | 1 |
| Fujinami, K; Ikeda, I; Iwasaki, A; Kubota, Y; Noguchi, K; Noguchi, S; Uemura, H; Yanagisawa, M | 1 |
| Furukawa, K; Hosaka, M; Ishida, J; Matsushima, Y; Saito, M | 1 |
| Gross-Goupil, M; Pasticier, G; Ravaud, A; Roca, S | 1 |
| Berruti, A; Buttigliero, C; Coleman, RE; Cook, R; Lee, KA; Lipton, A; Saad, F; Smith, MR; Tampellini, M | 1 |
| Autio, KA; Morris, MJ; Scher, HI | 1 |
| Henk, H; Kaura, S; Teitelbaum, A | 1 |
| Botteman, MF; Carter, JA | 1 |
| Chen, YM; Costa, L; Hadji, P; Kosmidis, P; Lipton, A | 1 |
| Botteman, MF; Carter, JA; Kaura, S; Snedecor, SJ | 2 |
| Burke, N; Goeree, R; Hopkins, R; Tarride, JE; Xie, F | 1 |
| Eastham, J; Saad, F; Segal, S | 1 |
| Diener, M; Namjoshi, M; Sorg, R; Wu, EQ; Xie, J | 1 |
| Birkholz, K; Gruenwald, V; Kindler, M; May, C; Miller, K; Ruebel, A; Schultze-Seemann, W; Schulze, M; Stenzl, A; Strauss, A; Tunn, UW; Wirth, MP; Zantl, N | 1 |
| Chen, AH; Tu, SM | 1 |
| Abe, M; Shinohara, N; Takahashi, S; Takeda, K; Tokuhashi, Y | 1 |
| Hirschberg, R | 1 |
| Albert, I; Barbera, S; de Marinis, F; Engel-Riedel, W; Kosmidis, P; Kuo, HP; Manegold, C; Perez, JR; Sallo, V; Scagliotti, GV; Schallier, D; Schreurs, AJM | 1 |
| Clezardin, P; Coleman, R; Gnant, M; Morgan, G | 1 |
| Gődény, M; Láng, I; Nagy, T; Rubovszky, G; Szász, A | 1 |
| Sun, L; Yu, S | 1 |
| Chiba, Y; Fujiwara, K; Kawaguchi, A; Morita, T; Nakao, M; Nishida, S; Tsubaki, M; Yamazoe, Y; Yanae, M | 1 |
| Ben Rhouma, S; Benrais, N; Cherif, K; Horchani, A; Sallami, S | 1 |
| Arao, T; Mori, H; Okada, Y; Tanaka, Y; Torimoto, K | 1 |
| Chung, K; Cleeland, CS; Fallowfield, LJ; Feng, A; Goldwasser, F; Henry, DH; Hungria, V; Novello, S; Patrick, DL; Qian, Y; Vadhan-Raj, S; von Moos, R; Yeh, H | 1 |
| Cheng, RL; Li, ZX; Sun, LL; Sun, ZW; Ye, ZM | 1 |
| Canuto, RA; Carossa, S; Maggiora, M; Martinasso, G; Mozzati, M; Muzio, G; Oraldi, M; Scoletta, M; Zambelli, M | 1 |
| Bishr, M; Saad, F | 1 |
| Bell, R; Bourgeois, H; Braun, A; Brufsky, A; Chung, K; Dansey, R; Diel, I; Eniu, A; Fallowfield, L; Fan, M; Fujiwara, Y; Jassem, J; Jiang, Q; Martin, M; Paterson, AH; Ritchie, D; Steger, GG; Stopeck, A; Vogel, C | 1 |
| Lopez-Olivo, MA; Peddi, P; Pratt, GF; Suarez-Almazor, ME | 1 |
| Kagamu, H; Miura, S; Saijyo, Y | 1 |
| Boikos, SA; Hammers, HJ | 1 |
| Body, JJ; Braun, A; Chung, K; Cleeland, CS; Clemons, M; Dansey, R; de Boer, R; Fallowfield, L; Jiang, Q; Lipton, A; Masuda, N; Mathias, SD; Oliveira, CT; Patrick, DL; Qian, Y; Salvagni, S; Stopeck, A; Tonkin, K; von Moos, R | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Lipton, A | 1 |
| Fujii, Y; Fukui, I; Kitsukawa, S; Takahashi, S; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J; Yuasa, T | 1 |
| Beuzeboc, P; Bilynskyy, B; Braun, A; Brown, JE; Charu, V; Clemens, M; Fizazi, K; Henry, DH; Jun, S; Ke, C; Lipton, A; Maroto, P; Rader, M; Richardson, GE; Saad, F; Siena, S; Stopeck, AT; Viniegra, M; Yardley, DA | 1 |
| Caraglia, M; Castellano, M; De Cicco, F; Leonetti, C; Misso, G; Porru, M; Santini, D; Stoppacciaro, A | 1 |
| Goto, K; Kubota, K; Niho, S; Ohe, Y; Ohmatsu, H; Yoh, K | 1 |
| Hashimoto, T; Kaise, H; Kohno, N; Koizumi, K; Okamoto, J; Tokuuye, K; Uchida, K; Yamada, K; Yoshimura, M | 1 |
| Houts, AC; Miller, PJ; Namjoshi, M; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Carducci, MA; Paller, CJ; Philips, GK | 1 |
| Hiraga, H; Isu, K; Kamata, H; Minami, A; Shinohara, N; Takeda, N | 1 |
| De La Cueva, L; Liévano, P; López Vélez, L; Navarro, P; Rodríguez Chacón, L; Sanz Moncasi, P | 1 |
| Smith, MR | 3 |
| Penson, DF; Resnick, MJ | 1 |
| Morgans, AK; Smith, MR | 1 |
| Barney, RB; Biskupiak, JE; Brandt, P; Gaffney, DK; Namjoshi, M; Nickman, NA; Young, J | 1 |
| Tao, H; Wang, M; Wang, Y; Wang, Z; Yu, X | 1 |
| Balakumaran, A; Ciuleanu, TE; García-Sáenz, JA; Henry, DH; Hirsh, V; Jacobs, I; Kanarev, V; Krzakowski, M; Lipton, L; Manegold, C; Mehta, ND; Pereira, JR; Prabhash, K; Rodriguez, G; Scagliotti, GV; Siena, S; Solal-Celigny, P; Wang, H; Woll, PJ | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Armstrong, AJ; Fizazi, K; Freedland, S; Pienta, K; Saad, F; Saylor, PJ; Smith, MR; Tombal, B | 1 |
| Feng, JY; Wang, SJ; Wu, CQ; Zhang, P; Zheng, XH | 1 |
| Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M | 1 |
| Gomez-Veiga, F; Martinez-Breijo, S; Morote, J; Planas, J; Ponce-Reixa, J | 1 |
| Collins, LI; Davis, JL; Faccio, R; Mach, RH; Novack, DV; Piwnica-Worms, D; Su, X; Vangveravong, S; Vora, P; Weilbaecher, KN; Yang, C; Zeng, R | 1 |
| Huang, B; Li, CL; Liang, R; Pan, LH; Qian, W; Zheng, WW; Zhong, JH; Zhu, M | 1 |
| Arai, E; Futamura, N; Ishiguro, N; Kozawa, E; Nishida, Y; Urakawa, H | 1 |
| Li, Z; Sun, L; Tang, J; Ye, Z | 1 |
| Bastit, L; El Kouri, C; Guérif, S; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X; Slimane, K | 1 |
| Garrett, Z; Jilani, A; Stevens, A; Sutcliffe, F | 1 |
| Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M | 1 |
| Datta, HK; Hanusch, B; Tuck, SP; Walker, J | 1 |
| Dedes, PG; Gialeli, Ch; Kanakis, I; Karamanos, NK; Kletsas, D; Theocharis, AD; Tsegenidis, T; Tzanakakis, GN | 1 |
| Hortobagyi, GN | 3 |
| Davies, M; Gates, J; Jo, M; Lee, YP; Lieberman, JR; Schwarz, EM; Wu, J; Zhang, X | 1 |
| Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ | 1 |
| Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA | 1 |
| Berenson, J; Chen, T; Deckert, F; Gilchick, A; Goodin, S; LoRusso, P; Ma, P; Ravera, C; Schran, H; Seaman, J; Skerjanec, A; Swift, R; Vescio, R | 1 |
| Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M | 1 |
| Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K | 1 |
| Brown, LG; Corey, E; Higano, CS; Poot, M; Quinn, JE; Roudier, MP; Vessella, RL | 1 |
| Goa, KL; Wellington, K | 1 |
| Cook, R; Major, PP | 1 |
| Harland, SJ; Oosterlinck, W; Rosen, L | 1 |
| Benson, MC; Gilbert, SM; McKiernan, JM; Olsson, CA | 1 |
| Green, JR | 2 |
| Rosen, LS | 1 |
| Rosenthal, M | 1 |
| Angeli, A; Berruti, A; Dogliotti, L; Scarpa, RM; Terrone, C; Tucci, M | 1 |
| Atkins, CD | 1 |
| Gaines, KK | 1 |
| Berenson, J; Hsu, C; Major, P; Miller, WH; Ravera, C; Schran, H; Seaman, J; Skerjanec, A; Waldmeier, F | 1 |
| Kirby, RS | 1 |
| Ashcroft, AJ; Davies, FE; Morgan, GJ | 1 |
| Bigos, ST | 1 |
| Khan, MA | 1 |
| Booth, B; Chen, G; Gobburu, JV; Hsieh, Y; Ibrahim, A; Leighton, J; Li, N; Pazdur, R; Rahman, A; Scher, N; Sridhara, R; Vause, D; Williams, G; Wood, R | 1 |
| Lin, SH; Logothetis, C; Tu, SM | 1 |
| Altomare, V; Avvisati, G; Battistoni, F; Bonsignori, M; Dicuonzo, G; Gavasci, M; Massacesi, C; Rocci, L; Santini, D; Tirindelli, MC; Tocchini, M; Tonini, G; Vincenzi, B | 1 |
| Baldi, A; Santini, D; Scarpa, S; Tonini, G; Vincenzi, B | 1 |
| de Souza, P; Gordon, D; Hirsh, V; Krzakowski, M; Pawlicki, M; Reitsma, D; Rosen, LS; Seaman, JJ; Tchekmedyian, S; Urbanowitz, G; Yanagihara, R; Zheng, M | 1 |
| Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Lipton, A; Seaman, J; Zheng, M | 1 |
| Heidenreich, A | 1 |
| Bankhead, C | 1 |
| Dearnaley, DP; Mason, MD; Moffat, LE; Naylor, SL; Parmar, MK; Powell, CS; Robinson, AC; Stott, M; Sydes, MR; Thompson, PM | 1 |
| Bouralexis, S; Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A | 1 |
| Coleman, RE; Neville-Webbe, Hl | 1 |
| Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ | 1 |
| Csermak, K; Tarassoff, P | 1 |
| Hohneker, J; Lacerna, L | 1 |
| Avvisati, G; Battistoni, F; Borzomati, D; Coppola, R; Dicuonzo, G; Gavasci, M; Rocci, L; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Cameron, D | 1 |
| Coleman, R; Croucher, P; Jagdev, S | 1 |
| Saad, F; Schulman, CC | 1 |
| Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J | 1 |
| Davis, LE; Li, EC | 1 |
| Berenson, JR | 4 |
| Castel, LD; Glendenning, GA; Li, Y; Schulman, KA; Timbie, JW; Weinfurt, KP | 1 |
| Colston, KW; Coxon, JP; Kirby, RS; Oades, GM | 1 |
| Glendenning, GA; Radeva, JI; Reed, SD; Saad, F; Schulman, KA | 1 |
| Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Xu, JK; Zheng, MH | 1 |
| Maung, K | 1 |
| Breen, TL; Shane, E | 1 |
| Price, N | 2 |
| Chern, B; Copeman, M; De Abreu Lourenco, R; Joseph, D; Joshua, D; Lowe, S; Lynch, K; Pittman, K; Richardson, G; Schou, M | 1 |
| La Cesa, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Figgitt, DP; Perry, CM | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Berenson, J; Hirschberg, R | 1 |
| Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ; Zheng, M | 1 |
| De Souza, P; Gordon, D; Hirsh, V; Krzakowski, M; Pawlicki, M; Reitsma, D; Rosen, LS; Seaman, J; Tchekmedyian, NS; Urbanowitz, G; Yanagihara, R; Zheng, M | 1 |
| Hiraga, T; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Berry, S; Winquist, E | 1 |
| Brown, MD; Clarke, NW; George, NJ; Hart, CA; Montague, R; Ramani, VA | 1 |
| Abbou, CC; Allory, Y; Chopin, D; de la Taille, A; Hoznek, A; Paule, B; Salomon, L; Vacherot, F; Vordos, D; Yiou, R | 1 |
| Blaine, TA; Chang, SS; Doppelt, JD; Jung, KM; Kim, TW; Lee, FY; Suratwala, SJ; Winchester, RJ; Zhang, HZ | 1 |
| Andreadis, C; Charalampidou, M; Chouchos, N; Diamantopoulos, N; Mouratidou, D | 1 |
| Bukowski, RM; Colombo-Berra, A; Lipton, A; Rosen, L; Urbanowitz, G; Zheng, M | 1 |
| Parker, CC | 2 |
| Michaelson, MD; Rosenthal, DI; Smith, MR | 1 |
| Coleman, R; Conte, P | 1 |
| Tanvetyanon, T | 2 |
| Hei, YJ; Hirsh, V; Rosen, LS; Tchekmedyian, NS; Zheng, M | 1 |
| Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH | 1 |
| Bergner, R; Diel, IJ | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Smith, M; Zheng, M | 1 |
| Karakiewicz, P; Perrotte, P; Saad, F | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Altundag, K; Altundag, O; Gunduz, M; Morandi, P | 1 |
| Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA | 1 |
| Grenader, T; Peretz, T; Shavit, L; Uziely, B | 1 |
| Harvey, HA | 1 |
| Aogi, K; Asaga, T; Goessl, C; Iino, Y; Kohno, N; Minami, H; Nakamura, S; Ohashi, Y; Takashima, S; Watanabe, T | 1 |
| Hines, E; Tanvetyanon, T | 1 |
| Battistoni, F; Dicuonzo, G; Gasparro, S; Gavasci, M; Grilli, C; La Cesa, A; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzì, V | 1 |
| Khuri, F; Saba, N | 2 |
| Brahmbhatt, V; Patel, K; Ramu, V | 1 |
| Rexer, H | 1 |
| Gralow, J | 1 |
| Langer, CJ | 1 |
| Parles, K | 1 |
| Balla, J | 1 |
| Lugassy, G | 1 |
| Bilhartz, DL; Cook, R; Gittelman, MC; Goessl, C; Hei, YJ; Higano, CS; Hussain, A; Kabbinavar, F; Linnartz, R; Murray, R; Saad, F; Schulman, C; Small, EJ; Smith, MR; Wynne, C; Zheng, M; Zinner, NR | 1 |
| Fan, D; Fidler, IJ; He, J; Kim, SJ; Langley, RR; Mathew, P; Uehara, H; Yazici, S | 1 |
| Barrett-Lee, P; Cameron, D; Davidson, N; Dodwell, D; Hong, A; Mansi, J; Mason, T; Murphy, R; Wardley, A | 1 |
| Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP | 2 |
| Galanos, A; Katsouda, E; Kelekis, A; Mystakidou, K; Parpa, E; Vlahos, L | 1 |
| Schwartz, JE | 1 |
| Brown, JE; Coleman, RE; Cook, R; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Seaman, J; Smith, M; Zheng, M | 1 |
| Bagan, JV; Jimenez-Soriano, Y | 1 |
| Brown, LG; Corey, E; Keller, ET; Quinn, JE; Vessella, RL; Zhang, J | 1 |
| Arena, G; Bertelli, G; Botto, A; Colantonio, I; Fea, E; Garrone, O; Giubergia, S; Heouaine, A; Merlano, M; Occelli, M | 1 |
| Gordon, DH | 1 |
| Higano, CS | 2 |
| Dunleavy, R; Liauw, W; Lih, A; Links, M; Segelov, E; Ward, R | 1 |
| Alimonti, A; Bordignon, V; Carlini, P; Cognetti, F; Cordiali Fei, P; D'Agosto, G; Di Cocco, B; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Papaldo, P; Salesi, N; Trento, E | 1 |
| Duan, X; Guan, H; Kleinerman, ES; Zhou, Z | 1 |
| Harmenberg, U; Hjelm-Eriksson, M; Kälkner, KM; Lennartsson, L; Lennernäs, B; Nilsson, S; Ullén, A | 1 |
| Cormio, G; Cuccovillo, A; Fattizzi, N; Loizzi, V; Selvaggi, L | 1 |
| Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P | 1 |
| Katsouda, E; Mystakidou, K; Parpa, E; Vlahos, L | 1 |
| Broumand, V; Fortin, M; Marx, RE; Sawatari, Y | 1 |
| Conti, G | 1 |
| Gouin, F; Heymann, D; Heymann, MF; Kamijo, A; Ory, B; Redini, F | 1 |
| Barkley, CS; Bilhartz, DL; Given, RW; Julian, SR; Karlin, GS; Lacerna, LV; McWhorter, LT; Metzger, C; Polascik, TJ; Vestal, JC | 1 |
| Nagy, Z | 1 |
| Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E | 1 |
| Arcara, C; Badalamenti, G; Casuccio, A; Cicero, G; Di Fede, G; Fulfaro, F; Gebbia, N; Intrivici, C; Leto, G; Rini, GB; Russo, A; Valerio, MR; Vitale, A | 1 |
| Cai, W; Gao, YJ; Li, PW; Liu, B; Mao, GG; Wang, SJ; Zhang, G; Zhang, Y; Zhou, YF | 1 |
| Brown, LG; Brubaker, KD; Corey, E; Vessella, RL | 1 |
| Klain, M; Liuzzi, R; Marinelli, A; Molino, L; Pace, L; Paone, G; Salvatore, M; Soricelli, A; Storto, G | 1 |
| Figg, WD; Macpherson, GR; Price, DK; Schimel, D; Singh, AS | 1 |
| Cornford, P; Manikandan, R; Mistry, R; Philip, J | 1 |
| Inoue, K; Iwase, H; Kawazoe, T; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yamamoto, Y; Yoshida, Y | 1 |
| Anstrom, KJ; Castel, LD; Saad, F; Schulman, KA; Weinfurt, KP | 1 |
| Ciccarelli, R; Fedele, S; Lo Muzio, L; Lo Russo, L; Mignogna, MD | 1 |
| Kaise, H; Kohno, N | 1 |
| Angeletti, S; Brown, JE; Budillon, A; Caraglia, M; Coleman, RE; Dicuonzo, G; Hannon, RA; Holen, I; La Cesa, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Arrich, F; Berger, W; Elbling, L; Heffeter, P; Kotz, R; Kubista, B; Micksche, M; Scotlandi, K; Sevelda, F; Sutterlüty, H; Toma, C; Trieb, K | 1 |
| Budman, DR; Calabro, A | 1 |
| Djokic, M | 1 |
| Dimitrakopoulos, I; Karakasis, D; Magopoulos, C | 1 |
| Iguchi, H; Levine, AL; Nadella, MV; Rosol, TJ; Tannehill-Gregg, SH | 1 |
| Colombel, M; Higano, CS; Mason, MD; Murray, R; Saad, F; Sartor, O; Schulman, C; Tubaro, A | 1 |
| Chamorey, E; Ciais, C; Ferrero, JM; Italiano, A; Largillier, R; Marcy, PY; Thyss, A | 1 |
| Brown, J; Coleman, R; Cook, RJ; Hei, YJ; Lipton, A; Major, P; Saad, F; Smith, MR | 2 |
| Elting, LS; Migliorati, CA; Siegel, MA | 1 |
| Budillon, A; Caraglia, M; Holen, I; Santini, D; Scarpa, S; Tonini, G; Vincenzi, B | 1 |
| Do, KA; Jonasch, E; Lin, P; Lin, SH; Mathew, P; Pagliaro, LC; Rhines, L; Siefker-Radtke, A; Tannir, N; Tibbs, R; Tu, SM | 1 |
| Biasotto, M; Cavalli, F; Chiandussi, S; Cova, MA; Di Lenarda, R; Dore, F | 1 |
| Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR | 1 |
| Acevedo, AC; Cavalcanti, MG; Figueiredo, PT; Guerra, EN; Leite, AF; Melo, NS; Paula, AP; Paula, LM | 1 |
| Kawashima, H; Kuratsukuri, K; Nakatani, T; Sugimura, K; Tanaka, T | 1 |
| Cauthen, LA; Davidoff, AM; Dickson, PV; Hamner, JB; McCarville, MB; Ng, CY | 1 |
| Barrick, M | 1 |
| Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G | 1 |
| Battaglia, S; Blanchard, F; Gouin, F; Heymann, D; Ory, B; Rédini, F | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA | 1 |
| Furlow, B | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Quintero Pérez, S | 1 |
| Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E | 1 |
| Agazzi, A; D'Orto, O; Derada Troletti, G; Diego, R; Fontanella, W; Marzano, U; Pagani, D; Pignataro, L | 1 |
| Igawa, M; Kikuno, N; Nakamura, S; Shiina, H; Urakami, S | 1 |
| Sakurai, T | 1 |
| Iguchi, H | 1 |
| Fratto, ME; Galluzzo, S; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Tombal, B | 1 |
| Fushiki, S; Horie, N; Kimura, S; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Sakabe, T; Takeshita, H | 1 |
| Adamus, AT; Sherer, JT | 1 |
| Anstrom, KJ; Castel, LD; DePuy, V; Saad, F; Schulman, KA; Weinfurt, KP | 1 |
| Antràs, L; Daskivich, T; Duh, MS; Evan, C; Nakabayashi, M; Neary, MP; Oh, WK; Proctor, K; Smith, M; Tormey, LK | 1 |
| Clézardin, P; Daubiné, F; Gasser, J; Green, J; Le Gall, C | 1 |
| Eickenberg, HU; Haus, U; Jung, K; Lein, M; Loening, SA; Meissner, S; Miller, K; Schmidt, K; Stephan, C; Weissbach, L; Wirth, M | 1 |
| Brunelli, C; Campa, T; De Conno, F; Fagnoni, E; Giardina, V; Pigni, A; Ripamonti, C | 1 |
| Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G | 1 |
| Cook, RJ; Lee, KA; Li, H | 1 |
| Duivenvoorden, WC; Kalina, M; Seidlitz, E; Singh, G; Vukmirović-Popović, S | 1 |
| Bergström, B; Body, JJ; Garnero, P; Lichinitser, M; Tjulandin, S | 1 |
| Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S | 1 |
| Fantini, M; Nicoletti, S; Poggi, B; Possenti, C; Sartori, S; Tamburini, E; Tassinari, D | 1 |
| Bylow, K; Demers, LM; Henderson, TO; Huo, D; Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Barrett-Lee, P; Bloomfield, D; Dougherty, L; Harries, M; Laing, R; Patel, H; Walker, M | 1 |
| Berenson, JR; Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR; Terpos, E | 1 |
| Aglietta, M; Faggiuolo, R; Gilardino, MO; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R | 1 |
| Bertelli, G; Jones, RM; Leonard, RC; Lewis, PD; Morgan, C; Thomas, GA | 1 |
| Fratto, E; Galluzzo, S; Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Nakabayashi, C; Nakanishi, M; Saito, K; Saya, H | 1 |
| Berman, AW; Brahim, JS; Denduluri, N; Goldman, ML; Guadagnini, JP; Kleiner, DE; Sausville, R; Swain, SM | 1 |
| Angeletti, S; Battistoni, F; Caraglia, M; Dicuonzo, G; Galluzzo, S; Rocci, L; Santini, D; Schiavon, G; Tonini, G; Uzzalli, F; Venditti, O; Vincenzi, B | 1 |
| Ashihara, E; Habuchi, T; Kimura, S; Maekawa, T; Yuasa, T | 1 |
| Addeo, R; Capasso, E; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Ferraro, G; Guarrasi, R; Montella, L; Nocera, V; Rossi, E; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Eagleton, MC; Hirbe, AC; Morgan, EA; Piwnica-Worms, D; Prior, JL; Rubin, J; Uluçkan, O; Weilbaecher, KN | 1 |
| Crescimanno, M; Flandina, C; Leto, G; Tumminello, FM | 1 |
| Kouvaris, C; Mouzopoulos, D; Mouzopoulos, G; Stamatakos, M; Tzurbakis, M | 1 |
| Díaz Rubio, E; García Paredes, B; García Sáenz, JA; López Tarruella, S; Rodríguez Lajusticia, L; Villalobos, L | 1 |
| Kinnane, N | 1 |
| Maxwell, C | 1 |
| Major, P | 1 |
| Fitch, MI | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC | 1 |
| Bellomi, M; Bruschini, R; Cossu Rocca, M; Goldhirsch, A; Nole, F; Preda, L; Sanna, G; Verri, E | 1 |
| Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S | 1 |
| DeClerck, YA; Groshen, SG; Moats, RA; Nelson, MD; Peng, H; Reynolds, CP; Sohara, Y; Ye, W | 1 |
| Dell'aia, P; Grasso, RF; Leoncini, E; Piciucchi, S; Quattrocchi, CC; Santini, D; Tonini, G; Vincenzi, B; Zobel, BB | 1 |
| Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR | 1 |
| Chen, YM; Chin, J; Gleason, DM; Saad, F | 1 |
| Arlen, PM; Dahut, WL; Gulley, JL; Wu, S | 1 |
| Battaglia, S; Duteille, F; Gouin, F; Heymann, D; Heymann, MF; Lamoureux, F; Ory, B; Pilet, P; Redini, F | 1 |
| Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH | 1 |
| Budillon, A; Caraglia, M; Facchini, G; Fiore, F; Iaffaioli, RV; Maiolino, P; Nasti, G; Ottaiano, A; Ruberto, M; Santini, D; Striano, S; Tonini, G; Zeppetella, GL | 1 |
| Dahmane, A; de Klerk, JM; Lam, MG; Stevens, WH; van Rijk, PP; Zonnenberg, BA | 1 |
| Ahn, H; Cho, HY; Cho, KS; Chung, BH; Hong, SJ; Kim, CS | 1 |
| Kohno, N; Yamada, K | 1 |
| Miki, T; Okihara, K | 1 |
| Newman, SA; Phillips, PM | 1 |
| Aksoy, S; Altundag, K; Cengiz, M; Dincer, M; Gullu, I; Harputluoglu, H | 1 |
| Nishizawa, S; Sawada, Y; Yamauchi, T | 1 |
| Camlica, H; Duranyildiz, D; Oguz, H; Tas, F; Topuz, E; Yasasever, V | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| McKeage, K; Plosker, GL | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Hirsh, V; Langer, CJ; Lipton, A; Major, PP; Smith, MR | 1 |
| Dhillon, S; Lyseng-Williamson, KA | 1 |
| Beith, JM; Moore, MM | 1 |
| Corey, E; Gross, TS; Morgan, TM; Pitts, TE; Poliachik, SL; Vessella, RL | 1 |
| Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H | 1 |
| Baldini, E; Barni, S; Berto, P; Cortesi, E; Dauria, G; Schivazappa, C | 1 |
| Badia, X; Chow, E; Costa, L; Lipton, A; Wardley, A | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Andrada, E; Cánovas, V; Carrato, A; Guillén-Ponce, C; Guirado-Risueño, M; Martín Hidalgo, A; Molina, MA; Molina, MJ; Molina-Garrido, MJ; Mora, A; Pastor, E | 1 |
| Moore, S; Reilly, MM | 1 |
| De Zorzi, Pde M; Lovat, CP; Reiriz, AB | 1 |
| Brown, JE; Coleman, RE; Cook, R; Garnero, P; Lipton, A; Major, P; Saad, F; Terpos, E | 1 |
| Badalamenti, G; D'Amico, C; Fulfaro, F; Incorvaia, L; Leto, G; Tumminello, FM | 1 |
| Fernandez, SA; Martin, CK; Nadella, MV; Pinzone, JJ; Rosol, TJ; Thudi, NK; Werbeck, JL | 1 |
| Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J | 1 |
| Andreu, FJ; Calvo, F; Casas, F; Ciria, JP; Contreras, J; de las Heras, M; Esco, R; Fuertes, J; López, C; Mañas, A; Márquez, M; Martín, C; Martínez, JC; Palacios, A; Pérez, L; Porto, C; Ramos, A; Romero, J; Sáez, J; Sánchez, E; Vayreda, J; Veiras, C; Victoria, C | 1 |
| Aguggini, S; Allevi, G; Angeli, A; Berruti, A; Bonardi, S; Bottini, A; Dogliotti, L; Dovio, A; Generali, D; Harris, AL; Milani, M; Tampellini, M; Tedoldi, S; Torta, M; Tucci, M | 1 |
| Delmas, PD; Lipton, A | 1 |
| Delmas, PD | 1 |
| Ziegler, J | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Possinger, K | 1 |
| Berenson, JR; Conde, F; Henick, K; Nishikubo, C; Rettig, M; Swift, RA; Vescio, R; Von Teichert, JM | 1 |
| Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ | 1 |
| Berenson, JR; Givant, E; Harvey, H; Hupkes, M; Lipton, A; Rosen, LS; Savage, A; Swift, R; Vescio, RA; VonTeichert, JM; Woo, M | 1 |
| Coleman, RE; Seaman, JJ | 1 |
| Coleman, RE; Major, PP | 1 |
| Hiraga, T; Mundy, GR; Yoneda, T | 1 |
| Fleisch, H | 1 |
| Ali, SM; Costa, L; Esteva, FJ; Harvey, H; Hortobagyi, G; Knight, R; Lipton, A; Seaman, J | 1 |
| Bajwa, K; DesHarnais Castel, L; Markle, JP; Schulman, KA; Timbie, JW; Zacker, C | 1 |
| Clézardin, P; Delmas, P; Pécheur, I; Peyruchaud, O; Serre, CM; Winding, B | 1 |
| Mykała-Cieśla, J; Stajszczyk, M | 1 |
| Heatley, S | 1 |
217 review(s) available for zoledronic acid and Bone Cancer
| Article | Year |
|---|---|
Dosimetry of Bone Seeking Beta Emitters for Bone Pain Palliation Metastases.
Topics: Bone and Bones; Bone Neoplasms; Humans; Lutetium; Pain; Radiopharmaceuticals; Rhenium; Tissue Distribution; Zoledronic Acid | 2022 |
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2022 |
Updated concepts in treatment of giant cell tumor of bone.
Topics: B7-H1 Antigen; Bone Cements; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Giant Cell Tumor of Bone; Humans; Randomized Controlled Trials as Topic; Zoledronic Acid | 2022 |
Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials.
Topics: Bone Neoplasms; Hormones; Humans; Male; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2022 |
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Female; Femoral Fractures; Humans; Incidence; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2019 |
Current concepts in the treatment of giant cell tumour of bone.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Giant Cell Tumor of Bone; Humans; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Zoledronic Acid | 2020 |
New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Osteosarcoma; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2020 |
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Multiple Myeloma; Randomized Controlled Trials as Topic; Zoledronic Acid | 2020 |
Bisphosphonates and breast cancer - From cautious palliation to saving lives.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Quality of Life; Tumor Microenvironment; Zoledronic Acid | 2020 |
Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2021 |
Comprehensive treatment for multicentric giant cell tumors of the pelvis and spine using apatinib: A case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Giant Cell Tumor of Bone; Humans; Pelvic Neoplasms; Pyridines; Spinal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2020 |
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Topics: Animals; Bone Neoplasms; Cell Differentiation; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Osteoclasts; Reactive Oxygen Species; Signal Transduction; Zoledronic Acid | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Adverse events associated with bone-directed therapies in patients with cancer.
Topics: Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Pamidronate; Zoledronic Acid | 2022 |
"The use of bisphosphonates to treat skeletal complications in solid tumours".
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Male; Quality of Life; Zoledronic Acid | 2021 |
Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Ibandronic Acid; Lung Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2021 |
Bone-modifying Agents (BMAs) in Breast Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2021 |
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Multiple Myeloma; Plasmacytoma; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2021 |
Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Humans; Radiopharmaceuticals; Radium; Zoledronic Acid | 2021 |
The Roadmap of RANKL/RANK Pathway in Cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Denosumab; Drug Repositioning; Female; Humans; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Zoledronic Acid | 2021 |
The role of bone-targeted therapies for prostate cancer in 2017.
Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Osteoclasts; RANK Ligand; Treatment Outcome; Zoledronic Acid | 2018 |
Therapeutic approaches for protecting bone health in patients with breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Practice Guidelines as Topic; Spinal Cord Compression; Zoledronic Acid | 2018 |
Bisphosphonates and other bone agents for breast cancer.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Topics: Abiraterone Acetate; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Taxoids; Zoledronic Acid | 2018 |
Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Health Care Costs; Humans; Pamidronate; Zoledronic Acid | 2019 |
Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options.
Topics: Bone Cements; Bone Density Conservation Agents; Bone Neoplasms; Bone Transplantation; Curettage; Denosumab; Giant Cell Tumor of Bone; Humans; Tibia; Zoledronic Acid | 2019 |
Zoledronic acid for the treatment of prostate cancer.
Topics: Androgen Antagonists; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2019 |
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2019 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2013 |
Zoledronic acid in lung cancer with bone metastases: a review.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid in genitourinary cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Quality of Life; Urogenital Neoplasms; Zoledronic Acid | 2013 |
Bone markers for monitoring efficacy in patients
with bone metastases receiving zoledronic acid:
a review of published data.
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Neoplasm Metastasis; Zoledronic Acid | 2013 |
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Male; Molecular Targeted Therapy; Osteoclasts; Patient Selection; Prostatic Neoplasms; RANK Ligand; Risk Factors; Treatment Outcome; Zoledronic Acid | 2014 |
Hypercalcemia and osteolytic lesions as presenting symptoms of acute lymphoblastic leukemia in childhood. The use of zoledronic acid and review of the literature.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Child; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Zoledronic Acid | 2014 |
Zoledronic acid in the treatment of metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Patient Compliance; Quality of Life; Zoledronic Acid | 2014 |
[Inhibition of RANK ligand to treat bone metastases].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2013 |
[Biomarkers of bone remodelling].
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Denosumab; Diphosphonates; Humans; Imidazoles; Predictive Value of Tests; Zoledronic Acid | 2013 |
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Molecular Targeted Therapy; Practice Guidelines as Topic; RANK Ligand; Treatment Outcome; Zoledronic Acid | 2014 |
Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Prognosis; Zoledronic Acid | 2014 |
Management of bone metastases in patients with castration-resistant prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Interdisciplinary Communication; Male; Medical Oncology; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2014 |
Atraumatic tooth extraction in patients taking bisphosphonates: a review of literature and experience with three cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Elastomers; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Orthodontic Appliances; Pancoast Syndrome; Prostatic Neoplasms; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2014 |
[The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Osteoclasts; Zoledronic Acid | 2014 |
Treatment of bone metastases in urologic malignancies.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cisplatin; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Prostatic Neoplasms; Quality of Life; Radiosurgery; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Zoledronic Acid | 2014 |
Pathologic fracture in patients with metastatic prostate cancer.
Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid | 2014 |
Treatment of multiple myeloma bone disease: experimental and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Quality of Life; Zoledronic Acid | 2015 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2015 |
Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Differentiation; Cell Proliferation; Cell Survival; Humans; In Vitro Techniques; Lung Neoplasms; Osteosarcoma; Zoledronic Acid | 2018 |
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid | 2015 |
Targeting bone metastases in prostate cancer: improving clinical outcome.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoblasts; Osteolysis; Pain; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Zoledronic Acid | 2015 |
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Prostatic Neoplasms; Radioisotopes; Radium; Zoledronic Acid | 2015 |
Management of bone metastases in prostate cancer: a review.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Zoledronic Acid | 2015 |
Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
Topics: Arm; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Buttocks; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Drug Eruptions; Erythema; Female; Humans; Imidazoles; Intertrigo; Lung Neoplasms; Middle Aged; Mixed Tumor, Malignant; Syndrome; Zoledronic Acid | 2015 |
Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Pamidronate; Treatment Outcome; Zoledronic Acid | 2015 |
Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2016 |
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Consensus; Diphosphonates; Europe; Female; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Surveys and Questionnaires; Zoledronic Acid | 2016 |
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Survival Rate; Taxoids; Zoledronic Acid | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Quality of Life; Sex Factors; Zoledronic Acid | 2016 |
Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Orthopedic Procedures; Prostatic Neoplasms; Radiotherapy; Spinal Cord Compression; Zoledronic Acid | 2017 |
Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Causality; Comorbidity; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Imidazoles; Male; Patient Safety; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Zoledronic Acid | 2016 |
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Topics: Absorptiometry, Photon; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Zoledronic acid: a review of its use in breast cancer.
Topics: Antineoplastic Agents; Area Under Curve; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Injections, Intravenous; Zoledronic Acid | 2008 |
Effect of bisphosphonates on pain and quality of life in patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Pain; Palliative Care; Quality of Life; Treatment Outcome; Zoledronic Acid | 2009 |
Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.
Topics: Apoptosis; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Melanoma; Middle Aged; T-Lymphocytes; TNF-Related Apoptosis-Inducing Ligand; Zoledronic Acid | 2009 |
Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Male; Pamidronate; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2009 |
Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Morbidity; Peptides; Quality of Life; Zoledronic Acid | 2009 |
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2009 |
[Antitumor activity of zoledronic acid].
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Lung Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Bone health and prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2010 |
Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Incidence; Lung Neoplasms; Neoplasm Metastasis; Zoledronic Acid | 2010 |
Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Practice Guidelines as Topic; Survival Analysis; Zoledronic Acid | 2009 |
Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Topics: Adult; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Zoledronic Acid | 2010 |
[Bone and Men's Health. Bisphosphonate therapy for prostate cancer].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid | 2010 |
Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.
Topics: Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Collagen Type I; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Peptides; Prognosis; Prostatic Neoplasms; RANK Ligand; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2010 |
[Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Neoplasm Metastasis; Neoplasms; Zoledronic Acid | 2010 |
Treatment and prevention of bone complications from prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoblasts; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
The evolving role of bone-conserving therapy in patients with breast cancer.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Survival Analysis; Zoledronic Acid | 2010 |
Maintaining bone health in prostate cancer throughout the disease continuum.
Topics: Androgen Antagonists; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2010 |
Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Humans; Imidazoles; Kidney Neoplasms; Survival Analysis; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
Bisphosphonates in lung cancer: more than a palliative therapy?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2010 |
Future directions of bone-targeted therapy for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cathepsin K; Chemoreceptor Cells; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Ligands; NF-kappa B; Parathyroid Hormone; RANK Ligand; src-Family Kinases; Transforming Growth Factor beta; Zoledronic Acid | 2010 |
Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Injections, Intravenous; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
[Bisphosphonates in adjuvant therapy of breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clinical Trials as Topic; Diphosphonates; Drug Approval; Estrogen Antagonists; Evidence-Based Medicine; Female; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Pamidronate; Survival Rate; Zoledronic Acid | 2010 |
The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Zoledronic Acid | 2010 |
Managing bone health with zoledronic acid: a review of randomized clinical study results.
Topics: Antineoplastic Agents; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2011 |
Zoledronic acid use in cancer patients: more than just supportive care?
Topics: Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Neoplasms; Osteolysis; Zoledronic Acid | 2011 |
The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Zoledronic Acid | 2011 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2011 |
The backbone of progress--preclinical studies and innovations with zoledronic acid.
Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imidazoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Osteoclasts; Zoledronic Acid | 2011 |
[Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Molecular Targeted Therapy; Osteoclasts; Pamidronate; RANK Ligand; Strontium; Zoledronic Acid | 2011 |
[Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
Topics: Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Male; Molecular Targeted Therapy; NF-kappa B; Prostatic Neoplasms; Radioisotopes; Radium; Receptor Activator of Nuclear Factor-kappa B; Strontium; Zoledronic Acid | 2011 |
New developments for treatment and prevention of bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Neoplasm Recurrence, Local; Osteonecrosis; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
Pharmacokinetic evaluation of zoledronic acid.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Drug Evaluation; Female; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2011 |
Zoledronic acid: multiplicity of use across the cancer continuum.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Zoledronic Acid | 2011 |
Denosumab: benefits of RANK ligand inhibition in cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Multiple Myeloma; RANK Ligand; Zoledronic Acid | 2011 |
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostate; Prostatic Neoplasms; Urogenital Neoplasms; Urogenital System; Zoledronic Acid | 2012 |
Anticancer activity of bisphosphonates in breast cancer.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2012 |
New role for an established drug? Bisphosphonates as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Diphosphonates; Drug Synergism; Female; Humans; Imidazoles; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteoclasts; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2012 |
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2012 |
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Topics: Algorithms; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Incidence; Male; Middle Aged; Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2012 |
Antiangiogenic effects of zoledronate on cancer neovasculature.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Neoplasms; Neovascularization, Pathologic; Zoledronic Acid | 2011 |
[A very elderly case of advanced gastric cancer with disseminated carcinomatosis of bone marrow and multiple bone metastasis, diagnosed by extremely elevated serum alkaline phosphatase levels, and treated with low-dose S-1 to avoid disseminated intravascu
Topics: Aged, 80 and over; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Bone Neoplasms; Carcinoma; Diphosphonates; Disseminated Intravascular Coagulation; Drug Combinations; Female; Humans; Imidazoles; Oxonic Acid; Stomach Neoplasms; Tegafur; Zoledronic Acid | 2011 |
Bisphosphonates and breast cancer incidence and recurrence.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Incidence; Zoledronic Acid | 2011 |
Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Treatment Outcome; Zoledronic Acid | 2011 |
Denosumab for the management of bone disease in patients with solid tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Availability; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Management; Humans; Imidazoles; Immunologic Factors; Neoplasm Metastasis; Neoplasms; Outcome Assessment, Health Care; Palliative Care; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2012 |
Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Carcinoma, Renal Cell; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Europe; Health Care Costs; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Zoledronic Acid | 2012 |
[Strategy in advanced castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Vaccines; Denosumab; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Organometallic Compounds; Organophosphorus Compounds; Pain Management; Prostatic Neoplasms; Strontium; Zoledronic Acid | 2012 |
Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Approval; Europe; Humans; Imidazoles; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration; Zoledronic Acid | 2012 |
Renal complications from bisphosphonate treatment.
Topics: Acute Kidney Injury; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney; Kidney Diseases; Nephrotic Syndrome; Pamidronate; Risk Factors; Zoledronic Acid | 2012 |
Effects of bone-targeted agents on cancer progression and mortality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Female; Goserelin; Humans; Imidazoles; Male; Menopause; Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid | 2012 |
Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Neoplasm Staging; Patient Safety; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2013 |
Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Neoplasm Metastasis; Prostatic Neoplasms; Women's Health; Zoledronic Acid | 2012 |
[The role of bisphosphonate in the treatment of bone metastases from prostate cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Preventing bone complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Life Style; Male; Prostatic Neoplasms; Selective Estrogen Receptor Modulators; Zoledronic Acid | 2012 |
Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2013 |
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Topics: Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Disease Progression; Female; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Zoledronic Acid | 2012 |
Denosumab and bone metastases. No better than a bisphosphonate.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Infusions, Intravenous; Injections, Subcutaneous; Risk Assessment; Risk Factors; Treatment Outcome; Zoledronic Acid | 2012 |
Management of bone metastases in refractory prostate cancer--role of denosumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Denosumab; Diphosphonates; Disease-Free Survival; Humans; Hypocalcemia; Imidazoles; Male; Orchiectomy; Osteonecrosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; RANK Ligand; Zoledronic Acid | 2012 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid | 2012 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid | 2012 |
New and emerging therapies for bone metastases in genitourinary cancers.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; RANK Ligand; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urothelium; Zoledronic Acid | 2013 |
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Double-Blind Method; Forecasting; Fractures, Spontaneous; Humans; Imidazoles; Male; Models, Biological; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Practice Guidelines as Topic; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2013 |
Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Musculoskeletal Pain; Pain Measurement; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2013 |
Novel approaches to the management of bone metastases in patients with breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2002 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid | 2002 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid | 2003 |
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Humans; Hypercalcemia; Imidazoles; Kidney; Zoledronic Acid | 2003 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2002 |
Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2002 |
The role of intravenous zoledronic acid in the management of high-risk prostate cancer.
Topics: Animals; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Palliative Care; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2003 |
Preclinical pharmacology of zoledronic acid.
Topics: Animals; Bone Density; Bone Neoplasms; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Humans; Imidazoles; Zoledronic Acid | 2002 |
Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Male; Palliative Care; Prostatic Neoplasms; Zoledronic Acid | 2002 |
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2002 |
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
Topics: Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Chemokines; Clinical Trials as Topic; Clodronic Acid; Cytokines; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteolysis; Patient Selection; Treatment Outcome; Zoledronic Acid | 2003 |
Selected therapy-related clinical research topics in osteoporosis.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Hip Fractures; Humans; Hypercalcemia; Imidazoles; Injections; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Osteoporosis; Zoledronic Acid | 2003 |
[The role of bisphosphonates in the treatment of bone metastases from urogenital cancer ].
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Male; Molecular Structure; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2003 |
Bisphosphonates in the management of metastatic prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Male; Pain; Palliative Care; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Topics: Bone Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Matrix Metalloproteinases; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.
Topics: Analgesics, Non-Narcotic; Antimetabolites; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2003 |
Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Osteolysis; Prognosis; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid | 2003 |
The anti-tumor potential of zoledronic acid.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Male; Mice; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteolysis; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Bisphosphonate therapy in the oncology setting.
Topics: Administration, Oral; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid | 2003 |
Role of bisphosphonates in prostate cancer.
Topics: Androgen Antagonists; Bone Neoplasms; Diphosphonates; Forecasting; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2004 |
Zoledronic acid: a new parenteral bisphosphonate.
Topics: Animals; Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Half-Life; Humans; Hypercalcemia; Imidazoles; Metabolic Clearance Rate; Neoplasms; Zoledronic Acid | 2003 |
Advances in the use of bisphosphonates in the prostate cancer setting.
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2004 |
Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone.
Topics: Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Palliative Care; Prostatic Neoplasms; Zoledronic Acid | 2002 |
Zoledronic acid: a review of its use in patients with advanced cancer.
Topics: Area Under Curve; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Drug Tolerance; Economics, Pharmaceutical; Female; Half-Life; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2004 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Osteoclast-targeted therapy for prostate cancer.
Topics: Adult; Aged; Androgens; Bone Density; Bone Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Osteoclasts; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2004 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2004 |
Bisphosphonates in the treatment of skeletal metastases.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Pamidronate; Zoledronic Acid | 2004 |
Recommendations for zoledronic acid treatment of patients with bone metastases.
Topics: Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Creatinine; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Kidney; Practice Guidelines as Topic; Zoledronic Acid | 2005 |
The role of bisphosphonates in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; Bone Density; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2005 |
Management of bone metastases in breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Middle Aged; Palliative Care; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Multicenter Studies as Topic; Nerve Compression Syndromes; Pain; Spinal Cord Compression; United States; Zoledronic Acid | 2005 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Osteonecrosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; United States; Women's Health; Zoledronic Acid | 2005 |
The role of bisphosphonates in the treatment of prostate cancer.
Topics: Androgen Antagonists; Bone Neoplasms; Clinical Trials, Phase III as Topic; Clodronic Acid; Diphosphonates; Forecasting; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Current status of treatment for patients with metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Docetaxel; Drug Monitoring; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2005 |
Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Bone Density; Bone Diseases; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Osteolysis; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid | 2005 |
Two cases of endometrial cancer diagnosis associated with bone metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cervical Vertebrae; Cyclophosphamide; Diphosphonates; Doxorubicin; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Imidazoles; Middle Aged; Platinum; Spinal Neoplasms; Tibia; Zoledronic Acid | 2006 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Pain; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Anti-tumour activity of zoledronic acid.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2005 |
[Zoledronic acid in the treatment of prostate cancer].
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Moving into the future: treatment of bone metastases and beyond.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2005 |
Zoledronic acid: past, present and future roles in cancer treatment.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2005 |
[Bisphosphonates for bone metastasis of malignant tumor].
Topics: Bone Neoplasms; Bone Resorption; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Membrane Glycoproteins; Osteoclasts; Pain; Quality of Life; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2006 |
Zometa in the treatment of diseminated prostate cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2005 |
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Practice Guidelines as Topic; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically Ill; Diphosphonates; Humans; Imidazoles; Jaw; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Time Factors; Zoledronic Acid | 2006 |
Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Drug Synergism; Humans; Imidazoles; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Maxillary Diseases; Osteonecrosis; Zoledronic Acid | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
[Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Topics: Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoporosis, Postmenopausal; Zoledronic Acid | 2007 |
[Molecular mechanism and potential targets for bone metastasis].
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplastic Cells, Circulating; Osteolysis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2007 |
Zoledronic acid in the management of metastatic bone disease.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2006 |
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
Topics: Biomarkers; Bone and Bones; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Predictive Value of Tests; Risk Factors; Survival Rate; Zoledronic Acid | 2007 |
New developments of aminobisphosphonates: the double face of Janus.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2007 |
Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Practice Guidelines as Topic; Treatment Outcome; Zoledronic Acid | 2007 |
Zoledronic acid - a multiplicity of anti-cancer action.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Synergism; Humans; Imidazoles; Rats; Zoledronic Acid | 2007 |
Burden of bone disease.
Topics: Activities of Daily Living; Bone Density Conservation Agents; Bone Neoplasms; Cost of Illness; Diphosphonates; Humans; Imidazoles; Incidence; Morbidity; Prevalence; Quality of Life; Risk Factors; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
Optimal management of metastatic bone disease.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Incidence; Morbidity; Pain; Palliative Care; Patient Selection; Practice Guidelines as Topic; Quality of Life; Risk Factors; Risk Reduction Behavior; Treatment Outcome; Zoledronic Acid | 2007 |
On the horizon: can bisphosphonates prevent bone metastases?
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Humans; Imidazoles; Models, Animal; Neoplasm Staging; Treatment Outcome; Zoledronic Acid | 2007 |
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2007 |
Emerging strategies in bone health management for the adjuvant patient.
Topics: Angiogenesis Inhibitors; Animals; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Zoledronic Acid | 2007 |
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoclasts; Pain; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Zoledronic Acid | 2007 |
[Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoporosis; Practice Guidelines as Topic; Prognosis; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Zoledronic Acid | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2008 |
[Bony lesion with prostate cancer].
Topics: Antibodies, Monoclonal; Azepines; Bone Neoplasms; Cathepsin K; Cathepsins; Diphosphonates; Enzyme Inhibitors; Humans; Imidazoles; Male; Matrix Metalloproteinases; Osteoclasts; Osteolysis; Osteoporosis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Sulfones; Zoledronic Acid | 2008 |
Impact of skeletal complications on patients' quality of life, mobility, and functional independence.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Health Status; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Zoledronic Acid | 2008 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
Clinical research update: zoledronate.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Mice; Multiple Myeloma; Rats; Zoledronic Acid | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2001 |
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Zoledronic Acid | 2001 |
Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2001 |
Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Topics: Animals; Bone and Bones; Bone Neoplasms; Diphosphonates; Drug Evaluation, Preclinical; Imidazoles; Mammary Neoplasms, Experimental; Mice; Models, Animal; Neoplasm Metastasis; Rats; Zoledronic Acid | 2001 |
Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease.
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2001 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2001 |
[Bisphosphonates in the treatment of breast carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Zoledronic Acid | 2001 |
Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pain; Zoledronic Acid | 2001 |
182 trial(s) available for zoledronic acid and Bone Cancer
| Article | Year |
|---|---|
Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cisplatin; Computational Biology; Deoxycytidine; Diphosphonates; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Safety; Young Adult; Zoledronic Acid | 2021 |
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Castration; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Zoledronic Acid | 2022 |
Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Pain; Quality of Life; Zoledronic Acid | 2022 |
Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study.
Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Osteosarcoma; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2023 |
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).
Topics: Bone Neoplasms; Humans; Lung Neoplasms; Zoledronic Acid | 2023 |
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Induction Chemotherapy; Male; Middle Aged; Sarcoma, Ewing; Vincristine; Young Adult; Zoledronic Acid | 2020 |
Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Disease-Free Survival; Female; Fractures, Spontaneous; Humans; Middle Aged; Risk Assessment; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2020 |
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Zoledronic Acid | 2020 |
A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Treatment Outcome; Zoledronic Acid | 2021 |
Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukocyte Count; Male; Middle Aged; Osteolysis; Platelet Count; Platelet-Rich Fibrin; Prostatic Neoplasms; Young Adult; Zoledronic Acid | 2021 |
Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.
Topics: Aged; Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Zoledronic Acid | 2022 |
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Markov Chains; Zoledronic Acid | 2017 |
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Diphosphonates; Doxorubicin; Etoposide; Female; France; Humans; Ifosfamide; Imidazoles; Kaplan-Meier Estimate; Male; Methotrexate; Neutropenia; Osteosarcoma; Young Adult; Zoledronic Acid | 2018 |
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Topics: Biomarkers, Tumor; Bone and Bones; Bone Development; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Early Detection of Cancer; Female; Humans; Infusions, Intravenous; Middle Aged; Prognosis; Standard of Care; United Kingdom; Zoledronic Acid | 2018 |
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2018 |
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Cost of Illness; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Health Expenditures; Humans; Imidazoles; Male; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; United States; Zoledronic Acid | 2018 |
Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study.
Topics: Adult; Aged; Body Mass Index; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Logistic Models; Male; Middle Aged; Multivariate Analysis; Risk Factors; Zoledronic Acid | 2018 |
Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoblasts; Palliative Care; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Safety; Survival Analysis; Zoledronic Acid | 2018 |
Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Young Adult; Zoledronic Acid | 2018 |
Clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in the treatment of metastatic bone tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bufanolides; Drugs, Chinese Herbal; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pain Measurement; Quality of Life; Zoledronic Acid | 2018 |
Comparison of clinical effect in treatment of bone tumor between zoledronic acid needle and ibandronate needle.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Child; Female; Humans; Ibandronic Acid; Injections; Male; Middle Aged; Pain Measurement; Quality of Life; Young Adult; Zoledronic Acid | 2018 |
A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers.
Topics: Adult; Aged; Biomarkers, Tumor; Bone Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pain; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Methotrexate; Middle Aged; Osteosarcoma; Survival Rate; Zoledronic Acid | 2019 |
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.
Topics: Artificial Intelligence; Biomarkers; Bone Density; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Zoledronic Acid | 2021 |
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; France; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Prognosis; Survival Rate; Young Adult; Zoledronic Acid | 2020 |
Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Topics: Age Factors; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Peptides; Radionuclide Imaging; Zoledronic Acid | 2013 |
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Edema; Extremities; Feasibility Studies; Female; Humans; Hypokalemia; Hyponatremia; Hypophosphatemia; Imidazoles; Kaplan-Meier Estimate; Male; Mucositis; Neoplasm Metastasis; Osteosarcoma; Pain; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Time Factors; Zoledronic Acid | 2013 |
RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Middle Aged; Osteoprotegerin; Peptides; Prospective Studies; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Zoledronic Acid | 2013 |
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Risk Factors; Survival Analysis; Zoledronic Acid | 2013 |
Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases.
Topics: Aged; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Survival Rate; Zoledronic Acid | 2013 |
Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
Topics: Aged; Androgen Antagonists; Androgens; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Goserelin; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Zoledronic Acid | 2013 |
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Pain; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Young Adult; Zoledronic Acid | 2013 |
Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Zoledronic Acid | 2013 |
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comprehension; Diphosphonates; England; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pain Measurement; Patient Preference; Patient Satisfaction; Patients; Qualitative Research; Quality of Life; Time Factors; Treatment Outcome; Wales; Zoledronic Acid | 2013 |
Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Bone Neoplasms; Child; Diphosphonates; Female; Humans; Imidazoles; Male; Pamidronate; Prospective Studies; Radiography; Time Factors; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2014 |
Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
Topics: Adult; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Radioimmunoassay; Zoledronic Acid | 2014 |
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Zoledronic Acid | 2014 |
Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Therapy, Combination; Early Detection of Cancer; Humans; Imidazoles; Leuprolide; Male; Middle Aged; New South Wales; Peptide Fragments; Prevalence; Procollagen; Prostatic Neoplasms; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Zoledronic Acid | 2014 |
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Immunohistochemistry; Middle Aged; Neoplastic Cells, Circulating; Zoledronic Acid | 2014 |
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Imaging; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2014 |
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Chi-Square Distribution; Diphosphonates; Drug Administration Schedule; Europe; Humans; Imidazoles; Kallikreins; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid | 2015 |
An effective therapy to painful bone metastases: cryoablation combined with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Cryosurgery; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pain; Prognosis; Prospective Studies; Zoledronic Acid | 2014 |
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease-Free Survival; Docetaxel; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2014 |
Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Peptides; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult; Zoledronic Acid | 2014 |
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Infusions, Intravenous; Middle Aged; Odds Ratio; Postmenopause; Risk; Zoledronic Acid | 2014 |
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Imidazoles; Male; Prostatic Neoplasms; Strontium Radioisotopes; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2015 |
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Collagen Type I; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Peptides; Prospective Studies; Sirolimus; Treatment Outcome; Zoledronic Acid | 2015 |
Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome; Zoledronic Acid | 2014 |
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid | 2015 |
Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial.
Topics: Aged; Aged, 80 and over; Amino Acids; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Chromatography, High Pressure Liquid; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Radiation Injuries; Radiotherapy; Zoledronic Acid | 2015 |
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Denosumab; Diphosphonates; Double-Blind Method; Hemoglobins; Humans; Imidazoles; Kallikreins; Male; Middle Aged; Multivariate Analysis; Peptides; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2015 |
Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Topics: Acute Disease; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney; Middle Aged; Prospective Studies; Zoledronic Acid | 2015 |
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proportional Hazards Models; Zoledronic Acid | 2015 |
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
Topics: Analgesics; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Pain; Zoledronic Acid | 2016 |
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Topics: Administration, Cutaneous; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Long-Term Care; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2016 |
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Palliative Care; Pamidronate; Quality of Life; Treatment Outcome; Zoledronic Acid | 2016 |
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Topics: Administration, Cutaneous; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Treatment Outcome; Zoledronic Acid | 2016 |
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid | 2016 |
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Collagen Type I; Denosumab; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; PAX5 Transcription Factor; Peptides; Zoledronic Acid | 2016 |
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast; Breast Neoplasms; Dasatinib; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Receptor, ErbB-2; src-Family Kinases; Zoledronic Acid | 2016 |
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiopharmaceuticals; Strontium; United Kingdom; Zoledronic Acid | 2017 |
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Neoplasm, Residual; Zoledronic Acid | 2016 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Studies; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Diphosphonates; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Imidazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Osteosarcoma; Prognosis; Survival Rate; Young Adult; Zoledronic Acid | 2016 |
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quality-Adjusted Life Years; Strontium Radioisotopes; Taxoids; Zoledronic Acid | 2016 |
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Radiosurgery; Zoledronic Acid | 2016 |
Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Prostatic Neoplasms; Radiography, Panoramic; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2016 |
A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Follow-Up Studies; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Time Factors; Treatment Failure; Zoledronic Acid | 2017 |
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Prostatic Neoplasms; Sample Size; Spinal Cord Compression; Spinal Fractures; Zoledronic Acid | 2017 |
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid | 2017 |
A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Topics: Aged; Arabinofuranosyluracil; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Diphosphonates; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Reproducibility of Results; Tomography, X-Ray Computed; Zoledronic Acid | 2017 |
[Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer].
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Pain; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2008 |
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Colorectal Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Fever; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pain, Intractable; Pamidronate; Peptides; Prospective Studies; Vomiting; Zoledronic Acid | 2008 |
[Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer].
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Regeneration; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Pain; Pain Management; Radiotherapy; Zoledronic Acid | 2008 |
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Pain Measurement; Palliative Care; Radiotherapy Dosage; Zoledronic Acid | 2010 |
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imatinib Mesylate; Imidazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Prostatic Neoplasms; Pyrimidines; Sarcoma; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.
Topics: 25-Hydroxyvitamin D 2; Aged; Alkaline Phosphatase; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Calcifediol; Cohort Studies; Collagen Type I; Diphosphonates; Female; Folic Acid; Homocysteine; Humans; Imidazoles; Isoenzymes; Male; Paget Disease, Extramammary; Peptides; Pilot Projects; Time Factors; Vitamin B 12; Zoledronic Acid | 2010 |
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Middle Aged; Osteonecrosis; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Medronate; Zoledronic Acid | 2010 |
Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Young Adult; Zoledronic Acid | 2011 |
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Egypt; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pain; Placebo Effect; Prospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Peptides; Zoledronic Acid | 2010 |
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; China; Collagen Type I; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Mucin-1; Peptides; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2010 |
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Pain; Pain Measurement; Prostatic Neoplasms; Spinal Cord Compression; Survival Rate; Zoledronic Acid | 2010 |
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; RANK Ligand; Zoledronic Acid | 2010 |
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Research Design; Treatment Outcome; United Kingdom; Zoledronic Acid | 2010 |
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Topics: Adult; Biomarkers; Biphenyl Compounds; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cathepsin K; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid | 2010 |
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Nasopharyngeal Neoplasms; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasms; RANK Ligand; Survival Rate; Treatment Outcome; Young Adult; Zoledronic Acid | 2011 |
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands.
Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Europe; Health Care Costs; Hormones; Humans; Imidazoles; Male; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Zoledronic Acid | 2011 |
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Diphosphonates; Europe; Fractures, Bone; Health Care Costs; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Spinal Cord Compression; Zoledronic Acid | 2011 |
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Diphosphonates; Female; Humans; Imidazoles; Infant; Male; Maximum Tolerated Dose; Neuroblastoma; Survival Analysis; Zoledronic Acid | 2011 |
Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Topics: Administration, Metronomic; Adult; Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Young Adult; Zoledronic Acid | 2011 |
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Disease Progression; Drug Costs; Health Care Costs; Humans; Imidazoles; Male; Markov Chains; Models, Economic; Multivariate Analysis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Sensitivity and Specificity; United States; Zoledronic Acid | 2011 |
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrroles; Zoledronic Acid | 2011 |
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Arthralgia; Bone Marrow Cells; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Treatment Outcome; Zoledronic Acid | 2012 |
Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Imidazoles; Male; Middle Aged; Multivariate Analysis; Parathyroid Hormone; Prognosis; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid | 2012 |
Treatment of bone metastases before the onset of pain.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Randomized Controlled Trials as Topic; Zoledronic Acid | 2013 |
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2014 |
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Spinal Cord Compression; Tomography, X-Ray Computed; Zoledronic Acid | 2012 |
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Calcium; Carcinoma, Non-Small-Cell Lung; Dietary Supplements; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vitamin D; Young Adult; Zoledronic Acid | 2012 |
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Pain; Quality of Life; RANK Ligand; Treatment Outcome; Zoledronic Acid | 2012 |
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Quality of Life; RANK Ligand; Zoledronic Acid | 2012 |
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Topics: Analgesics; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Pain; Zoledronic Acid | 2013 |
Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2012 |
(89)Sr imaging with bremsstrahlung in patients with metastatic breast cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Electromagnetic Radiation; Female; Humans; Imidazoles; Middle Aged; Pain Management; Radionuclide Imaging; Strontium Radioisotopes; Zoledronic Acid | 2012 |
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Spinal Cord Compression; Strontium; Zoledronic Acid | 2013 |
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Denosumab; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; RANK Ligand; Small Cell Lung Carcinoma; Survival Rate; Young Adult; Zoledronic Acid | 2012 |
[Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Zoledronic Acid | 2012 |
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2002 |
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Time Factors; Zoledronic Acid | 2002 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid | 2003 |
Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2002 |
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2002 |
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Alkaline Phosphatase; Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Parathyroid Hormone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.
Topics: Adult; Aged; Area Under Curve; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Zoledronic Acid | 2003 |
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Neoplasm Metastasis; Placebos; Prostatic Neoplasms; Time Factors; United States; United States Food and Drug Administration; Zoledronic Acid | 2003 |
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Topics: Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Placebos; Zoledronic Acid | 2003 |
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Female; Fractures, Bone; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Placebos; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2003 |
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Topics: Administration, Oral; Aged; Analgesics, Non-Narcotic; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Digestive System; Diphosphonates; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Imidazoles; Male; Middle Aged; Odds Ratio; Pain; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2003 |
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2004 |
Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
Topics: Bone Neoplasms; Breast Neoplasms; Canada; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Outcome and Process Assessment, Health Care; Pamidronate; Prospective Studies; Quality of Life; United States; Zoledronic Acid | 2004 |
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.
Topics: Aged; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2004 |
Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases.
Topics: Aged; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2002 |
Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Morbidity; Prognosis; Zoledronic Acid | 2004 |
Bisphosphonate infusions: patient preference, safety and clinic use.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Confidence Intervals; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Outpatients; Pamidronate; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Zoledronic Acid | 2004 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Incidence; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2004 |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Lung Neoplasms; Placebos; Zoledronic Acid | 2004 |
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2004 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Retrospective Studies; Zoledronic Acid | 2004 |
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2004 |
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Japan; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
[Use of zoledronic acid for high risk prostate cancer patients].
Topics: Animals; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Europe; Humans; Hypercalcemia; Imidazoles; Injections, Intravenous; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2005 |
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Male; Placebos; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid | 2005 |
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
Topics: Activities of Daily Living; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Cross-Over Studies; Diphosphonates; Emotions; Female; Hospitals, Community; Humans; Imidazoles; Infusions, Intravenous; Inpatients; Middle Aged; Outpatients; Pain; Pain Measurement; Quality of Life; Zoledronic Acid | 2005 |
Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline.
Topics: Aged; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2005 |
Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
Topics: Aged; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Pain; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2005 |
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cytokines; Diphosphonates; Female; Fibroblast Growth Factor 2; Humans; Imidazoles; Interferon-gamma; Interleukins; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Metalloproteases; Middle Aged; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2005 |
In focus: prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Protocols; Diphosphonates; Humans; Imidazoles; Male; Patient Selection; Prostatic Neoplasms; Zoledronic Acid | 2003 |
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2005 |
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Zoledronic Acid | 2005 |
[Phase II randomized clinical trail of zoledronic acid in treating metastatic bone pain of malignancy].
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Mannitol; Middle Aged; Pain, Intractable; Pamidronate; Prospective Studies; Zoledronic Acid | 2005 |
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Pain; Pain Measurement; Placebos; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Male; Multicenter Studies as Topic; Multivariate Analysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Zoledronic Acid | 2006 |
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Interferon-gamma; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Thalidomide; Zoledronic Acid | 2006 |
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid | 2006 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease Progression; Drug Resistance; Female; Humans; Imidazoles; Middle Aged; Pain; Palliative Care; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |
CALGB 90202.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2006 |
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteocalcin; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2007 |
Zoledronic acid treatment at home: safety data from an observational prospective trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Home Care Services; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Multiple Myeloma; Observation; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Time Factors; Zoledronic Acid | 2007 |
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2007 |
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Castration; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid | 2007 |
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Creatinine; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Osteoclasts; Osteolysis; Pamidronate; Peptides; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2007 |
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Musculoskeletal System; Quality of Life; Zoledronic Acid | 2007 |
A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2007 |
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Canada; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoclasts; Peptides; Retrospective Studies; Time Factors; Treatment Outcome; United States; Zoledronic Acid | 2008 |
Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Radiation; Female; Humans; Imidazoles; Male; Middle Aged; Pain; Pain Management; Pain Measurement; Quality of Life; Radiotherapy; Zoledronic Acid | 2008 |
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Calcium; Circadian Rhythm; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteocalcin; Parathyroid Hormone; Peptides; Zoledronic Acid | 2008 |
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Topics: Adult; Aged; Anorexia; Biomarkers; Bone Neoplasms; Bone Resorption; Constipation; Diphosphonates; Female; Fever; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2001 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen; Collagen Type I; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pamidronate; Peptides; Zoledronic Acid | 2001 |
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors; Zoledronic Acid | 2001 |
The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2001 |
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Zoledronic Acid | 2001 |
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pamidronate; Time Factors; Zoledronic Acid | 2001 |
524 other study(ies) available for zoledronic acid and Bone Cancer
| Article | Year |
|---|---|
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Topics: Bone Neoplasms; Carbonic Anhydrase Inhibitors; Cell Line; Diphosphonates; Enzyme Activation; Humans; Imidazoles; Inhibitory Concentration 50; Matrix Metalloproteinase Inhibitors; Molecular Structure; Zoledronic Acid | 2014 |
CORR Insights®: Does Local Zoledronate Applied to Pasteurized Bone Autografts Improve the Likelihood of Union of Graft-Host Junctions after Limb-sparing Surgery?
Topics: Autografts; Bone Neoplasms; Bone Transplantation; Humans; Osteosarcoma; Zoledronic Acid | 2022 |
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Propensity Score; Retrospective Studies; Zoledronic Acid | 2022 |
Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Denosumab; Diphosphonates; Humans; Multiple Myeloma; Retrospective Studies; Vitamin D; Zoledronic Acid | 2023 |
Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Germany; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2022 |
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Drug Synergism; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prognosis; Retrospective Studies; Survival Analysis; Zoledronic Acid | 2021 |
Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Incidence; Male; Prognosis; Retrospective Studies; Zoledronic Acid | 2022 |
A bone-targeting drug delivery vehicle of a metal-organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis.
Topics: Animals; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Humans; Metal-Organic Frameworks; Mice; Nanoparticles; Photothermal Therapy; Zoledronic Acid | 2022 |
Fracture rate and time to fracture in dogs with appendicular osteosarcoma receiving finely fractionated compared to coarsely fractionated radiation therapy: A single institution study.
Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Fractures, Spontaneous; Humans; Osteosarcoma; Retrospective Studies; Zoledronic Acid | 2022 |
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Pamidronate; Quality of Life; Risk Assessment; Zoledronic Acid | 2022 |
Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Denosumab; Diphosphonates; Humans; Male; Pamidronate; Retrospective Studies; Zoledronic Acid | 2022 |
Efficacy Evaluation of Zoledronic Acid Combined with Chemotherapy in the Treatment of Lung Cancer Spinal Metastases on Computed Tomography Images on Intelligent Algorithms.
Topics: Algorithms; Alopecia; Bayes Theorem; Bone Neoplasms; Cisplatin; Disease Progression; Humans; Lung Neoplasms; Pain; Spinal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2022 |
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Humans; Male; Medicare; Osteoporotic Fractures; Prostatic Neoplasms, Castration-Resistant; United States; Zoledronic Acid | 2023 |
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Incidence; Multiple Myeloma; Osteonecrosis; Prognosis; Retrospective Studies; Zoledronic Acid | 2022 |
Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells.
Topics: Bone Neoplasms; CD28 Antigens; Diphosphonates; Humans; Imidazoles; Leukocytes, Mononuclear; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2022 |
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid | 2022 |
Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
Topics: Acridine Orange; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; DNA Nucleotidylexotransferase; Female; Imidazoles; Mice; Osteolysis; X-Ray Microtomography; Zoledronic Acid | 2022 |
Zoledronic acid-associated osteonecro sis of the jaw in patients with EGFR-sensitive mutant lung cancer: two case reports.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Humans; Lung Neoplasms; Quality of Life; Zoledronic Acid | 2023 |
Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
Topics: Androgen Antagonists; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Heterografts; Humans; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2023 |
Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma.
Topics: Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Ferroptosis; Humans; Imidazoles; Osteosarcoma; Quality of Life; Reactive Oxygen Species; Zoledronic Acid | 2023 |
Cisplatin and zoledronic acid: two drugs combined in a Pt(II) complex with potential antitumor activity towards bone tumors and metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Diphosphonates; Humans; Ligands; Pharmaceutical Preparations; Zoledronic Acid | 2023 |
A colloidal hydrogel-based drug delivery system overcomes the limitation of combining bisphosphonates with bioactive glasses: in vitro evidence of a potential selective bone cancer treatment allied with bone regeneration.
Topics: Bone Neoplasms; Bone Regeneration; Diphosphonates; Drug Delivery Systems; Humans; Hydrogels; Osteosarcoma; Tumor Microenvironment; Zoledronic Acid | 2023 |
Bisphosphonate treatment in inaccessible osteoid osteomas: An alternative therapeutic approach.
Topics: Adult; Bone Neoplasms; Diphosphonates; Humans; Male; Osteoma, Osteoid; Pain; Treatment Outcome; Zoledronic Acid | 2023 |
Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression.
Topics: Bone Marrow Diseases; Bone Neoplasms; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Immunosuppression Therapy; Micelles; Osteolysis; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2023 |
[Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Osteonecrosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2023 |
Polymeric Nanoformulation of Zoledronic Acid Rescues Osteoblasts from the Harmful Effect of its Native Form: An In Vitro Investigation of Cytotoxic Potential on Osteoblasts and Osteosarcoma Cells.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Delayed-Action Preparations; Diphosphonates; Humans; Imidazoles; Mice; Osteoblasts; Osteosarcoma; Zoledronic Acid | 2023 |
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Retrospective Studies; Zoledronic Acid | 2023 |
Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclins; Denosumab; Female; Humans; Respiratory Distress Syndrome; Zoledronic Acid | 2023 |
Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium, Dietary; Denosumab; Dietary Supplements; Female; Germany; Guideline Adherence; Humans; Lung Neoplasms; Male; Oncologists; Practice Patterns, Physicians'; Prostatic Neoplasms; Retrospective Studies; Surveys and Questionnaires; Vitamin D; Vitamins; Zoledronic Acid | 2020 |
Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Proportional Hazards Models; Retrospective Studies; Zoledronic Acid | 2019 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Topics: Ankle; Anorexia; Antithyroid Agents; Aromatase Inhibitors; Arthralgia; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen Type I; Denosumab; Deprescriptions; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Graves Disease; Humans; Hypercalcemia; Methimazole; Middle Aged; Parathyroid Hormone; Peptides; Potassium Iodide; Radionuclide Imaging; Tartrate-Resistant Acid Phosphatase; Thirst; Zoledronic Acid | 2020 |
Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Middle Aged; Retrospective Studies; Zoledronic Acid | 2020 |
Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Risk Factors; Zoledronic Acid | 2019 |
Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.
Topics: Adolescent; Adult; Aged; Bone and Bones; Bone Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Young Adult; Zoledronic Acid | 2020 |
Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cohort Studies; Denosumab; Female; Humans; Hypercalcemia; Hypocalcemia; Incidence; Male; Middle Aged; Retrospective Studies; Zoledronic Acid | 2019 |
Bisphosphonates as a therapeutic choice for multifocal epithelioid hemangioma of bone: A case report.
Topics: Biopsy; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Combined Modality Therapy; Diagnosis, Differential; Diphosphonates; Drug Monitoring; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Orthopedic Procedures; Treatment Outcome; Zoledronic Acid | 2019 |
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Denosumab; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Peptides; Prognosis; Prospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2020 |
Metal-Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Metal-Organic Frameworks; Mice; Nanoparticles; Oligodeoxyribonucleotides; Osteoclasts; Osteolysis; Tumor-Associated Macrophages; Zoledronic Acid | 2020 |
Successful percutaneous treatment of bone tumors using microwave ablation in combination with Zoledronic acid infused PMMA cementoplasty.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Cementoplasty; Female; Humans; Male; Microwaves; Multiple Myeloma; Pelvis; Polymethyl Methacrylate; Radiofrequency Therapy; Spine; Zoledronic Acid | 2020 |
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Female; Humans; Middle Aged; Neoplasm Metastasis; Osteolysis; Pamidronate; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Spine; Zoledronic Acid | 2020 |
[177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinoma.
Topics: Bone Neoplasms; Carcinoma, Bronchogenic; Humans; Lutetium; Radioisotopes; Zoledronic Acid | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Medication-Related Osteonecrosis of the Jaw.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Maxilla; Necrosis; Prostatic Neoplasms; Tomography, X-Ray Computed; Zoledronic Acid | 2020 |
DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Palliative Care; Quality Control; Radiopharmaceuticals; Zoledronic Acid | 2020 |
Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Hypocalcemia; Hypophosphatemia; Magnetic Resonance Imaging; Middle Aged; Positron-Emission Tomography; Vitamin D Deficiency; Zoledronic Acid | 2021 |
Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Musculoskeletal Abnormalities; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2021 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Disease-Free Survival; Humans; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid | 2021 |
Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Retrospective Studies; Zoledronic Acid | 2021 |
Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Jaw; Male; Osteonecrosis; Prognosis; Retrospective Studies; Zoledronic Acid | 2021 |
Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteonecrosis; Prospective Studies; Zoledronic Acid | 2021 |
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2021 |
Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid | 2022 |
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13).
Topics: Adult; Aged; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Taxoids; Zoledronic Acid | 2021 |
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Topics: Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Female; Humans; Incidence; Jaw; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Tooth Extraction; Zoledronic Acid | 2021 |
Intractable Fractures of the Bilateral Proximal Ulnae After 8 Years of Zoledronate Treatment for Breast Cancer Bone Metastasis.
Topics: Bone Neoplasms; Bone Plates; Breast Neoplasms; Female; Fracture Fixation, Internal; Humans; Ulna; Ulna Fractures; Zoledronic Acid | 2022 |
Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Drug Synergism; Humans; Mice; Mice, Nude; Osteolysis; Osteosarcoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2021 |
A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Liberation; Erythrocyte Membrane; Humans; Metal-Organic Frameworks; Mice, Inbred BALB C; Mice, Nude; Osteolysis; Osteosarcoma; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2021 |
Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Denmark; Denosumab; Diphosphonates; Humans; Male; Sweden; Zoledronic Acid | 2021 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |
Does Local Zoledronate Applied to Pasteurized Bone Autografts Improve the Likelihood of Union of Graft-Host Junctions after Limb-sparing Surgery?
Topics: Adolescent; Adult; Autografts; Bone Density Conservation Agents; Bone Neoplasms; Bone Transplantation; Female; Graft Survival; Humans; Limb Salvage; Male; Pasteurization; Retrospective Studies; Young Adult; Zoledronic Acid | 2022 |
Lung adenocarcinoma presents with diffuse bone metastasis.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Zoledronic Acid | 2021 |
Use and safety of denosumab in cancer patients.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Denosumab; Diphosphonates; Female; Follow-Up Studies; Guideline Adherence; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Practice Guidelines as Topic; Retrospective Studies; Tertiary Care Centers; Vitamin D; Zoledronic Acid | 2017 |
A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Incidence; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Risk Factors; Time Factors; Zoledronic Acid | 2017 |
Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
Topics: Administration, Metronomic; Agaricales; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Liver Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Tibia; Zoledronic Acid | 2017 |
Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Plant Extracts; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Europe; Female; Humans; Imidazoles; Infusions, Intravenous; Injections, Subcutaneous; Male; Time and Motion Studies; Zoledronic Acid | 2017 |
Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Drug Substitution; Female; Germany; Humans; Imidazoles; Middle Aged; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Survival Analysis; Young Adult; Zoledronic Acid | 2017 |
The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fever; Humans; Imidazoles; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Zoledronic Acid | 2017 |
Use of Leukocyte- and Platelet-Rich Fibrin in the Treatment of Medication-Related Osteonecrosis of the Jaws.
Topics: Aged; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Debridement; Female; Humans; Leukocytes; Membranes, Artificial; Platelet-Rich Fibrin; Suture Techniques; Zoledronic Acid | 2018 |
Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Uveitis, Anterior; Zoledronic Acid | 2017 |
Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Combined Modality Therapy; Diphosphonates; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Mice; Mice, Nude; Oncolytic Virotherapy; Osteoclasts; Osteosarcoma; RANK Ligand; RAW 264.7 Cells; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Female; Gadolinium; Humans; Luminescent Agents; Mice; Mice, Nude; Nanoparticles; Naphthoquinones; Optical Imaging; Osteocytes; Silicon Dioxide; Theranostic Nanomedicine; Zoledronic Acid | 2017 |
Bone targeted therapies in advanced breast cancer
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2017 |
Re: Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial.
Topics: Bone Neoplasms; Diphosphonates; Humans; Zoledronic Acid | 2017 |
[Can 12- instead of 4‑weekly zoledronic acid administration reduce skeletal events in patients with bone metastases?]
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2017 |
Metastatic Hepatocellular Carcinoma Treated With Zoledronic Acid.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Zoledronic Acid | 2018 |
Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; DNA, Neoplasm; Estradiol; Female; Humans; Imidazoles; MCF-7 Cells; Neoplasms, Hormone-Dependent; Zoledronic Acid | 2017 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Medical Oncology; Ontario; Pain; Pamidronate; Societies, Medical; United States; Zoledronic Acid | 2017 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Adjuvant zoledronic acid to treat breast cancer: not for all.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2017 |
In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Topics: Adult; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Proliferation; Denosumab; Giant Cell Tumor of Bone; Humans; In Vitro Techniques; Male; Middle Aged; Osteoclasts; Prognosis; Tumor Cells, Cultured; Zoledronic Acid | 2019 |
Re: Effect of Longer-interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2018 |
Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Drug Utilization; Humans; Longitudinal Studies; Male; Middle Aged; Practice Patterns, Physicians'; Prostatic Neoplasms; Time Factors; United States; Zoledronic Acid | 2018 |
Longitudinal resting-state functional magnetic resonance imaging in a mouse model of metastatic bone cancer reveals distinct functional reorganizations along a developing chronic pain state.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chronic Pain; Disease Models, Animal; Female; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Oxygen; Pain Measurement; Rest; Zoledronic Acid | 2018 |
An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cohort Studies; Denosumab; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Zoledronic Acid | 2018 |
Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Topics: Alendronate; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Cytotoxins; Diphosphonates; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression; Gingiva; Humans; Imidazoles; Inflammation; Osteoblasts; Osteosarcoma; Real-Time Polymerase Chain Reaction; Zoledronic Acid | 2018 |
Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Retrospective Studies; Risk Factors; Zoledronic Acid | 2018 |
Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Fractures, Spontaneous; Humans; Male; Middle Aged; Multivariate Analysis; Propensity Score; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid | 2018 |
Topics: Actinium; Alpha Particles; Animals; Bone Density Conservation Agents; Bone Neoplasms; Chelating Agents; Heterocyclic Compounds; Kidney; Organometallic Compounds; Radioimmunotherapy; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution; Zoledronic Acid | 2018 |
Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Chemoradiotherapy; Female; Fractures, Spontaneous; Humans; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Spinal Cord Compression; Sunitinib; Survival Rate; Treatment Outcome; Zoledronic Acid | 2018 |
Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
Topics: Alloys; Apoptosis; Biocompatible Materials; Bone and Bones; Bone Neoplasms; Calcium Phosphates; Cell Movement; Cytoskeleton; Diphosphonates; Giant Cell Tumor of Bone; Humans; Magnesium; Mitochondria; Neoplasm Metastasis; Neoplasms; NF-kappa B; Osteoclasts; Osteolysis; Oxidative Stress; Recurrence; Risk Factors; Signal Transduction; Strontium; Zoledronic Acid | 2018 |
Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone.
Topics: Animals; Bone Marrow; Bone Neoplasms; Cathepsin K; Cell Line, Tumor; Diphosphonates; Disease Progression; Female; Humans; Intravital Microscopy; Male; Mice; Mice, Nude; Miniaturization; Osteolysis; Stromal Cells; Tissue Engineering; Tissue Scaffolds; Treatment Outcome; Zoledronic Acid | 2018 |
Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chemotherapy, Adjuvant; Female; Gene Knockdown Techniques; GTPase-Activating Proteins; Humans; Middle Aged; Neoplasm Grading; Neoplasm Proteins; Prognosis; Proteomics; Risk Assessment; Tumor Cells, Cultured; Up-Regulation; Young Adult; Zoledronic Acid | 2019 |
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Middle Aged; United States; Zoledronic Acid | 2019 |
Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China.
Topics: Bone Density Conservation Agents; Bone Neoplasms; China; Cost-Benefit Analysis; Humans; Lung Neoplasms; Models, Economic; Quality-Adjusted Life Years; Zoledronic Acid | 2019 |
Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome; Zoledronic Acid | 2019 |
Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicin.
Topics: Animals; Apoptosis; Bone Neoplasms; Cardiotonic Agents; Caspase 2; Cell Cycle; Cell Line, Tumor; Doxorubicin; Enzyme Activation; Eye Proteins; Fetus; Humans; Mice, Inbred BALB C; Nerve Growth Factors; Osteosarcoma; Serpins; Zoledronic Acid | 2019 |
Effective Use of Sirolimus and Zoledronic Acid for Multiosteotic Pseudomyogenic Hemangioendothelioma of the Bone in a Child: Case Report and Review of Literature.
Topics: Bone Neoplasms; Child; Hemangioendothelioma; Humans; Male; Multimodal Imaging; Sirolimus; Zoledronic Acid | 2019 |
Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Particle Size; Phototherapy; Porosity; Surface Properties; Tumor Cells, Cultured; Tumor Microenvironment; Zoledronic Acid | 2019 |
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Incidence; Male; Mexico; Middle Aged; Osteoclasts; Retrospective Studies; Risedronic Acid; Time Factors; Zoledronic Acid | 2019 |
Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3β activation.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Glycogen Synthase Kinase 3 beta; Humans; Osteosarcoma; Signal Transduction; Zoledronic Acid | 2019 |
[A case of recurrent breast cancer with multiple bone metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Oxonic Acid; Recurrence; Tegafur; Zoledronic Acid | 2013 |
[Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
Topics: Adult; Aged; Aged, 80 and over; Benchmarking; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Home Infusion Therapy; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Nurse-Patient Relations; Nursing Staff; Patient Compliance; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Prostatic Neoplasms; Surveys and Questionnaires; Zoledronic Acid | 2013 |
Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Mucin-1; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2013 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Transformation, Neoplastic; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Metabolic Networks and Pathways; Neoplasm Metastasis; Neoplasms; Zoledronic Acid | 2013 |
Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cat Diseases; Cats; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diphosphonates; Disease Models, Animal; Heterografts; Humans; Imidazoles; Male; Meloxicam; Mice; Mice, Nude; Mouth Neoplasms; Neoplasms, Squamous Cell; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thiazines; Thiazoles; Treatment Outcome; Zoledronic Acid | 2015 |
Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cachexia; Cell Proliferation; Diphosphonates; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA, Neoplasm; Doxorubicin; Female; Imidazoles; Kaplan-Meier Estimate; Mice; Osteoblasts; Osteoclasts; Radioisotopes; Radium; Stem Cells; Tumor Cells, Cultured; Zoledronic Acid | 2013 |
Zooming in on the schedule of bone-modifying drugs.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2013 |
Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Bone Neoplasms; Diphosphonates; Female; Heart Ventricles; Humans; Imidazoles; Male; Middle Aged; Zoledronic Acid | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Peptide Fragments; Procollagen; Prospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Zoledronic Acid | 2013 |
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Internationality; Palliative Care; Treatment Outcome; Zoledronic Acid | 2013 |
[Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Humans; Imidazoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Zoledronic Acid | 2013 |
[Use of zoledronic acid for lung cancer with bone metastases - a study on reossification of osteolytic bone metastases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoporosis; Quality of Life; Young Adult; Zoledronic Acid | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2014 |
Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Incidence; Male; Middle Aged; Zoledronic Acid | 2013 |
Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Denosumab; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Zoledronic Acid | 2014 |
Osteonecrosis of the jaw related to everolimus: a case report.
Topics: Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Everolimus; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Osteonecrosis; Sirolimus; Thyroid Neoplasms; Thyroidectomy; Zoledronic Acid | 2013 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Immunohistochemistry; Integrins; Jaw; Microscopy, Electron, Scanning; Mouth Mucosa; Osteonecrosis; Pamidronate; Sarcoglycans; Zoledronic Acid | 2013 |
[Case of prostate cancer associated with bisphosphonate-related osteonecrosis of the jaw followed by retropharyngeal abscess].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drainage; Fatal Outcome; Humans; Imidazoles; Jaw; Male; Prostatic Neoplasms; Retropharyngeal Abscess; Taxoids; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
Stimulation of osteogenic differentiation in stromal cells of giant cell tumour of bone by zoledronic acid.
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Giant Cell Tumor of Bone; Humans; Imidazoles; Immunoenzyme Techniques; Osteocalcin; Osteogenesis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sp7 Transcription Factor; Stromal Cells; Transcription Factors; Tumor Cells, Cultured; Zoledronic Acid | 2013 |
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Heterografts; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; X-Ray Microtomography; Zoledronic Acid | 2013 |
Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Quality of Life; Taiwan; Zoledronic Acid | 2013 |
Which bisphosphonate to treat bone metastases?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Zoledronic Acid | 2014 |
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Follow-Up Studies; Gingival Crevicular Fluid; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Osteoprotegerin; Prognosis; RANK Ligand; Survival Rate; Zoledronic Acid | 2014 |
Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Femur; Frontal Bone; Germany; Humans; Imidazoles; Male; Mandible; Maxilla; Middle Aged; Prostatic Neoplasms; Radionuclide Imaging; Retrospective Studies; Sex Factors; Zoledronic Acid | 2014 |
Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
Topics: Adult; Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Femur; Follow-Up Studies; Frontal Bone; Humans; Imidazoles; Jaw; Mandible; Maxilla; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Whole Body Imaging; Zoledronic Acid | 2014 |
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy].
Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diphosphonates; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lung Neoplasms; Medicine, Chinese Traditional; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Treatment Failure; Triazoles; Zoledronic Acid | 2013 |
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density Conservation Agents; Bone Neoplasms; cdc42 GTP-Binding Protein; Cell Line, Tumor; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; L Cells; Lymphocyte Activation; MCF-7 Cells; Mevalonic Acid; Mice; Osteoblasts; Osteogenesis; Osteoprotegerin; Prenylation; Pyrroles; Rho Factor; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms; Wnt3A Protein; Zoledronic Acid | 2014 |
Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diagnostic Imaging; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Maxillary Neoplasms; Middle Aged; Zoledronic Acid | 2014 |
Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion, Malignant; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2014 |
Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Femur; Frontal Bone; Humans; Image Processing, Computer-Assisted; Imidazoles; Jaw Diseases; Mandible; Maxilla; Middle Aged; Osteonecrosis; Radionuclide Imaging; RANK Ligand; Retrospective Studies; Zoledronic Acid | 2014 |
Characterization of the attenuation of breast cancer bone metastasis in mice by zoledronic acid using (99m)Tc bone scintigraphy.
Topics: Animals; Biomarkers, Tumor; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Radionuclide Imaging; Radiopharmaceuticals; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Medronate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Diphosphonates; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Sarcoma, Ewing; Tumor Burden; Tumor Cells, Cultured; Zoledronic Acid | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cellular Microenvironment; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Osteoclasts; Ovariectomy; Postmenopause; Premenopause; Real-Time Polymerase Chain Reaction; X-Ray Microtomography; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Prostate cancer: preventing metastasis to bone: is this the end of the story?
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid | 2014 |
Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Topics: Aged; Ambulatory Care; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Canada; Costs and Cost Analysis; Cross-Sectional Studies; Diphosphonates; Equipment and Supplies; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pamidronate; Prospective Studies; Prostatic Neoplasms; Time Factors; Zoledronic Acid | 2014 |
Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diagnosis, Oral; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Zoledronic Acid | 2014 |
Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Choice Behavior; Denosumab; Diphosphonates; Female; France; Germany; Humans; Imidazoles; Kidney Diseases; Male; Middle Aged; Osteonecrosis; Pain; Patient Participation; Patient Preference; RANK Ligand; Treatment Outcome; United Kingdom; Zoledronic Acid | 2015 |
Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Topics: Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Green Fluorescent Proteins; Humans; Imidazoles; Immunocompromised Host; Mice, Inbred BALB C; Mice, Nude; Organ Size; Osteoblasts; Osteoclasts; Reproducibility of Results; Zoledronic Acid | 2014 |
Fluorescence-guided surgery of prostate cancer bone metastasis.
Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease-Free Survival; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Lymphatic Metastasis; Male; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm, Residual; Optical Imaging; Prostatic Neoplasms; Red Fluorescent Protein; Zoledronic Acid | 2014 |
Assessing treatment response of osteolytic lesions by manual volumetry, automatic segmentation, and RECIST in experimental bone metastases.
Topics: Algorithms; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cone-Beam Computed Tomography; Diphosphonates; Disease Models, Animal; Follow-Up Studies; Imidazoles; Indoles; Pyrroles; Radiographic Image Interpretation, Computer-Assisted; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Zoledronic Acid | 2014 |
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Cell Line, Tumor; Diphosphonates; Humans; Imidazoles; Male; Mice, Inbred BALB C; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid | 2014 |
Everolimus and zoledronic acid--a potential synergistic treatment for lung adenocarcinoma bone metastasis.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Everolimus; Humans; Imidazoles; Lung Neoplasms; Mice; Neoplasm Invasiveness; Phosphorylation; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Zoledronic Acid | 2014 |
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Topics: Biomarkers; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Neoplastic Cells, Circulating; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2014 |
[A case of recurrent lung cancer with bone metastases treated with tegafur-uracil and zoledronic acid for long-term survival].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Male; Recurrence; Tegafur; Time Factors; Treatment Outcome; Uracil; Zoledronic Acid | 2014 |
Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clusterin; Diphosphonates; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Mice; Mice, Nude; Osteosarcoma; Reverse Transcriptase Polymerase Chain Reaction; Thionucleotides; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
Topics: Apoptosis; Bone Neoplasms; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Survival; Cytosol; Depression, Chemical; Diphosphonates; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Imidazoles; Liver Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Signal Transduction; Zoledronic Acid | 2015 |
Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acid.
Topics: Acetabulum; Aged; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Spontaneous; Hip Prosthesis; Humans; Imidazoles; Osteoarthritis, Hip; Periprosthetic Fractures; Prosthesis Failure; Reoperation; Zoledronic Acid | 2014 |
Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies.
Topics: Animals; Animals, Newborn; Bone Development; Bone Neoplasms; Child; Craniofacial Abnormalities; Diphosphonates; Female; Humans; Imidazoles; Mice, Inbred C57BL; Phenotype; Tibia; X-Ray Microtomography; Zoledronic Acid | 2014 |
Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Middle Aged; Positron-Emission Tomography; Stomach Neoplasms; Treatment Outcome; Zoledronic Acid | 2015 |
Hypernociceptive responses following the intratibial inoculation of RM1 prostate cancer cells in mice.
Topics: Animals; Bone Neoplasms; Calcium-Binding Proteins; Cell Line, Tumor; Chemokines; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Glial Fibrillary Acidic Protein; Hyperalgesia; Imidazoles; Immunohistochemistry; Male; Mice, Inbred C57BL; Microfilament Proteins; Morphine; Neoplasm Transplantation; Nerve Tissue Proteins; Nociceptive Pain; Prostatic Neoplasms; Receptors, CCR2; Spinal Cord; Tibia; Zoledronic Acid | 2015 |
The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Topics: Administration, Metronomic; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Camellia sinensis; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Liver Neoplasms; Luminescent Measurements; Lung Neoplasms; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Osteolysis; Plant Extracts; Zoledronic Acid | 2015 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
Local administration of zoledronic acid for giant cell tumor of bone.
Topics: Administration, Topical; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Substitutes; Combined Modality Therapy; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult; Zoledronic Acid | 2015 |
Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Female; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Lebanon; Male; Middle Aged; Osteoporosis; Physicians; Surveys and Questionnaires; Zoledronic Acid | 2015 |
[Two cases of dural metastasis of breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemoradiotherapy; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Zoledronic Acid | 2014 |
Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Pain; Peptides; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Spinal Cord Compression; Thyroid Neoplasms; Zoledronic Acid | 2015 |
Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage.
Topics: Adolescent; Adult; Bone Cements; Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Combined Modality Therapy; Curettage; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Male; Polyradiculopathy; Retrospective Studies; Sacrum; Young Adult; Zoledronic Acid | 2015 |
VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.
Topics: Adult; Aged; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Zoledronic Acid | 2015 |
Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Logistic Models; Middle Aged; Retrospective Studies; Risk Factors; Trastuzumab; Treatment Outcome; Zoledronic Acid | 2015 |
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Topics: Aged; Bone Neoplasms; Calcitonin; Diphosphonates; Diuretics; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pamidronate; Quality of Health Care; Treatment Outcome; Zoledronic Acid | 2015 |
Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Diphosphonates; Humans; Imidazoles; Osteosarcoma; Receptor, ErbB-2; T-Lymphocytes, Cytotoxic; Trastuzumab; Zoledronic Acid | 2015 |
Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.
Topics: Acid Sensing Ion Channels; Analgesics; Animals; Biomarkers; Bone Neoplasms; Cell Line, Tumor; Collagen Type I; Diphosphonates; Drug Evaluation, Preclinical; Female; Ganglia, Spinal; Hyperalgesia; Imidazoles; Neoplasm Transplantation; Osteoclasts; Paclitaxel; Pain; Peptides; Proto-Oncogene Proteins c-fos; Rats, Wistar; Spinal Cord; Zoledronic Acid | 2015 |
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Topics: Antineoplastic Agents; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Incidence; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Vitamin D Deficiency; Zoledronic Acid | 2015 |
Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
Topics: Adult; Aged; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Peptides; Prospective Studies; Zoledronic Acid | 2015 |
[A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Colorectal Neoplasms; Diphosphonates; Fanconi Syndrome; Female; Humans; Imidazoles; Positron-Emission Tomography; Zoledronic Acid | 2015 |
A mouse model of luciferase-transfected stromal cells of giant cell tumor of bone.
Topics: Animals; Benzamides; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Giant Cell Tumor of Bone; Heterografts; Humans; Imidazoles; Luciferases; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Stromal Cells; Transduction, Genetic; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.
Topics: Animals; Benzoquinones; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Mice; Organ Specificity; Proto-Oncogene Mas; Proto-Oncogene Proteins c-raf; Small Cell Lung Carcinoma; Zoledronic Acid | 2016 |
Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models.
Topics: Animals; Biological Therapy; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Green Fluorescent Proteins; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Salmonella Infections, Animal; Salmonella typhimurium; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Biomarkers; Bone Neoplasms; Carcinoma, Hepatocellular; Combined Modality Therapy; Diphosphonates; Femoral Fractures; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Macrophages; Male; Osteoclasts; Protein Precursors; Prothrombin; Severity of Illness Index; Zoledronic Acid | 2015 |
Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Disease Models, Animal; Female; Hemiterpenes; Humans; Hyperthermia, Induced; Imidazoles; Organophosphorus Compounds; rap1 GTP-Binding Proteins; Ultrasonic Waves; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Flow Cytometry; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Receptors, Estrogen; Tumor Microenvironment; X-Ray Microtomography; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
Topics: Adjuvants, Immunologic; Adoptive Transfer; Adult; Animals; Bone Neoplasms; Cell Line, Tumor; Cells, Cultured; Chondrosarcoma; Cytotoxicity, Immunologic; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, Antigen, T-Cell, gamma-delta; Specific Pathogen-Free Organisms; T-Lymphocyte Subsets; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
Topics: Adaptor Proteins, Signal Transducing; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Microfilament Proteins; Molecular Targeted Therapy; Nuclear Proteins; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Reproducibility of Results; Zoledronic Acid | 2016 |
Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.
Topics: Biological Transport; Bone Density Conservation Agents; Bone Neoplasms; Cadherins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Diphosphonates; Diterpenes; Epithelial-Mesenchymal Transition; Farnesol; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasm Invasiveness; Nuclear Proteins; Osteoporosis; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prenylation; Proto-Oncogene Proteins pp60(c-src); rho-Associated Kinases; Snail Family Transcription Factors; Twist-Related Protein 1; Zoledronic Acid | 2016 |
Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphosphonates; Drug Resistance, Neoplasm; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Pamidronate; Proportional Hazards Models; Retrospective Studies; Risk Factors; Zoledronic Acid | 2016 |
[PREVENTION OF THE BONES METASTASES OCCURRENCE IN THE PATIENTS WITH RENAL-CELL CANCER].
Topics: Acid Phosphatase; Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Drug Administration Schedule; Female; Gene Expression; Humans; Imidazoles; Isoenzymes; Kidney Neoplasms; Male; Middle Aged; Radiography; Tartrate-Resistant Acid Phosphatase; Tomography, Emission-Computed; Treatment Outcome; Zoledronic Acid | 2015 |
Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Collagen Type I; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Peptides; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Zoledronic Acid | 2017 |
The enhancing effect of a laser photochemotherapy with cisplatin or zolendronic acid in primary human osteoblasts and osteosarcoma cells in vitro.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Cisplatin; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Osteoblasts; Osteosarcoma; Zoledronic Acid | 2016 |
Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dog Diseases; Dogs; Female; Gene Expression Regulation, Neoplastic; Imidazoles; Male; Neoplasm Metastasis; Osteosarcoma; Receptors, CXCR4; Zoledronic Acid | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Zoledronate-Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Diagnosis, Differential; Diphosphonates; Dog Diseases; Dogs; Imidazoles; Male; Osteosarcoma; Zoledronic Acid | 2016 |
Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bicuspid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Cementoplasty; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Laser Therapy; Lasers, Solid-State; Lung Neoplasms; Male; Margins of Excision; Middle Aged; Multiple Myeloma; Optical Imaging; Postoperative Complications; Tooth Extraction; Zoledronic Acid | 2016 |
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Comparative Effectiveness Research; Denosumab; Diphosphonates; Humans; Imidazoles; Japan; Kidney Function Tests; Male; Middle Aged; Neoplasm Staging; Outcome and Process Assessment, Health Care; Retrospective Studies; Urogenital Neoplasms; Zoledronic Acid | 2016 |
Bone-Targeted Mesoporous Silica Nanocarrier Anchored by Zoledronate for Cancer Bone Metastasis.
Topics: A549 Cells; Bone Neoplasms; Diphosphonates; Doxorubicin; Drug Carriers; Humans; Imidazoles; Microscopy, Electron, Scanning; Silicon Dioxide; Zoledronic Acid | 2016 |
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Metastasis; Peptides; Prognosis; Prospective Studies; Receptors, Estrogen; Zoledronic Acid | 2016 |
Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Diphosphonates; DNA Damage; DNA Repair; Epithelial-Mesenchymal Transition; Female; Gamma Rays; Humans; Imidazoles; Immunohistochemistry; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Phosphorylation; Radiation Dosage; Radiation-Sensitizing Agents; Reactive Oxygen Species; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.
Topics: Antineoplastic Agents; Biomarkers; Blotting, Western; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Denosumab; Diphosphonates; Everolimus; Gene Expression; Humans; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; MCF-7 Cells; Models, Biological; Osteoclasts; Osteonectin; RANK Ligand; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Zoledronic Acid | 2016 |
Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Separation; Diphosphonates; Female; Flow Cytometry; Follow-Up Studies; Humans; Imidazoles; Immunophenotyping; Leukocytes; Lipopolysaccharide Receptors; Middle Aged; Monocytes; Prospective Studies; Zoledronic Acid | 2017 |
Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocyte Activation; Mice, Inbred NOD; Mice, SCID; Osteolysis; Phenotype; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Cytotoxic; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Zoledronic Acid in First-Line Treatment of Prostate Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2017 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
Tissue-Engineered Model of Human Osteolytic Bone Tumor.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cell Differentiation; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Mesenchymal Stem Cells; Models, Biological; Osteoblasts; Osteoclasts; Osteolysis; Sarcoma, Ewing; Tissue Engineering; Zoledronic Acid | 2017 |
Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Disease Progression; Enzyme Activation; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Models, Biological; Multimodal Imaging; Osteoclasts; Tumor Burden; Tumor Microenvironment; Zoledronic Acid | 2017 |
Long interval zoledronic acid use in bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2017 |
Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Diphosphonates; Fatal Outcome; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Mandible; Mandibular Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid | 2017 |
Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Zoledronic Acid | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Colitis, Ulcerative; Data Interpretation, Statistical; Diphosphonates; Female; Gastrointestinal Agents; Humans; Ibandronic Acid; Imidazoles; Intention to Treat Analysis; Male; Medication Adherence; Mesalamine; Models, Statistical; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Treatment Outcome; Zoledronic Acid | 2017 |
Use of intravenous bisphosphonates in older women with breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Multivariate Analysis; Pain; Pamidronate; Prevalence; SEER Program; Survival Rate; United States; Zoledronic Acid | 2008 |
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2008 |
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Follow-Up Studies; Germany; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prevalence; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Tooth Extraction; Zoledronic Acid | 2008 |
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Immunohistochemistry; Mice; Mice, Nude; Zoledronic Acid | 2008 |
[A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2008 |
Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents, Local; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Debridement; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Oroantral Fistula; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2009 |
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
Topics: Academies and Institutes; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity: a novel molecular mechanism.
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Osteoclasts; Survival Rate; Zoledronic Acid | 2008 |
Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; bcl-X Protein; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Incidence; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Peptides; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2008 |
[Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Carcinoma, Renal Cell; Chronic Disease; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Infusions, Intravenous; Interleukin-2; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Renal Dialysis; Thalidomide; Zoledronic Acid | 2008 |
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Humans; Imidazoles; Insurance Claim Reporting; Lung Neoplasms; Male; Medical Records; Middle Aged; Prostatic Neoplasms; Retrospective Studies; United States; Zoledronic Acid | 2008 |
[Prescription of bisphosphonates in prostate cancer].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Ibandronic Acid; Imidazoles; Injections; Male; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zoledronic Acid | 2008 |
Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteogenesis; Pain Measurement; Pamidronate; Radiotherapy, Adjuvant; Zoledronic Acid | 2008 |
Zoledronic acid for the treatment of appendicular osteosarcoma in a dog.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Dog Diseases; Dogs; Euthanasia, Animal; Forelimb; Imidazoles; Lameness, Animal; Lymph Node Excision; Lymphatic Metastasis; Male; Osteosarcoma; Radiography; Zoledronic Acid | 2009 |
Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pain Management; Palliative Care; Pyrroles; Quality of Life; Sunitinib; Zoledronic Acid | 2008 |
Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2009 |
Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunophenotyping; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; RNA; T-Lymphocytes; Zoledronic Acid | 2008 |
[Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cancer Care Facilities; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Zoledronic Acid | 2009 |
Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Positron-Emission Tomography; Radiopharmaceuticals; Zoledronic Acid | 2009 |
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Imidazoles; Incidence; Jaw; Middle Aged; Osteonecrosis; Risk Factors; Zoledronic Acid | 2009 |
Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunohistochemistry; Immunotherapy; Lung Neoplasms; Male; Mice; Mice, SCID; Parathyroid Hormone-Related Protein; Radiography; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Diphosphonates; Drug Administration Schedule; Fatal Outcome; Female; Humans; Imidazoles; Radiography; Urinary Bladder Neoplasms; Zoledronic Acid | 2009 |
Effect of zoledronic acid on bone pain secondary to metastatic bone disease.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Pain; Zoledronic Acid | 2009 |
Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.
Topics: Adult; Bone and Bones; Bone Density; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Medical Oncology; Middle Aged; Neoplasm Metastasis; Osteoblasts; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Osteonecrosis; Pancreatic Neoplasms; Zoledronic Acid | 2009 |
Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Implants; Humans; Imidazoles; Male; Models, Biological; Prostatic Neoplasms; Testis; Zoledronic Acid | 2009 |
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Incidence; Kidney; Male; Middle Aged; Serum Albumin; Zoledronic Acid | 2009 |
Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion.
Topics: Antineoplastic Agents, Alkylating; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Diphosphonates; Humans; Imidazoles; Male; Melanoma; Melphalan; Positron-Emission Tomography; Skin Neoplasms; Tibia; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; Zoledronic Acid | 2009 |
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Enzyme Activation; Geranyltranstransferase; Imidazoles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Osteoclasts; Protein Prenylation; Zoledronic Acid | 2009 |
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2009 |
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pain; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2009 |
Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.
Topics: Absorptiometry, Photon; Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Female; Imidazoles; Mandible; Osteogenesis; Ribs; Tibia; Zoledronic Acid | 2010 |
[The role of oncology nurses in treatment outcomes. What can we do for the patients' compliance treated with intravenous zoledronic acid?].
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Zoledronic Acid | 2009 |
Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
Topics: Aged; Analgesics, Non-Narcotic; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Male; Organometallic Compounds; Organophosphorus Compounds; Pain; Prostatic Neoplasms; Radiopharmaceuticals; Zoledronic Acid | 2009 |
Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Mice; Mice, Nude; Osteoclasts; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Models, Biological; Osteoclasts; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
Bifocal sarcomatous transformation of Paget's disease: a case report.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Transformation, Neoplastic; Diphosphonates; Humans; Imidazoles; Male; Osteitis Deformans; Osteosarcoma; Pleural Effusion; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2009 |
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Endothelin-1; Humans; Imidazoles; Killer Cells, Natural; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoblasts; Osteolysis; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pleural Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Immunosuppressive Agents; Incidental Findings; Interferon-alpha; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiotherapy, Adjuvant; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaw and left thumb.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Curettage; Diphosphonates; Female; Finger Phalanges; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Osteotomy; Radiography; Thumb; Zoledronic Acid | 2009 |
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Caspases; Cell Proliferation; Diphosphonates; Imidazoles; Lung Neoplasms; Male; Osteosarcoma; Rats; Rats, Inbred F344; Zoledronic Acid | 2010 |
A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat.
Topics: Animals; Bone Neoplasms; Diphosphonates; Femur; Imidazoles; Male; Osteoblasts; Osteoclasts; Osteolysis; Prostatic Neoplasms; Rats; X-Ray Microtomography; Zoledronic Acid | 2010 |
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Health Care Costs; Health Resources; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney; Kidney Function Tests; Middle Aged; Renal Insufficiency; State Medicine; Zoledronic Acid | 2010 |
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Castration; Collagen Type I; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Peptides; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Case 36-2009: A man with cough, hoarseness, and abnormalities on chest imaging.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Receptor, IGF Type 1; Sarcoma, Ewing; Zoledronic Acid | 2010 |
A clinico-pathologic correlation. Bisphosphonate-related osteonecrosis of the jaws.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diagnosis, Differential; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Osteonecrosis; Zoledronic Acid | 2010 |
[Difference in treatment for metastatic bone tumors due to differences in opinion among departments--the role of medical teams for metastatic bone tumors].
Topics: Bone Neoplasms; Diphosphonates; Female; Health Knowledge, Attitudes, Practice; Hospital Departments; Humans; Imidazoles; Japan; Male; Middle Aged; Patient Care Team; Surveys and Questionnaires; Zoledronic Acid | 2010 |
Zoledronic acid and atrial fibrillation in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Electrocardiography; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Risk Factors; Smoking; Zoledronic Acid | 2011 |
Bone disease in prostate cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2010 |
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Male; Middle Aged; Recurrence; Spinal Neoplasms; Zoledronic Acid | 2010 |
Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid | 2010 |
Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Leukopenia; Male; Mice; Mice, Nude; Osteoclasts; Osteoprotegerin; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2010 |
Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Bone Neoplasms; Breast Neoplasms; Contrast Media; Diphosphonates; Humans; Imidazoles; Indoles; Longitudinal Studies; Magnetic Resonance Imaging; Pyrroles; Random Allocation; Rats; Rats, Nude; Sunitinib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multicenter Studies as Topic; Pain; Pain Measurement; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Neoplasms; Orchiectomy; Placebos; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2010 |
Bisphosphonates for bone pain #113.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neoplasms; Pain; Pamidronate; Renal Insufficiency; Zoledronic Acid | 2010 |
[Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Humans; Imidazoles; Oxonic Acid; Pleural Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2010 |
Combined effects of bisphosphonate and radiation on osteosarcoma cells.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Imidazoles; Mice; Osteosarcoma; Zoledronic Acid | 2010 |
Predicting skeletal complications in metastatic breast cancer raises challenges.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Pain; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Prognosis; Prospective Studies; Statistics, Nonparametric; Zoledronic Acid | 2010 |
Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases.
Topics: Amino Acid Sequence; Animals; Bone Neoplasms; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Molecular Sequence Data; RNA, Messenger; Zoledronic Acid | 2011 |
[Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2010 |
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Osteoclasts; Treatment Outcome; Tumor Cells, Cultured; Young Adult; Zoledronic Acid | 2010 |
Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cost-Benefit Analysis; Diphosphonates; Female; Financing, Government; France; Germany; Humans; Imidazoles; Male; Models, Economic; Neoplasm Staging; Quality-Adjusted Life Years; Retrospective Studies; Sensitivity and Specificity; Severity of Illness Index; United Kingdom; Zoledronic Acid | 2011 |
Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Humans; Imidazoles; Male; Mice; Mice, SCID; Molecular Targeted Therapy; NIH 3T3 Cells; Prostatic Neoplasms; Receptor, Platelet-Derived Growth Factor alpha; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Recurrent scrotal hemangiomas during treatment with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Genital Neoplasms, Male; Hemangioma; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Recurrence; Scrotum; Skin Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cyclophosphamide; Diphosphonates; Drug Synergism; Humans; Ifosfamide; Imidazoles; Male; Mice; Mice, Nude; Sarcoma, Ewing; Zoledronic Acid | 2010 |
Skeletal complications and survival in renal cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Spinal Cord Compression; Survival Analysis; Time Factors; Zoledronic Acid | 2011 |
Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Sarcoma, Ewing; Treatment Outcome; Zoledronic Acid | 2010 |
Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chondrosarcoma; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Formazans; Humans; Imidazoles; Male; Tetrazolium Salts; Zoledronic Acid | 2011 |
Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Debridement; Diphosphonates; Doxycycline; Female; Fluorescence; Fluorescent Dyes; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pilot Projects; Prospective Studies; Surgical Flaps; Surgical Wound Dehiscence; Treatment Outcome; Wound Healing; Zoledronic Acid | 2011 |
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Humans; Imidazoles; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Osteosarcoma; Protein Prenylation; ras Proteins; Rats; Sirolimus; TOR Serine-Threonine Kinases; Zoledronic Acid | 2010 |
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Male; Osteonecrosis; Pamidronate; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2010 |
Bone scans, bisphosphonates, and a lack of acute changes within the mandible.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Femur; Humans; Imidazoles; Infusions, Intravenous; Mandible; Middle Aged; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Single-Blind Method; Technetium Tc 99m Medronate; Thigh; Time Factors; Zoledronic Acid | 2011 |
Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
Topics: Adult; Aged; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Osteoclasts; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2011 |
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Cohort Studies; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Incidence; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Risk; Treatment Outcome; Zoledronic Acid | 2011 |
Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Conjunctivitis, Acute Hemorrhagic; Diphosphonates; Humans; Imidazoles; Inflammation; Male; Neoplasms, Second Primary; Neurofibroma; Orbital Diseases; Orbital Neoplasms; Prostatic Neoplasms; Zoledronic Acid | 2010 |
Zoledronic acid in myeloma: MRC Myeloma IX.
Topics: Administration, Oral; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Hospitalization; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Zoledronic Acid | 2011 |
Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clinical Trials as Topic; Collagen Type I; Diphosphonates; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Surveys and Questionnaires; Zoledronic Acid | 2011 |
Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Incidence; Male; Middle Aged; Neoplasms; Retrospective Studies; Time Factors; Zoledronic Acid | 2012 |
The use of zoledronic acid in pediatric cancer patients.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Child; Child, Preschool; Diphosphonates; Female; Humans; Imidazoles; Infant; Male; Sarcoma; Zoledronic Acid | 2011 |
New strategies to prevent and manage bone complications in cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Bone Remodeling; Denosumab; Diphosphonates; Humans; Imidazoles; RANK Ligand; Zoledronic Acid | 2011 |
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; RANK Ligand; Societies, Medical; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
Breast cancer bone metastases: denosumab or zoledronic acid?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; RANK Ligand; Zoledronic Acid | 2011 |
Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2011 |
Unravelling the role of denosumab in prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Dog Diseases; Dogs; Female; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2011 |
[A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Diphosphonates; Estramustine; Fatal Outcome; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2011 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Diphosphonates; Female; Fluorouracil; Humans; Hypercalcemia; Imidazoles; Leucovorin; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure; Vinblastine; Vinorelbine; Zoledronic Acid | 2011 |
Denosumab for bone metastases from breast cancer: a new therapy option?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney; Osteonecrosis; RANK Ligand; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Dental Care; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Peptides; Periodontal Diseases; Radiography, Panoramic; Risk Factors; Tooth Extraction; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Incidence; Jaw Diseases; Osteonecrosis; RANK Ligand; Zoledronic Acid | 2011 |
Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
Topics: Aged; Analgesics, Non-Narcotic; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Interactions; Humans; Imidazoles; Male; Middle Aged; Musculoskeletal Pain; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radiopharmaceuticals; Retrospective Studies; Zoledronic Acid | 2012 |
[A successful case treated with S-1 and zoledronic acid for multiple bone metastasis of breast cancer].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Middle Aged; Oxonic Acid; Quality of Life; Tegafur; Zoledronic Acid | 2011 |
[Effects of zoledronic acid in the treatment of breast cancer].
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Neoadjuvant Therapy; Osteoporosis; Zoledronic Acid | 2011 |
Prostate cancer: targeted therapy for prostate cancer metastases to bone.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Drug Delivery Systems; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2011 |
Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Collagen Type I; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2012 |
Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Imidazoles; Incidence; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate; Zoledronic Acid | 2011 |
Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; RANK Ligand; ras Proteins; Treatment Outcome; Zoledronic Acid | 2011 |
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Regression Analysis; Zoledronic Acid | 2011 |
Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Neoplasm Regression, Spontaneous; Zoledronic Acid | 2011 |
[A case of recurrent endometrial cancer metastasis successfully treated with zoledronic Acid].
Topics: Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid | 2011 |
Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient.
Topics: Animals; Bone Development; Bone Neoplasms; Child; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Male; Mice; Mice, Inbred C57BL; Osteosarcoma; Zoledronic Acid | 2011 |
Locally administered zoledronic Acid therapy for giant cell tumor of bone.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Substitutes; Bone Transplantation; Curettage; Diphosphonates; Giant Cell Tumor of Bone; Humans; Hydroxyapatites; Imidazoles; Knee Joint; Male; Necrosis; Osteoclasts; Osteolysis; Prostheses and Implants; Radiography; Range of Motion, Articular; Remission Induction; Tibia; Zoledronic Acid | 2011 |
Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro.
Topics: Angiogenesis Inhibitors; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Imidazoles; Mice; Microvilli; Neovascularization, Pathologic; Organ Culture Techniques; Osteosarcoma; Protein Transport; rhoA GTP-Binding Protein; Zoledronic Acid | 2011 |
Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Debridement; Diphosphonates; Fascia; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Neck Muscles; Plastic Surgery Procedures; Surgical Flaps; Suture Techniques; Treatment Outcome; Wound Closure Techniques; Zoledronic Acid | 2012 |
Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Neoplasms; Prognosis; Proportional Hazards Models; Zoledronic Acid | 2011 |
Suppurative arthritis of the temporomandibular joint associated with bisphosphonate: a case report.
Topics: Aged; Antineoplastic Agents; Arthritis, Infectious; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Imidazoles; Male; Temporomandibular Joint Disorders; Therapeutic Irrigation; Viridans Streptococci; Zoledronic Acid | 2012 |
Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Stress; Hip Fractures; Humans; Imidazoles; Middle Aged; Zoledronic Acid | 2011 |
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid | 2012 |
A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diaphyses; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; Middle Aged; Time Factors; Zoledronic Acid | 2015 |
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Insurance Claim Review; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Spinal Cord Compression; United States; Zoledronic Acid | 2012 |
Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil.
Topics: Bone Neoplasms; Brazil; Clodronic Acid; Cost-Benefit Analysis; Diphosphonates; Economics, Pharmaceutical; Financing, Government; Humans; Imidazoles; Insurance, Health, Reimbursement; Private Sector; Zoledronic Acid | 2011 |
Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
Topics: Adolescent; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Child; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interferon-gamma; Male; Osteosarcoma; Perforin; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; TNF-Related Apoptosis-Inducing Ligand; Young Adult; Zoledronic Acid | 2012 |
Lip ulceration associated with intravenous administration of zoledronic acid: report of a case.
Topics: Analgesics; Antidepressive Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Lip Diseases; Middle Aged; Osteonecrosis; Ulcer; Zoledronic Acid | 2012 |
[Renal insufficiency and breast cancer].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Creatinine; Dehydration; Diphosphonates; Female; Glomerular Filtration Rate; Humans; Imidazoles; Kidney; Middle Aged; Renal Insufficiency; Young Adult; Zoledronic Acid | 2012 |
Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Middle Aged; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Pamidronate; Retrospective Studies; Zoledronic Acid | 2012 |
Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Carriers; Humans; Imidazoles; Lactic Acid; Mice; Nanoparticles; Neoplasm Metastasis; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids; Zoledronic Acid | 2012 |
Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mice; Mice, Nude; Xenograft Model Antitumor Assays; Zoledronic Acid | 2011 |
Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic Acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Hand; Humans; Imidazoles; Liposarcoma; Male; Middle Aged; Soft Tissue Neoplasms; Treatment Outcome; Zoledronic Acid | 2011 |
Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Outcome Assessment, Health Care; Survival Analysis; United States; Urogenital Neoplasms; Zoledronic Acid | 2012 |
Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Lung Neoplasms; Male; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; United States; Zoledronic Acid | 2012 |
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Colorectal Neoplasms; Diphosphonates; Humans; Imidazoles; Retrospective Studies; Zoledronic Acid | 2012 |
Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Osteoblasts; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2012 |
Complete remission and long-term survival in a child with relapsed medulloblastoma with extensive osteosclerotic bony metastasis with a novel metronomic chemobiological approach.
Topics: Adolescent; Bone Neoplasms; Brain Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Medulloblastoma; Osteosclerosis; Recurrence; Zoledronic Acid | 2012 |
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Quality-Adjusted Life Years; United States; Zoledronic Acid | 2012 |
Efficacy of vinorelbine and zoledronate combination therapy against postoperative recurrence of lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Male; Neoplasm Staging; Recurrence; Vinblastine; Vinorelbine; Zoledronic Acid | 2012 |
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Neoplasms; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2012 |
Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Humans; Imidazoles; Quality of Life; Quality-Adjusted Life Years; Zoledronic Acid | 2012 |
Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Delphi Technique; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Nursing Staff, Hospital; Ontario; Pamidronate; Pharmacists; Quebec; Time Factors; Zoledronic Acid | 2012 |
Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Health Care Costs; Humans; Imidazoles; Markov Chains; Models, Economic; Multivariate Analysis; Outcome Assessment, Health Care; United States; Zoledronic Acid | 2012 |
Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Zoledronic Acid | 2012 |
[The importance of bone management for cancer bone disease--positioning of zoledronic acid for multiple myeloma, genitor-urinary cancers (renal cancer and prostate cancer), lung cancer and breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Quality of Life; Zoledronic Acid | 2012 |
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diphosphonates; Humans; Hyperthermia, Induced; Imidazoles; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Zoledronic Acid | 2013 |
[A survey of the dosage of zoledronic acid and investigation of the relationship between renal function and adverse events].
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Creatine; Diphosphonates; Female; Humans; Imidazoles; Kidney; Male; Middle Aged; Zoledronic Acid | 2012 |
A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Fanconi Syndrome; Female; Humans; Imidazoles; Middle Aged; Nephritis, Interstitial; Zoledronic Acid | 2012 |
[Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Interleukin-2; Leukocytes, Mononuclear; Lymphocyte Activation; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2012 |
Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cell Proliferation; Cytokines; Diphosphonates; Endothelial Cells; Female; Gingival Crevicular Fluid; Humans; Hydroxymethylglutaryl CoA Reductases; Imidazoles; Injections, Intravenous; Interleukin-6; Male; Middle Aged; Mouth Mucosa; Multiple Myeloma; Osteoclasts; Osteoprotegerin; RANK Ligand; Statistics, Nonparametric; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Disease Progression; Health Expenditures; Humans; Imidazoles; Male; Markov Chains; Models, Econometric; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; United States; Zoledronic Acid | 2013 |
[Management of bone metastasis originating from lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Quality of Life; Zoledronic Acid | 2012 |
Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Carcinoma, Renal Cell; Denosumab; Diphosphonates; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hypercalcemia; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Parathyroid Hormone; Risk Assessment; Zoledronic Acid | 2012 |
Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Middle Aged; Multivariate Analysis; Pamidronate; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2012 |
Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
Topics: Aged; Bone Neoplasms; Calcium; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Zoledronic Acid | 2013 |
Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Denosumab; Diphosphonates; Female; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; RANK Ligand; Xenograft Model Antitumor Assays; Zoledronic Acid | 2012 |
Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Quality of Life; Retrospective Studies; Socioeconomic Factors; Zoledronic Acid | 2013 |
Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Young Adult; Zoledronic Acid | 2012 |
Gorham's disease: 99mTc HMDP bone scan findings.
Topics: Biopsy; Bone Density Conservation Agents; Bone Neoplasms; Calcinosis; Calcium; Diagnosis, Differential; Diphosphonates; Drug Therapy, Combination; Edema; Humans; Humerus; Imidazoles; Male; Middle Aged; Multimodal Imaging; Osteolysis, Essential; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma, Synovial; Scapula; Shoulder Joint; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2012 |
Skeletal-related events in prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Gene Expression; Humans; Imidazoles; Male; Prostate; Prostatic Neoplasms; RANK Ligand; Spinal Cord; Zoledronic Acid | 2012 |
Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Musculoskeletal Pain; Palliative Care; Retrospective Studies; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2013 |
Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Molecular Structure; Oligopeptides; Osteoclasts; Osteoporosis; Xenograft Model Antitumor Assays; Zoledronic Acid | 2013 |
Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer.
Topics: Animals; Base Sequence; Blotting, Western; Bone Neoplasms; Diphosphonates; DNA Primers; Female; Humans; Hyaluronic Acid; Imidazoles; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Zoledronic Acid | 2013 |
[Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cytotoxicity, Immunologic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2013 |
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.
Topics: Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Fractures, Bone; Home Infusion Therapy; Humans; Imidazoles; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Nurses, Community Health; Osteonecrosis; Patient Compliance; Patient Satisfaction; Physicians; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2013 |
NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cancer Care Facilities; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Middle Aged; Pamidronate; Registries; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2013 |
Prostate cancer and osteoporosis.
Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2013 |
Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cathepsin K; Cell Line, Tumor; Coculture Techniques; Collagen Type I; Diphosphonates; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Integrin beta3; Macrophage Colony-Stimulating Factor; Models, Biological; Neoplasm Metastasis; Osteoclasts; Osteolysis; RANK Ligand; Zoledronic Acid | 2013 |
FDA grants priority review for ZOMETA.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Drug Approval; Imidazoles; United States; United States Food and Drug Administration; Zoledronic Acid | 2001 |
FDA approves ZOMETA for treatment of cancer-related bone complications.
Topics: Bone Neoplasms; Diphosphonates; Drug Approval; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; United States; United States Food and Drug Administration; Zoledronic Acid | 2002 |
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Hindlimb; Humans; Imidazoles; Male; Mice; Mice, SCID; Osteoblasts; Osteoclasts; Prostatic Neoplasms; Radiography; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2002 |
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid | 2002 |
[Bisphosphonates in bone metastases. Fewer fractures, less pain].
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Pain; Pamidronate; Zoledronic Acid | 2002 |
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
Topics: Animals; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Hyperalgesia; Hyperesthesia; Imidazoles; Models, Animal; Neoplasm Transplantation; Observer Variation; Pain; Pain Measurement; Pain Threshold; Pamidronate; Radiography; Rats; Rats, Sprague-Dawley; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Tibia; Touch; Treatment Outcome; Zoledronic Acid | 2002 |
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cathepsin K; Cathepsins; Cell Division; Diphosphonates; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Osteoblasts; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Prostatic Neoplasms; Zoledronic Acid | 2002 |
Zoledronic acid: a new advance in managing skeletal events in prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2003 |
The use of bisphosphonates in prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Bone Neoplasms; Cytokines; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Platelet-Derived Growth Factor; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2003 |
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Osteoblasts; Prostatic Neoplasms; Time Factors; Zoledronic Acid | 2003 |
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; Imidazoles; Luciferases; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Osteoclasts; Tegafur; Uracil; Zoledronic Acid | 2003 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid | 2003 |
Cancer patients with bone complications prefer infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Multicenter Studies as Topic; Pamidronate; Patient Satisfaction; Time Factors; Zoledronic Acid | 2003 |
Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
Topics: Anoikis; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Caspases; Cell Adhesion; Cell Division; Cell Line, Tumor; Cholesterol; Diphosphonates; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Imidazoles; Osteosarcoma; Zoledronic Acid | 2003 |
Avascular necrosis of the jaws: risk factors in metastatic cancer patients.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2003 |
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Female; Fever; Humans; Imidazoles; Interferon-gamma; Interleukin-6; Male; Middle Aged; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2003 |
Treatment strategies for myeloma bone disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Orthopedic Procedures; Pamidronate; Zoledronic Acid | 2003 |
Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Topics: Alendronate; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Giant Cell Tumor of Bone; Humans; Imidazoles; In Situ Nick-End Labeling; Osteoclasts; Pamidronate; Stromal Cells; Tumor Cells, Cultured; Zoledronic Acid | 2004 |
Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Prostatic Neoplasms; Vitamin D Deficiency; Zoledronic Acid | 2004 |
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasm Staging; Prognosis; Sampling Studies; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Diphosphonates; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Imidazoles; Luciferases; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Osteoclasts; Time Factors; Zoledronic Acid | 2004 |
Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Analysis of Variance; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2004 |
Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Epithelial Cells; Humans; Imidazoles; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Zoledronic Acid | 2004 |
Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.
Topics: Annexin A5; Apoptosis; Bone Neoplasms; Caspase 3; Caspases; Diphosphonates; Dose-Response Relationship, Drug; Flow Cytometry; Giant Cell Tumor of Bone; Humans; Imidazoles; Immunohistochemistry; Pamidronate; Poly Adenosine Diphosphate Ribose; Tumor Cells, Cultured; Zoledronic Acid | 2004 |
Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fluorouracil; Humans; Imidazoles; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Salvage Therapy; Tamoxifen; Zoledronic Acid | 2004 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Bone Neoplasms; Bone Resorption; Controlled Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2004 |
Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Male; Zoledronic Acid | 2004 |
Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.
Topics: Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2004 |
Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Bone Neoplasms; Creatinine; Diphosphonates; Half-Life; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Kidney; Safety; Zoledronic Acid | 2005 |
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Regeneration; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cohort Studies; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Peptides; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Zoledronic Acid | 2005 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Jaw; Male; Necrosis; Osteomyelitis; Osteopetrosis; Pain; Pain Measurement; Pamidronate; Prostatic Neoplasms; Quality of Life; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Diphosphonates; Humans; Imatinib Mesylate; Imidazoles; Male; Neoplasm Proteins; Palliative Care; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure; Zoledronic Acid | 2005 |
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; Hospitalization; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Time Factors; Zoledronic Acid | 2005 |
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Interferon-gamma; Neovascularization, Pathologic; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2005 |
Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Pain; Prostatic Neoplasms; Zoledronic Acid | 2005 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid | 2005 |
Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Squamous Cell; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Zoledronic Acid | 2005 |
Regarding "recommendations for zoledronic acid treatment of patients with bone metastases".
Topics: Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Creatinine; Diphosphonates; Education, Medical, Continuing; Humans; Imidazoles; Infusions, Intravenous; Kidney; Practice Guidelines as Topic; Zoledronic Acid | 2005 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Nude; Osteoclasts; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid | 2005 |
Ask us: Some drugs affect tooth movement.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoclasts; Tooth Movement Techniques; Zoledronic Acid | 2005 |
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteogenesis; Predictive Value of Tests; Prognosis; Zoledronic Acid | 2005 |
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2005 |
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Cell Proliferation; Densitometry; Diphosphonates; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; In Vitro Techniques; Male; Mice; Mice, SCID; Neoplasm Metastasis; Osteoclasts; Osteolysis; Osteoprotegerin; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Tibia; Time Factors; Zoledronic Acid | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Progression; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Glycoproteins; Humans; Imidazoles; Immunoenzyme Techniques; Mice; Mice, Nude; Osteoclasts; Osteoprotegerin; Paclitaxel; Radiography; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Zoledronic Acid | 2005 |
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Mitosis; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Quality-Adjusted Life Years; United Kingdom; Zoledronic Acid | 2005 |
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Recurrence; Zoledronic Acid | 2005 |
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred C3H; Osteosarcoma; Survival Analysis; Zoledronic Acid | 2005 |
Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Neoplasm Metastasis; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid | 2005 |
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Random Allocation; Taxoids; Tibia; Transplantation, Heterologous; Zoledronic Acid | 2006 |
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Pain; Palliative Care; Prostatic Neoplasms; Strontium Radioisotopes; Time Factors; Treatment Outcome; Zoledronic Acid | 2006 |
Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Transplantation; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Fetus; Green Fluorescent Proteins; Humans; Imidazoles; Luciferases; Luminescent Measurements; Male; Mice; Mice, SCID; Plasmids; Prostatic Neoplasms; Transfection; Xenograft Model Antitumor Assays; Zoledronic Acid | 2006 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Urogenital Neoplasms; Zoledronic Acid | 2006 |
[Two cases of stage IV breast cancer with severe hypercalcemia].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Goserelin; Humans; Hypercalcemia; Imidazoles; Leuprolide; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Quality of Life; Tamoxifen; Zoledronic Acid | 2006 |
Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw; Kidney Neoplasms; Male; Osteonecrosis; Pain; Zoledronic Acid | 2006 |
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Topics: Adult; Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2006 |
Anticancer effects of zoledronic acid against human osteosarcoma cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin D; Cyclin E; Cyclins; Diphosphonates; DNA; DNA Replication; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Farnesol; Humans; Imidazoles; Osteosarcoma; Protein Prenylation; Terpenes; Zoledronic Acid | 2006 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Male; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2006 |
The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Division; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Osteoprotegerin; Tibia; Transplantation, Heterologous; Zoledronic Acid | 2006 |
Home infusions of biphosphonate in cancer patients: a prospective study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Home Infusion Therapy; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pain; Patient Acceptance of Health Care; Patient Compliance; Patient Satisfaction; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
[The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
Topics: Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Efficacy of zoledronate against neuroblastoma.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Mice; Mice, SCID; Neoplasm Transplantation; Neuroblastoma; Zoledronic Acid | 2006 |
Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy.
Topics: Aftercare; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Early Diagnosis; Humans; Imidazoles; Nurse's Role; Nursing Assessment; Oncology Nursing; Pamidronate; Patient Care Planning; Patient Education as Topic; Quality of Life; Risk Assessment; Vitamin D; Zoledronic Acid | 2006 |
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
Topics: Animals; Apoptosis Inducing Factor; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Diphosphonates; DNA, Neoplasm; Endodeoxyribonucleases; Humans; Imidazoles; Microscopy, Confocal; Osteosarcoma; Protein Transport; Rats; S Phase; Tumor Suppressor Protein p53; Zoledronic Acid | 2007 |
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Drug Monitoring; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
Zoledronic acid palliation in bone-metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diphosphonates; Female; Humans; Imidazoles; Pain; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid | 2007 |
Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Mastectomy; Middle Aged; Osteonecrosis; Radiotherapy; Zoledronic Acid | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Zoledronic Acid | 2007 |
Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neoplasms; Bridged-Ring Compounds; Carboplatin; Dexamethasone; Diphosphonates; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Docetaxel and beyond.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Division; Diphosphonates; Drug Therapy, Combination; Imidazoles; Mice; Osteosarcoma; Zoledronic Acid | 2007 |
Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2007 |
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.
Topics: Aged; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Musculoskeletal System; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms; Quality of Life; Risk Factors; Survival; Treatment Outcome; Zoledronic Acid | 2007 |
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Renal Insufficiency; Retrospective Studies; Risk Factors; Zoledronic Acid | 2007 |
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Imidazoles; Luciferases; Mammary Neoplasms, Experimental; Mice; Osteolysis; Research Design; Zoledronic Acid | 2007 |
Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Italy; Male; Middle Aged; Pain Measurement; Pilot Projects; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Annual zoledronic acid: is less more?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2007 |
Non-inferiority trial design for recurrent events.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Diphosphonates; Female; Humans; Imidazoles; Models, Statistical; Research Design; Sample Size; Zoledronic Acid | 2007 |
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxycycline; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Hospitals; Humans; Imidazoles; Infusions, Intravenous; Medical Audit; Pamidronate; Time Factors; United Kingdom; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2007 |
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Minichromosome Maintenance Complex Component 2; Neoplasms, Hormone-Dependent; Nuclear Proteins; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bone Density Conservation Agents; Bone Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Diphosphonates; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Imidazoles; Osteosarcoma; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Tumor Suppressor Proteins; Zoledronic Acid | 2007 |
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Exostoses; Female; Humans; Imidazoles; Maxilla; Middle Aged; Osteonecrosis; Palate, Hard; Zoledronic Acid | 2006 |
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Prospective Studies; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2007 |
Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Pain; Pain Measurement; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Zoledronic Acid | 2008 |
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Division; Diphosphonates; Imidazoles; Kinetics; Macrophages; Mice; Mice, Knockout; Neoplasm Metastasis; Osteoclasts; Receptors, CXCR4; Zoledronic Acid | 2007 |
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cathepsin K; Cathepsins; Cystatin C; Cystatins; Diphosphonates; Disease Progression; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Prostatic Hyperplasia; Prostatic Neoplasms; ROC Curve; Zoledronic Acid | 2008 |
Spontaneous bilateral subcapital hip fracture due to multiple myeloma: an 18-month follow-up.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femoral Neck Fractures; Fracture Fixation, Internal; Fractures, Spontaneous; Humans; Imidazoles; Male; Multiple Myeloma; Radiography; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Role of the nurse in preserving patients' independence.
Topics: Activities of Daily Living; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Documentation; Drug Monitoring; Humans; Hypercalcemia; Imidazoles; Nurse's Role; Nursing Assessment; Nursing Records; Oncology Nursing; Pain; Patient Compliance; Patient Education as Topic; Social Support; Treatment Outcome; Zoledronic Acid | 2007 |
The role of nurses in preserving patients' functional independence: Zoledronic acid--evidence and experience in metastatic bone disease.
Topics: Activities of Daily Living; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Monitoring; Humans; Imidazoles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Zoledronic Acid | 2007 |
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Necrosis; Oral Fistula; Osteolysis; Osteomyelitis; Pamidronate; Prostatic Neoplasms; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid | 2007 |
The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Caspase 3; Cell Growth Processes; Cell Survival; Cyclophosphamide; Diphosphonates; Enzyme Activation; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Osteoclasts; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; ras Proteins; Topotecan; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Contrast Media; Diphosphonates; Female; Humans; Imidazoles; Iohexol; Male; Middle Aged; Prospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2007 |
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Marrow Cells; Bone Neoplasms; Bone Remodeling; Cell Cycle; Cell Proliferation; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Mice; Mice, Inbred C3H; Osteoblasts; Osteogenesis; Osteosarcoma; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Zoledronic Acid | 2008 |
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Orthognathic Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Prospective Studies; Zoledronic Acid | 2008 |
Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Metabolic Clearance Rate; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radioisotopes; Samarium; Zoledronic Acid | 2008 |
Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Orbital Pseudotumor; Prednisone; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Kidney; Longitudinal Studies; Male; Middle Aged; Time Factors; Zoledronic Acid | 2008 |
[Androgen-independent prostate cancer with bone metastasis successfully treated by intravenous administration of zoledronic acid and diethylstilbestrol diphosphate].
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neoplasms; Diethylstilbestrol; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fibroblast Growth Factor 2; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2008 |
Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
Topics: Administration, Oral; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Osteocalcin; Peptides; Procollagen; Prognosis; Sensitivity and Specificity; Zoledronic Acid | 2008 |
Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer.
Topics: Acute Disease; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Scleritis; Uveitis, Anterior; Zoledronic Acid | 2008 |
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Everolimus; Humans; Imidazoles; Male; Mice; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Zoledronic Acid | 2008 |
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid | 2008 |
Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis.
Topics: Aged; Anemia; Back Pain; Bone Density Conservation Agents; Bone Neoplasms; Diagnosis, Differential; Diphosphonates; Female; Humans; Hypertension; Imidazoles; Immunologic Factors; Interferon-alpha; Magnetic Resonance Imaging; Mastocytosis, Systemic; Osteolysis; Osteoporosis; Radionuclide Imaging; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Penicillin V; Risk Factors; Tooth Extraction; Zoledronic Acid | 2008 |
Bisphosphonates and osteonecrosis of the jaw: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Peptides; Retrospective Studies; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2008 |
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cystatin C; Diphosphonates; Female; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; ROC Curve; Zoledronic Acid | 2009 |
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Transformed; Diphosphonates; Disease Models, Animal; Dogs; Imidazoles; Incidence; Luminescent Proteins; Male; Mice; Mice, Nude; Osteoclasts; Osteolysis; Prostatic Neoplasms; Radiography; Zoledronic Acid | 2008 |
Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pamidronate; Zoledronic Acid | 2008 |
Pamidronate (Aredia) and zoledronate: update on clinical results. Introduction.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Organophosphorus Compounds; Osteoblasts; Pamidronate; Zoledronic Acid | 1996 |
Zoledronate.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteitis Deformans; Osteoporosis; Zoledronic Acid | 1996 |
Zoledronate in the treatment of osteolytic bone metastases.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 1996 |
Research on bone metastases quickens its pace.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid | 1997 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
[Significant therapeutic progression in tumor-induced bone diseases. This year's Robert Koch Award is awarded to Novartis Oncology].
Topics: Antineoplastic Agents; Awards and Prizes; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Pamidronate; Zoledronic Acid | 2000 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2000 |
[Bone metastasis. Can a new bisphosphonate offer control?].
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Osteoclasts; Treatment Outcome; Zoledronic Acid | 2001 |
Unmet needs in metastatic bone disease and its complications: is progress possible?
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2001 |
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Costs and Cost Analysis; Diphosphonates; Economics, Pharmaceutical; Humans; Imidazoles; Palliative Care; Pamidronate; Time and Motion Studies; Zoledronic Acid | 2001 |
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Mice; Mice, Nude; Microscopy, Fluorescence; Osteolysis; Recombinant Proteins; Tumor Cells, Cultured; Zoledronic Acid | 2001 |